var title_f6_33_6672="Contents: Myopericardial disease";
var content_f6_33_6672=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/3/5182\">",
"       Cardiovascular Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Myopericardial disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Myopericardial disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Asymptomatic left ventricular dysfunction",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/59/28601\">",
"           Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/12/20679\">",
"           Screening for asymptomatic left ventricular dysfunction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiomyopathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/53/35672\">",
"           Alcoholic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/34/28199\">",
"           Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/40/25226\">",
"           Cardiac involvement in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/19/17722\">",
"           Cardiac sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/46/41706\">",
"           Cardiotoxicity of anthracycline-like chemotherapy agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/21/34137\">",
"           Cardiotoxicity of radiation therapy for malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/0/19465\">",
"           Causes of dilated cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/59/14266\">",
"           Clinical manifestations and diagnosis of Chagas heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/10/23722\">",
"           Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/22/32106\">",
"           Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/42/36522\">",
"           Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/3/30777\">",
"           Definition and classification of the cardiomyopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/12/15562\">",
"           Echocardiographic recognition of cardiomyopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/32/40454\">",
"           Endomyocardial fibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/39/39545\">",
"           Evaluation and management of the cardiovascular complications of cocaine abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/59/5047\">",
"           Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/62/23528\">",
"           Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/41/39576\">",
"           Genetics of dilated cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/44/29386\">",
"           Genetics of hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/42/23207\">",
"           Idiopathic restrictive cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/20/1351\">",
"           Inherited syndromes associated with cardiac disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/51/41784\">",
"           Isolated left ventricular noncompaction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/55/10105\">",
"           Medical therapy in hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/4/32841\">",
"           Natural history of hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/21/7514\">",
"           Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/10/22696\">",
"           Overview of hypertrophic cardiomyopathy management including treatment of special problems",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/32/19975\">",
"           Pathology and pathogenesis of Chagas disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/62/18410\">",
"           Peripartum cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/51/16184\">",
"           Treatment and prognosis of Chagas heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/56/6025\">",
"           Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/25/23958\">",
"           Treatment of amyloid cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/59/28600\">",
"           Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/3/22586\">",
"           Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Etiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/53/35672\">",
"           Alcoholic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/40/25226\">",
"           Cardiac involvement in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/45/17111\">",
"           Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/46/41706\">",
"           Cardiotoxicity of anthracycline-like chemotherapy agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/21/34137\">",
"           Cardiotoxicity of radiation therapy for malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/0/19465\">",
"           Causes of dilated cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/10/23722\">",
"           Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/43/30392\">",
"           Etiology of pericardial disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/51/40759\">",
"           Lyme carditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/59/22456\">",
"           Non-coronary cardiac manifestations of systemic lupus erythematosus in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/31/24055\">",
"           Pericardial complications of myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/24/6533\">",
"           Pericarditis in renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/62/18410\">",
"           Peripartum cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/30/20968\">",
"           Post-cardiac injury syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/30/35303\">",
"           Purulent pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/25/23958\">",
"           Treatment of amyloid cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/54/15207\">",
"           Trichinellosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/16/26889\">",
"           Clinical manifestations and diagnosis of myocarditis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/42/36522\">",
"           Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/47/37625\">",
"           Clinical presentation and diagnostic evaluation of acute pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/3/34874\">",
"           Clinical utility of cardiovascular magnetic resonance imaging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/59/4025\">",
"           Diagnosis and treatment of pericardial effusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/3/29752\">",
"           Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/7/23669\">",
"           Electrocardiogram in pericarditis and pericardial effusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/26/7592\">",
"           Endomyocardial biopsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/59/28601\">",
"           Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/28/39369\">",
"           Evaluation of the patient with heart failure or cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/30/19945\">",
"           Evaluation of the patient with suspected heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/57/11158\">",
"           Pulsus paradoxus in pericardial disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/44/713\">",
"           Treatment of acute pericarditis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypertrophic cardiomyopathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/34/28199\">",
"           Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/42/36522\">",
"           Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/44/29386\">",
"           Genetics of hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/55/10105\">",
"           Medical therapy in hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/4/32841\">",
"           Natural history of hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/21/7514\">",
"           Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/10/22696\">",
"           Overview of hypertrophic cardiomyopathy management including treatment of special problems",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/59/28600\">",
"           Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/3/22586\">",
"           Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Myocarditis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/16/26889\">",
"           Clinical manifestations and diagnosis of myocarditis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/28/22986\">",
"           Etiology and pathogenesis of myocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/39/10874\">",
"           Natural history and therapy of myocarditis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/54/15207\">",
"           Trichinellosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathophysiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/12/12490\">",
"           Constrictive pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/28/22986\">",
"           Etiology and pathogenesis of myocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/41/39576\">",
"           Genetics of dilated cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/44/29386\">",
"           Genetics of hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/20/1351\">",
"           Inherited syndromes associated with cardiac disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/59/28600\">",
"           Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pericarditis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/40/25226\">",
"           Cardiac involvement in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/52/19273\">",
"           Cardiac tamponade",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/0/5126\">",
"           Chylopericardium and cholesterol pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/47/37625\">",
"           Clinical presentation and diagnostic evaluation of acute pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/12/12490\">",
"           Constrictive pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/59/4025\">",
"           Diagnosis and treatment of pericardial effusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/3/29752\">",
"           Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/7/23669\">",
"           Electrocardiogram in pericarditis and pericardial effusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/43/30392\">",
"           Etiology of pericardial disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/25/20886\">",
"           Management of pericardial diseases during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/60/41927\">",
"           Myopericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/31/24055\">",
"           Pericardial complications of myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/1/1050\">",
"           Pericardial disease associated with malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/32/2568\">",
"           Pericardial involvement in systemic autoimmune diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/24/6533\">",
"           Pericarditis in renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/30/20968\">",
"           Post-cardiac injury syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/57/11158\">",
"           Pulsus paradoxus in pericardial disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/30/35303\">",
"           Purulent pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/58/11177\">",
"           Recurrent pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/36/25159\">",
"           Technique of pericardiocentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/44/713\">",
"           Treatment of acute pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/36/2633\">",
"           Tuberculous pericarditis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/47/37625\">",
"           Clinical presentation and diagnostic evaluation of acute pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/59/4025\">",
"           Diagnosis and treatment of pericardial effusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/55/10105\">",
"           Medical therapy in hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/39/10874\">",
"           Natural history and therapy of myocarditis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/21/7514\">",
"           Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/10/22696\">",
"           Overview of hypertrophic cardiomyopathy management including treatment of special problems",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/58/11177\">",
"           Recurrent pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/36/25159\">",
"           Technique of pericardiocentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/44/713\">",
"           Treatment of acute pericarditis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-037CB5CED5-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f6_33_6672=[""].join("\n");
var outline_f6_33_6672=null;
var title_f6_33_6673="Tolciclate: International drug information";
var content_f6_33_6673=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tolciclate: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fungifos (DE);",
"     </li>",
"     <li>",
"      Kilmicen (CH, MX);",
"     </li>",
"     <li>",
"      Tolmicen (CZ, IT, PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1980377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1980380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of fungal infections",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1980376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Topical: Apply to affected area 2-3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1980379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Cream: 1% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Lotion: 1% (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Powder: 0.5% (100 g)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10439 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_33_6673=[""].join("\n");
var outline_f6_33_6673=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304017\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980377\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980380\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980376\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821088\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980379\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10439\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10439|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_33_6674="Misplaced nasogastric tube";
var content_f6_33_6674=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Misplaced nasogastric tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This adolescent had a nasogastric tube placed after a polydrug ingestion. Charcoal was administered, and the patient's respiratory status deteriorated. The chest radiograph shows the nasogastric tube in the left lower lung and alveolar opacification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_33_6674=[""].join("\n");
var outline_f6_33_6674=null;
var title_f6_33_6675="Rectal temperature PI";
var content_f6_33_6675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F74460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F74460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Measuring rectal temperature",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lay your child face down across your lap. Put a dab of petroleum jelly (sold as Vaseline&reg;) on the end of the thermometer. Then gently insert the thermometer into the child's anus until the silver tip is not visible (1/4 to 1/2 inch inside the anus). Hold the thermometer in place. A glass thermometer takes about 2 minutes. Most digital thermometers need less than 1 minute.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_33_6675=[""].join("\n");
var outline_f6_33_6675=null;
var title_f6_33_6676="McMurray test";
var content_f6_33_6676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    McMurray test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 469px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Passive flexion and extension of the knee is used to assess the smooth motion of the joint. The examiner's thumb and index fingers are placed on the medial and lateral joint lines. The knee is passively flexed. While applying torque to the foot, the knee is rotated medially to trap the lateral meniscus or laterally to trap the medial meniscus (noted by a painful click). The knee is then passively extended and the maneuver is repeated in a smooth back and forth motion, feeling for a popping sensation along the joint line. The test is positive when there is pain at the joint line, with or without a \"thunk,\" and limited range of motion. A positive test implies meniscal injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_33_6676=[""].join("\n");
var outline_f6_33_6676=null;
var title_f6_33_6677="Vaccinia immune globulin (intravenous): Drug information";
var content_f6_33_6677=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vaccinia immune globulin (intravenous): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/61/5076?source=see_link\">",
"    see \"Vaccinia immune globulin (intravenous): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9942323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F786671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CNJ-016&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F232749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Blood Product Derivative;",
"     </li>",
"     <li>",
"      Immune Globulin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F232740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Vaccinial infection:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Vaccinia immune globulin is currently not recommended for use in persons with contraindications to smallpox vaccine; inadvertent exposure to smallpox vaccine in high-risk populations should be reported to the CDC so that standardized treatment may be provided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: 6000 units/kg; may repeat dose based on severity of symptoms and response to treatment (specific data are lacking); 9000 units/kg may be considered if patient does not respond to initial dose. Doses up to 24,000 unit/kg were tolerated in healthy volunteers.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9942427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vaccinia immune globulin is currently not recommended for use in persons with contraindications to smallpox vaccine; inadvertent exposure to smallpox vaccine in high risk populations should be reported to the CDC so that standardized treatment may be provided.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F786673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Vaccinia immune globulin is currently not recommended for use in persons with contraindications to smallpox vaccine; inadvertent exposure to smallpox vaccine in high risk populations should be reported to the CDC so that standardized treatment may be provided.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F232741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution. In patients at risk of renal dysfunction, the rate of infusion and concentration of solution should be minimized; discontinue if renal function deteriorates.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F232728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free; solvent-detergent treated]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     CNJ-016&reg;: &ge;50,000 units/15 mL (15 mL) [contains maltose 10% and polysorbate 80 0.03%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F232715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11238291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vaccinia immune globulin is not available for general public use. All supplies are currently owned by the federal government for inclusion in the Strategic National Stockpile. The CDC Smallpox Adverse Events Clinical Consultation team will coordinate shipment. The State Health Department should be contacted first concerning severe or unexpected adverse events from smallpox vaccination.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F232730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not shake; avoid foaming. For intravenous use only. Predilution is not recommended. If dedicated line is not available, flush with NS prior to administration of VIGIV. Do not exceed recommended rates of infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients &ge;50 kg: Infuse at  &le;2 mL/minute; Patients &lt;50 kg: Infuse at &le;0.04 mL/kg/minute. Maximum assessed rate of infusion: 4 mL/minute. Decrease rate of infusion in patients who develop minor adverse reactions (eg, flushing) and in patients with risk factors for thrombosis/thromboembolism and/or renal insufficiency.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F232754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Y-site administration:",
"     </b>",
"     <b>",
"      Compatible",
"     </b>",
"     (in a dilution not to exceed 1:2, v/v) with NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F232729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of infectious complications of smallpox (vaccinia virus) vaccination, such as eczema vaccinatum, progressive vaccinia, and severe generalized vaccinia; treatment of  vaccinia infections in individuals with concurrent skin conditions or accidental virus exposure to eyes (except vaccinia keratitis), mouth, or other areas where viral infection would pose significant risk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      CDC guidelines for use:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Use is recommended for:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     - Inadvertent inoculation (considering severity, toxicity of affected person, and pain)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     - Eczema vaccinatum",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     - Generalized vaccinia (severe form or if underlying illness is present)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     - Progressive vaccinia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Use may be considered for:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     - Severe ocular complications except isolated keratitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Use is not recommended for:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     - Inadvertent inoculation that is not severe",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     - Mild or limited generalized vaccinia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     - Nonspecific rashes, erythema multiforme, or Stevens-Johnson syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     - Postvaccinial encephalitis or encephalomyelitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F232747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Actual frequency varies by dose and rate of infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Cold or hot feeling, dizziness, fatigue, headache, pain, pallor, pyrexia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Erythema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Appetite decreased, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Local: Injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, paraesthesia, muscle spasm, rigors, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Abdominal pain, anaphylaxis, apnea, acute respiratory distress syndrome, arthralgia, aseptic meningitis, blood pressure changes, bronchospasm, bullous dermatitis, cardiac arrest, chills, coma, Coombs' test positive, cyanosis, diarrhea, dyspnea, epidermolysis, erythema multiforme, flushing, hemolysis, hepatic dysfunction, hypersensitivity reactions, hypoxemia, hypotension, intravascular hemolysis, leukopenia, loss of consciousness, lung injury (transfusion associated), malaise, myalgia, osmotic nephropathy, pancytopenia, proximal tubular nephropathy, pulmonary edema, renal dysfunction/failure (acute), seizure, Stevens-Johnson syndrome, syncope, tachycardia, thrombocytopenia, thromboembolism, transfusion-related acute lung injury (TRALI), urticaria, vascular collapse, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F232733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to immune globulin or any component of the formulation; isolated vaccinia keratitis; selective IgA deficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F232718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; immediate treatment (including epinephrine 1:1000) should be available. Contains trace amounts of IgA; use caution in IgA-deficient patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: Aseptic meningitis syndrome (AMS) has been reported with intravenous immune globulin administration (rare); may occur with high doses (&ge;2 g/kg).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolysis: Intravenous immune globulin has been associated with antiglobulin hemolysis; monitor for signs of hemolytic anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary edema: Monitor for transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with intravenous immune globulin use. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, and fever in the presence of normal left ventricular function. Usually occurs within 1-6 hours after infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Acute renal dysfunction (increased serum creatinine, oliguria, acute renal failure) can rarely occur; usually within 7 days of use (more likely with products stabilized with sucrose). Use with caution in the elderly, patients with renal disease, diabetes mellitus, volume depletion, sepsis, paraproteinemia, and nephrotoxic medications due to risk of renal dysfunction. In patients at risk of renal dysfunction, the rate of infusion and concentration of solution should be minimized; discontinue if renal function deteriorates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombotic events: Thrombotic events have been reported with administration of intravenous immune globulin; use with caution in patients with cardiovascular risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypovolemia: Patients should not be volume depleted prior to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Postvaccinial encephalitis: Not effective for use in postvaccinial encephalitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Maltose: Product may contain maltose.",
"     <b>",
"      [U.S. Boxed Warning]: Maltose in vaccinia immune globulin can interact with glucose monitoring systems and test strips.",
"     </b>",
"     Falsely-elevated blood glucose readings may result in unnecessary insulin use and life-threatening hypoglycemia. Glucose specific monitoring systems and test strips are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: For intravenous administration only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Vaccinia immune globulin is currently not recommended for use in persons with contraindications to smallpox vaccine; inadvertent exposure to smallpox vaccine in high-risk populations should be reported to the CDC so that standardized treatment may be provided.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F232722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Yellow Fever Vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F232724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F232734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Immune globulins cross the placenta in increased amounts after 30 weeks gestation. There are no adequate and well-controlled studies in pregnant women. Vaccinia immune globulin is currently not recommended for use in persons with contraindications to smallpox vaccine; inadvertent exposure to smallpox vaccine in high risk populations (eg pregnant women) should be reported to the CDC so that standardized treatment may be provided.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F232743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F232726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function and urine output (at baseline and at appropriate intervals). Baseline assessment of blood viscosity in patients at risk for hyperviscosity. During infusion, monitor patient for signs of infusion-related reactions, including (but not limited to) flushing, fever, chills, respiratory distress, blood pressure or heart rate changes. Transfusion-related lung injury (typically 1-6 hours after infusion) and hemolysis have been reported with infusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F232717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antibodies obtained from pooled human plasma of individuals immunized with the smallpox vaccine provide passive immunity",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F232732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 6630 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 30 days (range: 13-67 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Time to peak, plasma: &le;2 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Medical Management of Smallpox (Vaccinia) Vaccine Adverse Reactions: Vaccinia Immune Globulin and Cidofovir.&rdquo; Available at",
"      <a href=\"file://emergency.cdc.gov/agent/smallpox/vaccination/mgmt-adv-reactions.asp\" target=\"_blank\">",
"       file://emergency.cdc.gov/agent/smallpox/vaccination/mgmt-adv-reactions.asp",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cono J, Casey CG, and Bell DM, &ldquo;Smallpox Vaccination and Adverse Reactions. Guidance for Clinicians,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2003, 52(RR-4):1-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/33/6677/abstract-text/12617510/pubmed\" id=\"12617510\" target=\"_blank\">",
"        12617510",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10332 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-EA571C30FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_33_6677=[""].join("\n");
var outline_f6_33_6677=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9942323\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786671\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232749\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232740\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9942427\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786673\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232741\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232728\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232715\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11238291\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232730\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232754\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232729\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232747\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232733\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232718\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300200\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232722\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232724\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232734\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232743\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232726\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232717\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232732\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10332\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10332|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/61/5076?source=related_link\">",
"      Vaccinia immune globulin (intravenous): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_33_6678="Radionuclide myocardial perfusion imaging in predischarge risk stratification of medically treated patients with non-ST elevation acute coronary syndrome";
var content_f6_33_6678=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radionuclide myocardial perfusion imaging in predischarge risk stratification of medically treated patients with non-ST elevation acute coronary syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/33/6678/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/33/6678/contributors\">",
"     Rabih R Azar, MD, MSc, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/33/6678/contributors\">",
"     Gary V Heller, MD, PhD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/33/6678/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/33/6678/contributors\">",
"     Ami E Iskandrian, MD, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/33/6678/contributors\">",
"     Jeroen J Bax, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/33/6678/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/33/6678/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/33/6678/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of antithrombotic and anti-ischemic medications has markedly improved the short-term outcome in patients with non-ST elevation acute coronary syndrome (NSTEACS). At present, almost all patients with NSTEACS are managed with early cardiac catheterization and, if appropriate, revascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A minority of patients with NSTEACS are at low short-term risk [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6678/abstract/1\">",
"     1",
"    </a>",
"    ] and can be treated medically since they may not benefit from revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6678/abstract/2\">",
"     2",
"    </a>",
"    ]. This is also true for an occasional patient at intermediate risk (",
"    <a class=\"graphic graphic_table graphicRef55745 \" href=\"UTD.htm?6/60/7117\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6678/abstract/3\">",
"     3",
"    </a>",
"    ]. However, some of these patients have ongoing ischemia and may develop new coronary events after hospital discharge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=see_link\">",
"     \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible value of radionuclide myocardial perfusion imaging in risk stratification of medically treated patients with NSTEACS will be reviewed here. Previous studies of such patients, performed before the widespread use of early revascularization, illustrated the persistent risk following medical therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the TIMI III registry, the incidence of MI or cardiac death at six week follow-up was 3.2 and 3.1 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?6/33/6678/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the TIMI IIIB trial, the one year non-fatal MI and cardiac death rate were 8.8 and 4.3 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?6/33/6678/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these reports were not limited to low risk patients and therefore overstate the risk with current management. Furthermore, evidence of persistent ischemia on perfusion imaging before discharge is now considered an indication for revascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link&amp;anchor=H28#H28\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\", section on 'Recurrent ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of acute rest radionuclide myocardial perfusion imaging in the early diagnosis and management of acute coronary syndromes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3496?source=see_link\">",
"     \"Acute rest radionuclide myocardial perfusion imaging for the evaluation of suspected non-ST elevation acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STUDIES WITH THALLIUM-201",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thallium-201 scintigraphy has been evaluated in patients with a non-ST elevation ACS during exercise testing and during pharmacologic stress testing with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential value of exercise planar thallium-201 scintigraphy was assessed in a series of 158 patients; scintigraphy was performed before or within four weeks after hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6678/abstract/6\">",
"     6",
"    </a>",
"    ]. At one-year, death or nonfatal MI was much more likely in patients with a reversible defect (21 versus 2 percent in those with normal scintigrams) (",
"    <a class=\"graphic graphic_figure graphicRef55966 \" href=\"UTD.htm?24/60/25549\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar findings were noted in a report of 52 patients with a non-ST elevation ACS treated medically who underwent exercise thallium imaging within one week of hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6678/abstract/7\">",
"     7",
"    </a>",
"    ]. After a mean follow-up of 39 months cardiac death or nonfatal MI occurred more often in patients with, compared to those without, thallium redistribution (26 versus 3 percent). All cardiac events (cardiac death, nonfatal MI, unstable angina, revascularization) were more common in patients with reversible defects compared to those with a fixed defect or those with a normal study (70 versus 29 and 20 percent, respectively).",
"   </p>",
"   <p>",
"    Another study compared exercise thallium-201 to 24 hour ambulatory monitoring (to detect silent ischemia), exercise stress testing, and cardiac catheterization with coronary angiography for predicting cardiac events in 54 patients with a non-ST elevation ACS who were stabilized with medical therapy and discharged without revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6678/abstract/8\">",
"     8",
"    </a>",
"    ]. At six month follow-up, 26 percent of patients had a cardiac event (cardiac death, nonfatal MI, or recurrent unstable angina).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major findings predictive of a cardiac event were a lower double product at peak exercise (18,000 versus 24,000 in those without a cardiac event), a larger size reversible defect on thallium imaging (17 versus 6 percent of total myocardium imaged), and more vessels with &ge;50 percent stenosis (2.1 versus 1.1) were predictive of a cardiac event.",
"     </li>",
"     <li>",
"      With multiple logistic regression analysis, a history of previous MI was the most powerful predictor of outcome while, in patients without a prior MI, a reversible exercise thallium perfusion defect size was the only predictor.",
"     </li>",
"     <li>",
"      Among the factors",
"      <strong>",
"       NOT",
"      </strong>",
"      predictive of a cardiac event were the duration of silent ischemia on ambulatory monitoring, exercise test duration, ST segment depression at peak exercise, and left ventricular ejection fraction estimated from the left ventriculogram.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increased lung thallium uptake with exercise testing, a marker of left ventricular dysfunction and elevated filling pressures, is also useful for predicting future events in patients with a non-ST elevation ACS, even in the absence of myocardial perfusion abnormalities. Of 1271 patients enrolled in the TIMI IIIB study, 227 (18 percent) had increased lung uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6678/abstract/9\">",
"     9",
"    </a>",
"    ]. At one year follow-up, patients with increase lung uptake had a higher cardiac event rate (18 versus 10 percent for those without increased lung uptake) regardless of the presence or absence of perfusion abnormalities on scintigraphy (",
"    <a class=\"graphic graphic_figure graphicRef65652 \" href=\"UTD.htm?7/19/7487\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dipyridamole thallium imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     Dipyridamole",
"    </a>",
"    thallium scintigraphy provides diagnostic and prognostic information after a non-ST elevation ACS that is similar to that of an exercise thallium image; in addition, it may offer the advantage of early rapid diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One report evaluated the safety and accuracy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    perfusion scintigraphy in 170 patients with a non-ST elevation ACS who were stabilized medically [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6678/abstract/10\">",
"     10",
"    </a>",
"    ]. All patients were pain free for at least 24 hours at the time of the study and all had coronary angiography performed within two months. The sensitivity and specificity of dipyridamole thallium imaging to diagnose a coronary artery lesion of &ge;70 percent were 91 and 79 percent respectively. After a six month follow-up, coronary revascularization was required in 89 percent of patients with reversible scintigraphic abnormalities.",
"   </p>",
"   <p>",
"    A second study involved 68 patients with unstable angina or an acute MI who underwent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    thallium scanning after medical stabilization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6678/abstract/11\">",
"     11",
"    </a>",
"    ]. After an average follow-up of 12 months, patients with an abnormal scan were more likely to have a cardiac event (72 versus 7 percent). With regression analysis, a reversible thallium defect and the extent of coronary disease on angiography were the only variables significantly predictive of subsequent cardiac events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     STUDIES WITH TECHNETIUM-99M SESTAMIBI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comparable results have been reported with exercise SPECT technetium-99m sestamibi. In one study, for example, maximal exercise stress testing with Tc-99m sestamibi was performed before hospital discharge in 126 patients who were treated medically for a non-ST elevation ACS and followed for 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6678/abstract/12\">",
"     12",
"    </a>",
"    ]. The only clinical or scintigraphic variable with independent predictive value was the presence of a reversible perfusion defect, which was associated with a relative risk of 3.8 for any cardiac event and 19.2 for MI or cardiac death.",
"   </p>",
"   <p>",
"    In patients with limited exercise capacity,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    technetium-99m sestamibi imaging provides prognostic information similar to that obtained by exercise testing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6678/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In one series of 128 medically treated patients with a non-ST elevation ACS, an abnormal dipyridamole sestamibi scan performed before hospital discharge was associated with a significant increase in the incidence of a cardiac event at 16 months (69 versus 10 percent in those with a normal scan, relative risk 4.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6678/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the aggregate, the available literature demonstrates the value of SPECT myocardial perfusion imaging to risk stratify patients with NSTEMI in selective stable patients. Our approach to the use of noninvasive stress testing with myocardial perfusion imaging in patients following an acute coronary syndrome treated medically is in accord with the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of patients with unstable",
"    <span class=\"nowrap\">",
"     angina/NSTEMI",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6678/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with unstable angina or a non-ST elevation ACS who are free of ischemia or heart failure for at least 12 to 24 hours should undergo predischarge risk stratification with exercise or pharmacologic stress using current agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , adenosine, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    . The preferred imaging agent is either technetium-99m sestamibi or tetrofosmin. Currently, neither thallium-201 alone nor the dual isotope protocol with",
"    <span class=\"nowrap\">",
"     thallium-201/technetium",
"    </span>",
"    is recommended due to radiation exposure concerns. This approach is preferable to a submaximal exercise test, which underestimates the presence and severity of coronary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with moderate to large or multiple areas of reversible ischemia are usually referred for coronary angiography and, if necessary, revascularization (",
"    <a class=\"graphic graphic_table graphicRef67639 \" href=\"UTD.htm?26/30/27116\">",
"     table 2",
"    </a>",
"    ). Those with no ischemia (either fixed perfusion abnormalities or normal results) on SPECT MPI have an excellent long-term outcome and generally do not require coronary angiography. However, aggressive medical therapy is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15040856\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At present, many patients with non-ST elevation acute coronary syndrome (NSTEACS) are managed with early cardiac catheterization and, if appropriate, revascularization. However, a minority of patients with NSTEACS are at low short-term risk and can be treated medically in the absence of ongoing ischemia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myocardial perfusion imaging studies with both thallium-201 and technetium-99m isotopes have been used to successfully risk stratify patients following NSTEACS. However, current recommendations favor technetium-based agents over thallium-201. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Studies with thallium-201'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Studies with technetium-99m sestamibi'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with unstable angina or a non-ST elevation ACS who are free of ischemia or heart failure for at least 12 to 24 hours should undergo predischarge risk stratification with exercise or pharmacologic technetium-99m sestamibi or tetrofosmin SPECT MPI. Patients with moderate to large or multiple areas of reversible ischemia are usually referred for coronary angiography and, if necessary, revascularization (",
"      <a class=\"graphic graphic_table graphicRef67639 \" href=\"UTD.htm?26/30/27116\">",
"       table 2",
"      </a>",
"      ). Those with no ischemia on the perfusion scan have an excellent long-term outcome and generally do not require coronary angiography. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6678/abstract/1\">",
"      Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6678/abstract/2\">",
"      Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6678/abstract/4\">",
"      Stone PH, Thompson B, Anderson HV, et al. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. JAMA 1996; 275:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6678/abstract/5\">",
"      Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 1995; 26:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6678/abstract/6\">",
"      Madsen JK, Stubgaard M, Utne HE, et al. Prognosis and thallium-201 scintigraphy in patients admitted with chest pain without confirmed acute myocardial infarction. Br Heart J 1988; 59:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6678/abstract/7\">",
"      Brown KA. Prognostic value of thallium-201 myocardial perfusion imaging in patients with unstable angina who respond to medical treatment. J Am Coll Cardiol 1991; 17:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6678/abstract/8\">",
"      Marmur JD, Freeman MR, Langer A, Armstrong PW. Prognosis in medically stabilized unstable angina: early Holter ST-segment monitoring compared with predischarge exercise thallium tomography. Ann Intern Med 1990; 113:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6678/abstract/9\">",
"      Jain D, Thompson B, Wackers FJ, Zaret BL. Relevance of increased lung thallium uptake on stress imaging in patients with unstable angina and non-Q wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI)-IIIB Study. J Am Coll Cardiol 1997; 30:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6678/abstract/10\">",
"      Zhu YY, Chung WS, Botvinick EH, et al. Dipyridamole perfusion scintigraphy: the experience with its application in one hundred seventy patients with known or suspected unstable angina. Am Heart J 1991; 121:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6678/abstract/11\">",
"      Younis LT, Byers S, Shaw L, et al. Prognostic value of intravenous dipyridamole thallium scintigraphy after an acute myocardial ischemic event. Am J Cardiol 1989; 64:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6678/abstract/12\">",
"      Stratmann HG, Younis LT, Wittry MD, et al. Exercise technetium-99m myocardial tomography for the risk stratification of men with medically treated unstable angina pectoris. Am J Cardiol 1995; 76:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6678/abstract/13\">",
"      Stratmann HG, Tamesis BR, Younis LT, et al. Prognostic value of predischarge dipyridamole technetium 99m sestamibi myocardial tomography in medically treated patients with unstable angina. Am Heart J 1995; 130:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6678/abstract/14\">",
"      Brown KA, Heller GV, Landin RS, et al. Early dipyridamole (99m)Tc-sestamibi single photon emission computed tomographic imaging 2 to 4 days after acute myocardial infarction predicts in-hospital and postdischarge cardiac events: comparison with submaximal exercise imaging. Circulation 1999; 100:2060.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5318 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-9DBBEBA25B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_33_6678=[""].join("\n");
var outline_f6_33_6678=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15040856\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STUDIES WITH THALLIUM-201",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Exercise testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dipyridamole thallium imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      STUDIES WITH TECHNETIUM-99M SESTAMIBI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15040856\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5318\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5318|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/60/25549\" title=\"figure 1\">",
"      Thallium defects and outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/19/7487\" title=\"figure 2\">",
"      Lung thallium unstable AP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5318|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/60/7117\" title=\"table 1\">",
"      Risk of death or MI in UA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/30/27116\" title=\"table 2\">",
"      Noninvasive risk stratification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3496?source=related_link\">",
"      Acute rest radionuclide myocardial perfusion imaging for the evaluation of suspected non-ST elevation acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=related_link\">",
"      Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_33_6679="Symptomatic management of nephrotic syndrome in children";
var content_f6_33_6679=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Symptomatic management of nephrotic syndrome in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/33/6679/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/33/6679/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/33/6679/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/33/6679/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/33/6679/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/33/6679/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/33/6679/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nephrotic syndrome (NS) is caused by renal diseases that increase the permeability across the glomerular filtration barrier. It is classically characterized by four clinical features, but the first two are used diagnostically because the last two may not be seen in all patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nephrotic range proteinuria &mdash; Urine protein excretion greater than 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day",
"     </li>",
"     <li>",
"      Hypoalbuminemia &mdash; Serum albumin &lt;3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (30",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"     </li>",
"     <li>",
"      Edema",
"     </li>",
"     <li>",
"      Hyperlipidemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Idiopathic NS is the most common form of NS in children, representing more than 90 percent of cases before 10 years of age and 50 percent after 10 years of age. The majority of children with NS will respond to steroid therapy. However, symptomatic treatment is important in the early course of therapy as response to steroid therapy may take several weeks. Symptomatic treatment also becomes the mainstay of therapy in children who fail to respond to steroids, especially those with genetic mutations that cause their NS.",
"   </p>",
"   <p>",
"    The symptomatic management of nephrotic syndrome in children will be reviewed here. Specific treatment of nephrotic syndrome in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EDEMA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Salt restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Edema is treated by salt restriction because renal retention of sodium is one of two principal mechanisms that leads to edema in the NS. In an already edematous patient, salt restriction alone will not significantly improve edema but can reduce further accumulation of fluid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36008?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\", section on 'Evidence supporting primary renal sodium retention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although diuretics are commonly used in adults with NS, their role in often severely hypoalbuminemic children is less clear. Affected children may be intravascularly volume depleted and aggressive diuresis may lead to further volume depletion, thereby possibly precipitating acute renal failure and increasing the risk of thrombosis in this already susceptible group of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Rarely, diuretics can contribute to severe volume depletion that results in hypovolemic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25974?source=see_link&amp;anchor=H8#H8\">",
"     \"Complications of idiopathic nephrotic syndrome in children\", section on 'Hypovolemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diuretics should only be given in cases of severe edema and only if there is not significant intravascular volume depletion. In a study of 30 children with NS and severe edema, the use of fractional excretion of sodium (FeNa) distinguished patients with volume expansion (FeNa &gt;2 percent) from those with volume contraction (FeNa &lt;2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/4\">",
"     4",
"    </a>",
"    ]. Diuretic therapy alone was used successfully in 10 of 11 patients with FeNa greater than 2 percent. In one patient with an elevated FeNa, albumin was added to diuretic therapy because of a rise in serum creatinine and the development of hyponatremia. The volume contracted group (ie, FeNa &lt;2 percent) also had higher serum renin, aldosterone, and antidiuretic hormone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     Furosemide",
"    </a>",
"    may be given intravenously or orally without albumin, although it is somewhat less effective, it can be useful when given alone. Ongoing oral use of furosemide can still cause hypovolemia and hypokalemia and close monitoring of the patient is required.",
"   </p>",
"   <p>",
"    Other diuretics used in childhood NS include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=see_link\">",
"       Spironolactone",
"      </a>",
"      (5 to 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose) &mdash; Although spironolactone interferes with the sodium retention of the cortical collecting tubule, the theoretical site of enhanced sodium reabsorption in NS, its weak potency limits its usefulness. However, in combination with loop diuretics such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"       furosemide",
"      </a>",
"      , its potassium sparing effect may decrease the risk of hypokalemia.",
"     </li>",
"     <li>",
"      Thiazide diuretic &mdash; Thiazide diuretics, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/50/30501?source=see_link\">",
"       metolazone",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose), in combination with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"       furosemide",
"      </a>",
"      appear to enhance the natriuretic and diuretic effects of furosemide alone &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/5\">",
"       5",
"      </a>",
"      ]. However, this combination of diuretics is associated with hypokalemia.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/58/17317?source=see_link\">",
"       Amiloride",
"      </a>",
"      &mdash; Amiloride is a potassium-sparing diuretic that decreases sodium channel activity of the cortical collecting tubule. Like",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=see_link\">",
"       spironolactone",
"      </a>",
"      , it can be used in combination with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"       furosemide",
"      </a>",
"      to decrease the risk of hypokalemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the potential for serious complications, diuretic management should be supervised by a nephrologist who has expertise in treating children with NS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H339346562\">",
"    <span class=\"h3\">",
"     Furosemide and albumin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with anasarca (generalized and massive edema) may be treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose) in combination with salt-poor albumin (0.5 to 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    infused over four hours). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25974?source=see_link&amp;anchor=H7#H7\">",
"     \"Complications of idiopathic nephrotic syndrome in children\", section on 'Anasarca'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Albumin raises the intravascular oncotic pressure and thereby protects the intravascular compartment against volume contraction. Albumin infusion also increases protein-binding of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    , which improves the rate of delivery to the kidney resulting in increased renal salt excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36008?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective study, albumin and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    therapy in children with NS effectively removed fluid with a mean loss of 0.4 kg (1.2 percent of body weight) per infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the effect is transient and can be associated with complications resulting from increased vascular volume, including hypertension and respiratory distress. As a result, aggressive diuresis with albumin and furosemide therapy should be reserved for patients with anasarca who have respiratory compromise due to ascites",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pleural effusions, severe scrotal edema sufficient to threaten perforation, peritonitis, or severe tissue breakdown [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Other measures, such as salt and fluid restriction, are needed to prevent reaccumulation of fluid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fluid restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is debate on the role of fluid restriction, initial restriction of fluid intake to an equivalent volume of the patient's insensible losses plus",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    urine output will result in stabilizing &nbsp;the patient's weight without further accumulation of edema. In patients with hyponatremia with a serum sodium of 130",
"    <span class=\"nowrap\">",
"     mEq/L,",
"    </span>",
"    fluid restriction is required as fluid accumulation is a result of inappropriate antidiuretic hormone secretion, secondary to intravascular volume depletion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=see_link&amp;anchor=H7#H7\">",
"     \"Maintenance fluid therapy in children\", section on 'Sensible and insensible water loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HYPERCOAGULABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrotic patients with severe hypoalbuminemia are at risk for thromboembolic complications. Preventative measures include mobilization, avoidance of hemoconcentration resulting from hypovolemia, and early treatment of sepsis or volume depletion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25974?source=see_link&amp;anchor=H5#H5\">",
"     \"Complications of idiopathic nephrotic syndrome in children\", section on 'Thromboembolism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=see_link&amp;anchor=H6#H6\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most clinicians do not give prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy initially. However, a few will initially treat high-risk patients with albumin concentration of less than 2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (20",
"    <span class=\"nowrap\">",
"     g/L),",
"    </span>",
"    a fibrinogen level of more than 6",
"    <span class=\"nowrap\">",
"     g/L,",
"    </span>",
"    or an antithrombin III level less than 70 percent of normal. Alternatively, high-risk patients can be treated with low-dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/43/11958?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , although there are no controlled trials that demonstrate their efficacy in thrombus prevention in children with NS.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     Heparin",
"    </a>",
"    is given if thrombi do occur. However, the dose necessary to obtain a therapeutic effect is often greater than normal because of decreased antithrombin III, a cofactor required for heparin activity.",
"   </p>",
"   <p>",
"    In patients with previous thromboembolic complications, we will start treatment anticoagulation therapy if the patient remains nephrotic, which places them at continued risk for thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=see_link&amp;anchor=H16#H16\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\", section on 'Anticoagulation for a thromboembolic event'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bacterial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrotic children are at increased risk of developing infection (eg, peritonitis, pneumonia, and sepsis) due to encapsulated bacteria, in part due to reduced serum concentrations of immunoglobulin, decreased cellular immunity, and the administration of immunosuppressive therapy. The most common agent is streptococcus pneumoniae followed by Escherichia coli. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25974?source=see_link&amp;anchor=H3#H3\">",
"     \"Complications of idiopathic nephrotic syndrome in children\", section on 'Bacterial infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylactic antimicrobials are not recommended, but infections that do occur should be promptly treated. Although antibody response can be blunted, all children with NS should receive 23-valent polysaccharide vaccine (PPSV23) pneumococcal vaccine (if not already immunized). Although immunization is ideally administered when the child is in remission and off of daily corticosteroid therapy, children who received immunization at the onset of their NS while on high-dose daily",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    responded with a 10-fold increase in antibody levels to PPSV23 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/8\">",
"     8",
"    </a>",
"    ]. As a result, in children with idiopathic NS and who are steroid dependent resulting in a high risk for pneumococcal disease, administration of PPSV23 should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link&amp;anchor=H5#H5\">",
"     \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Varicella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with NS who require immunosuppressive therapy are at increased risk for developing varicella. Varicella vaccination has been shown to be effective in children with NS, and should be given to all patients with negative varicella titers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/9\">",
"     9",
"    </a>",
"    ]. It is ideally administered as a two-dose regimen when the child is in remission and on low-dose alternative days or off of corticosteroid therapy.",
"   </p>",
"   <p>",
"    In cases of exposure of patients who are receiving immunosuppressive therapy and do not have immunity to varicella, VariZIG, a",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/47/1781?source=see_link\">",
"     varicella zoster immune globulin",
"    </a>",
"    product, can be administered. VariZIG should be administered within 96 hours of the exposure at a recommended dose of 125",
"    <span class=\"nowrap\">",
"     units/10",
"    </span>",
"    kg body weight, up to a maximum of 625 units (five vials); the minimum dose is 125 units. Patients should be monitored for varicella for 28 days after exposure, since VariZIG may prolong the incubation period. Any patient who receives VariZIG should receive",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    . Vaccine should be given five months after administration of VariZIG.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"     Acyclovir",
"    </a>",
"    , a synthetic nucleoside analog that inhibits replication of human herpesviruses, is effective therapy for primary varicella infection. It should be instituted promptly in any patient who is receiving immunosuppressive therapy and exhibits any sign of varicella infection. Acyclovir has also been used prophylactically in children exposed to varicella while receiving immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OTHER DIETARY MEASURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Caloric intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased caloric consumption as a result of appetite stimulation of corticosteroid therapy can lead to excessive weight gain. Dietary measures that limit excessive caloric consumption, including a low-fat diet, will help children avoid large weight gains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Calcium and vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in bone histology can be seen in patients with NS, primarily due to two processes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss of vitamin D binding protein &mdash; In children with NS, urinary loss of vitamin D binding protein may result in low ionized calcium and 25-OH Vitamin D3 (25-hydroxycholecalciferol) concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prolonged corticosteroid therapy may lead to abnormalities in bone histology [",
"      <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/12\">",
"       12",
"      </a>",
"      ] and, subsequently, osteoporosis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/13\">",
"       13",
"      </a>",
"      ]. However, one study using dual-energy x-ray absorptiometry did not find any difference in spinal or whole body mineral content of glucocorticoid treated children with NS compared to control patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the above, calcium (500",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and vitamin D (2000 to 4000 units) supplements often are prescribed especially when there are documented low calcium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin D concentrations, however there are currently no data that have shown this intervention to be effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     HYPERLIPIDEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent hyperlipidemia is a risk factor for atherosclerosis and may play a role in the progression of chronic renal failure. The lipid abnormalities induced by the NS reverse with remission.",
"   </p>",
"   <p>",
"    The optimal treatment of hyperlipidemia in children with persistent NS is unknown. In children with NS, statin therapy based on limited short-term observational data is effective and safe in reducing total and LDL cholesterol, and triglyceride levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/15\">",
"     15",
"    </a>",
"    ]. Nevertheless, statins should be used with caution until controlled studies are performed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from adults with persistent proteinuria demonstrate the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dietary modification has been shown to have little benefit.",
"     </li>",
"     <li>",
"      The most successful hypolipidemic agents with persistent NS are the statins [",
"      <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. These agents generally produce few side effects and can lower the plasma total and low-density lipoprotein (LDL) cholesterol concentrations by 20 to 45 percent. There is a smaller reduction in triglyceride levels. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=see_link&amp;anchor=H11#H11\">",
"       \"Lipid abnormalities in nephrotic syndrome\", section on 'Statins'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the above evidence as well as data on the benefit of statin therapy in children with familial hypercholesterolemia, we treat children who remain persistently nephrotic and have hyperlipidemia with statin therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Familial hypercholesterolemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=see_link\">",
"     \"Management of pediatric dyslipidemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=see_link&amp;anchor=H894554#H894554\">",
"     \"Management of pediatric dyslipidemia\", section on 'Rationale and criteria for pharmacologic therapy'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    LDL apheresis with steroid therapy has been proposed in patients with hyperlipidemia and refractory nephritic syndrome. In one study involving 11 children, this treatment resulted in complete remission in five and partial remission in two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more complete discussion on the treatment of hyperlipidemia in adults with NS is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=see_link&amp;anchor=H8#H8\">",
"     \"Lipid abnormalities in nephrotic syndrome\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     HYPERTENSION AND ACE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with NS and persistent hypertension are more likely to have chronic kidney disease with poor outcome. As a result, in patients with hypertension, angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) are the preferred anti-hypertensive agents because of their potential additive antiproteinuric benefit and ability to slow progression of renal impairment. The maximal anti-proteinuric effect is observed after four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/19\">",
"     19",
"    </a>",
"    ]; the antiproteinuric effect can be increased by low salt diet",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diuretics [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6679/abstract/20\">",
"     20",
"    </a>",
"    ]. ACE inhibitor and ARBs should be terminated if hyperkalemia cannot be controlled or the plasma creatinine concentration increases more than 30 percent above the baseline value. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other antihypertensive agents that have been used in children with NS include beta-blockers and calcium channel blockers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of hypertension in children and adolescents\", section on 'Pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of children with nephrotic syndrome (NS) will respond to steroid therapy. However, symptomatic management is important in the early course of therapy as response to steroid therapy may take several weeks and it is the mainstay of therapy in children who fail to respond to steroids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptomatic management includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with persistent proteinuria, salt and fluid restriction, and diuretics (alone or in combination with salt-pore albumin) are used to control edema. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Edema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preventive measures to avoid thromboembolic complication include mobilization, avoidance of hemoconcentration resulting from hypovolemia, and early treatment of sepsis or volume depletion. We suggest not using routine prophylactic anticoagulation therapy in children with NS (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hypercoagulability'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=see_link&amp;anchor=H14#H14\">",
"       \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\", section on 'Prophylactic anticoagulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with NS are at increased risk for both bacterial and viral infections. We recommend that these children receive 23-valent polysaccharide vaccine (PPSV23) pneumococcal and varicella vaccines (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal treatment of hyperlipidemia in children with persistent NS is unknown. Based upon data from adults with NS and hyperlipidemia, we suggest administering statin therapy to children who remain persistently nephrotic and have hyperlipidemia (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Hyperlipidemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=see_link&amp;anchor=H8#H8\">",
"       \"Lipid abnormalities in nephrotic syndrome\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with NS and persistent hypertension are more likely to have chronic kidney disease with poor outcome. In these patients, we suggest angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) be used to treat their hypertension because of their potential additive antiproteinuric benefit and ability to slow progression of renal impairment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Hypertension and ACE inhibitors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/1\">",
"      Hogg RJ, Portman RJ, Milliner D, et al. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 2000; 105:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/2\">",
"      Sullivan MJ 3rd, Hough DR, Agodoa LC. Peripheral arterial thrombosis due to the nephrotic syndrome: the clinical spectrum. South Med J 1983; 76:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/3\">",
"      YAMAUCHI H, HOPPER J Jr. HYPOVOLEMIC SHOCK AND HYPOTENSION AS A COMPLICATION IN THE NEPHROTIC SYNDROME. REPORT OF TEN CASES. Ann Intern Med 1964; 60:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/4\">",
"      Kapur G, Valentini RP, Imam AA, Mattoo TK. Treatment of severe edema in children with nephrotic syndrome with diuretics alone--a prospective study. Clin J Am Soc Nephrol 2009; 4:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/5\">",
"      Garin EH. A comparison of combinations of diuretics in nephrotic edema. Am J Dis Child 1987; 141:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/6\">",
"      Haws RM, Baum M. Efficacy of albumin and diuretic therapy in children with nephrotic syndrome. Pediatrics 1993; 91:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/7\">",
"      Welch TR, Gianis J, Sheldon CA. Perforation of the scrotum complicating nephrotic syndrome. J Pediatr 1988; 113:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/8\">",
"      Ulinski T, Leroy S, Dubrel M, et al. High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone. Pediatr Nephrol 2008; 23:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/9\">",
"      Furth SL, Arbus GS, Hogg R, et al. Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group. J Pediatr 2003; 142:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/10\">",
"      Goldstein SL, Somers MJ, Lande MB, et al. Acyclovir prophylaxis of varicella in children with renal disease receiving steroids. Pediatr Nephrol 2000; 14:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/11\">",
"      Weng FL, Shults J, Herskovitz RM, et al. Vitamin D insufficiency in steroid-sensitive nephrotic syndrome in remission. Pediatr Nephrol 2005; 20:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/12\">",
"      Freundlich M, Jofe M, Goodman WG, Salusky IB. Bone histology in steroid-treated children with non-azotemic nephrotic syndrome. Pediatr Nephrol 2004; 19:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/13\">",
"      Gulati S, Godbole M, Singh U, et al. Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease? Am J Kidney Dis 2003; 41:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/14\">",
"      Leonard MB, Feldman HI, Shults J, et al. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 2004; 351:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/15\">",
"      Prescott WA Jr, Streetman DA, Streetman DS. The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome. Ann Pharmacother 2004; 38:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/16\">",
"      Coleman JE, Watson AR. Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatr Nephrol 1996; 10:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/17\">",
"      Sanjad SA, al-Abbad A, al-Shorafa S. Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. J Pediatr 1997; 130:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/18\">",
"      Hattori M, Chikamoto H, Akioka Y, et al. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 2003; 42:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/19\">",
"      Gansevoort RT, de Zeeuw D, de Jong PE. Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition. Kidney Int 1993; 44:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6679/abstract/20\">",
"      Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36:272.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6113 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-194.187.108.93-5353394DC6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_33_6679=[""].join("\n");
var outline_f6_33_6679=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EDEMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Salt restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H339346562\">",
"      - Furosemide and albumin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fluid restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HYPERCOAGULABILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bacterial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Varicella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OTHER DIETARY MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Caloric intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Calcium and vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HYPERLIPIDEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HYPERTENSION AND ACE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25974?source=related_link\">",
"      Complications of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=related_link\">",
"      Management of pediatric dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36008?source=related_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=related_link\">",
"      Treatment of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_33_6680="Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis";
var content_f6_33_6680=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/33/6680/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/33/6680/contributors\">",
"     Laura C Collins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/33/6680/contributors\">",
"     Christine Laronga, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/33/6680/contributors\">",
"     Julia S Wong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/33/6680/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/33/6680/contributors\">",
"     Lori J Pierce, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/33/6680/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/33/6680/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/33/6680/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/33/6680/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/33/6680/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H556311110\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of neoplastic lesions confined to the breast ducts and lobules that differ in histologic appearance and biological potential. The diagnosis has increased dramatically with the introduction of breast cancer screening mammography [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/1\">",
"     1",
"    </a>",
"    ]. The goal of therapy of DCIS is to prevent the occurrence of an invasive breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H556311117\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of DCIS markedly increased from 5.8 per 100,000 women in the 1970s to 32.5 per 100,000 women in 2004 and then reached a plateau [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Approximately 25 percent of breast cancers diagnosed in the United States are DCIS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/4\">",
"     4",
"    </a>",
"    ]. This increase is attributed primarily to the utilization of breast cancer screening by mammography.",
"   </p>",
"   <p>",
"    DCIS is less common than invasive breast cancer, but, like invasive breast cancer, the risk increases with age. DCIS is uncommon in women younger than 30. The rate of DCIS increases with age from 0.6 per 1000 screening examinations in women aged 40 to 49 years to 1.3 per 1000 screening examinations in women aged 70 to 84 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Risk of development of metastases",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    death in a patient diagnosed with pure DCIS is rare (&lt;1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H556311124\">",
"    <span class=\"h2\">",
"     Mammographic screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The widespread adoption of mammographic screening in the United States, Europe, and other high-income countries dramatically increased the number of cases of DCIS. More than 90 percent of all cases of DCIS are detected only on imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H556311131\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors for DCIS and invasive breast cancer are similar, and include family history of breast cancer, increased breast density, obesity, and nulliparity or late age at first birth [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. DCIS is also a component of the inherited breast-ovarian cancer syndrome defined by deleterious mutations in BRCA1 and BRCA2 genes; mutation rates are similar to those for invasive breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to invasive breast cancer, DCIS tends to occur at a younger age in women with inherited BRCA mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/13\">",
"     13",
"    </a>",
"    ]. An association between long-term use of postmenopausal hormone replacement therapy and DCIS, unlike invasive breast cancer, has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/11,14,15\">",
"     11,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"       \"Factors that modify breast cancer risk in women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"       \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"       \"Postmenopausal hormone therapy: Benefits and risks\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H556311145\">",
"    <span class=\"h2\">",
"     Chemoprevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Surgical Breast and Bowel Project (NSABP-P2) randomized trial provided evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    decreases the risk of DCIS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=see_link\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100032938\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24099782\">",
"    <span class=\"h2\">",
"     Patient presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the era of screening mammography, there are no specific clinical manifestations for patients with DCIS. Most patients with an abnormal mammogram suggestive of DCIS will present with no breast-related symptoms or findings on physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Prior to the use of widespread screening mammograms, DCIS presented as a palpable mass, nipple discharge, or Paget&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=see_link\">",
"     \"Nipple discharge\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=see_link\">",
"     \"Paget disease of the breast\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100032954\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100033227\">",
"    <span class=\"h3\">",
"     Mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ninety percent of women with DCIS have microcalcifications on mammography [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/19\">",
"     19",
"    </a>",
"    ] and DCIS accounts for 80 percent of all breast cancers presenting with calcifications [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/20\">",
"     20",
"    </a>",
"    ]. Less common findings include a mass or other soft tissue change [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some mammographic patterns of microcalcifications are highly suggestive of DCIS. Linear branching or segmental types of pleomorphic microcalcifications are frequently associated with high nuclear grade, comedo type lesions, while fine, granular calcifications are primarily associated with low grade, micropapillary or cribriform lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/20\">",
"     20",
"    </a>",
"    ]. However, most patients diagnosed with DCIS have microcalcifications of indeterminate morphology. The advent of digital mammography has led to improved detection of microcalcifications and thus increased the number of women diagnosed with DCIS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/22\">",
"     22",
"    </a>",
"    ]. The recall rate and numbers of short-term follow-ups have also increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mammography often underestimates the extent of DCIS and the number of tumor foci in instances of multifocal disease. This underestimation increases with increasing tumor size. High-grade lesions tend to be continuous but over half of low to intermediate grade lesions are multifocal, with interfoci gaps up to 1 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/19,20,23\">",
"     19,20,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All patients with suspected DCIS should have a diagnostic bilateral mammogram with magnification views to assess the morphology and full extent of any calcifications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100033269\">",
"    <span class=\"h3\">",
"     Role of magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) has high sensitivity but low specificity in the imaging of breast cancer. Its optimal utility in evaluation of DCIS is unclear, but may be helpful to determine the extent of DCIS, identify multicentric disease and synchronous disease in the contralateral breast [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. While highly sensitive, MRI also fails to identify some mammographically detected occult foci of DCIS (false-negatives) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Neither technique is fail-safe.",
"   </p>",
"   <p>",
"    MRI estimates of size of DCIS correlates only moderately well with the pathologic evaluation. Like mammography, MRI frequently underestimates the size of a DCIS lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Size is also overestimated in up to 25 percent of cases, particularly if the MRI findings are heterogeneous [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/32\">",
"     32",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    MRI appears to be no better than mammography for distinguishing DCIS from benign, atypical proliferative lesions (false positives), or microinvasion, but advanced technologies such as dynamic contrast enhanced magnetic resonance, magnetic resonance spectroscopy, and magnetic resonance mammography may improve this capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/27,32-34\">",
"     27,32-34",
"    </a>",
"    ]. At present, MRI is not routinely indicated in the evaluation of newly diagnosed DCIS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\", section on 'Breast MRI'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23002?source=see_link\">",
"     \"MRI of the breast and emerging technologies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100032985\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of DCIS is confirmed by a breast biopsy, such as a core or excisional biopsy, typically for an abnormal lesion detected by a screening mammogram or breast MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100033001\">",
"    <span class=\"h2\">",
"     Pathologic diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;DCIS is characterized by proliferation of presumably malignant epithelial cells within the mammary ductal system, with no evidence of invasion into the surrounding stroma on routine light microscopic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/3\">",
"     3",
"    </a>",
"    ]. DCIS is categorized by the size, the nuclear grade, the presence and extent of comedo necrosis, and to a lesser extent, the architectural pattern. A discussion of the pathologic criteria for DCIS is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16040?source=see_link&amp;anchor=H1220079795#H1220079795\">",
"     \"Pathology of breast cancer\", section on 'Ductal carcinoma in situ'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064112\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abnormal lesion detected by a mammogram or breast MRI can be assessed by a core tissue sampling, or as an excisional or incisional biopsy, depending upon the patient&rsquo;s ability to conform to the technical rigors of the stereotactic procedure, size of the breast, and location of the lesion. Fine needle aspiration, which provides a sampling of cells rather than tissue, is inadequate to distinguish between invasive and in situ disease. Breast biopsy techniques are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064173\">",
"    <span class=\"h2\">",
"     Core biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A core biopsy performed under stereotactic guidance is preferred for evaluation of mammographically or MRI detected microcalcification clusters [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Ultrasound guided biopsies can be performed for evaluation of a palpable or nonpalpable mass with or without calcification. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H4#H4\">",
"     \"Breast biopsy\", section on 'Core needle biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following a core biopsy, approximately 20 to 25 percent of lesions histologically interpreted as atypical ductal hyperplasia are upgraded to DCIS or invasive cancer at the time of a surgical excision, while approximately 10 to 20 percent of lesions interpreted as DCIS on a core biopsy are upgraded to invasive cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vacuum-assisted biopsy (VAB) techniques obtain a greater volume of tissue sampling and have lower false negative rates compared with non-VAB approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/36,40\">",
"     36,40",
"    </a>",
"    ]. VAB is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H5#H5\">",
"     \"Breast biopsy\", section on 'Vacuum-assisted biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most, but not all, patients with microcalcifications are candidates for stereotactic core biopsy. The thickness of the breast must be adequate, and abnormalities just beneath the skin or in deep posterior locations (adjacent to the chest wall) may be technically inaccessible. In addition, patients who are unable to lie prone are not suitable candidates for this approach. Upright stereotactic tables are an option but not always available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064180\">",
"    <span class=\"h2\">",
"     Wire localization and excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are not candidates for stereotactic procedures, the alternative is the wire localization and excisional biopsy. In general, an incisional biopsy is reserved for lesions &gt;5 cm, depending upon the size of the breast. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H9#H9\">",
"     \"Breast biopsy\", section on 'Wire localization breast biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100032970\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100033965\">",
"    <span class=\"h2\">",
"     Microinvasive carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most important goals in the histologic examination of DCIS is the identification of minute foci of stromal invasion, also termed microinvasion. If microinvasive disease is found, the management recommendations are changed accordingly. The management of microinvasive disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/14998?source=see_link\">",
"     \"Microinvasive breast carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100033991\">",
"    <span class=\"h2\">",
"     Atypical ductal hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical ductal hyperplasia (ADH) is characterized by a proliferation of uniform epithelial cells with monomorphic round nuclei filling part, but not all, of the involved duct. ADH shares some of the cytologic and architectural features of low-grade ductal carcinoma in situ (DCIS) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=see_link&amp;anchor=H20980336#H20980336\">",
"     \"Atypia and lobular carcinoma in situ: High risk lesions of the breast\", section on 'Atypical hyperplasia (AH)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100034972\">",
"    <span class=\"h2\">",
"     Lobular carcinoma in situ",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lobular carcinoma in situ (LCIS) is a noninvasive lesion that arises from the lobules and terminal ducts of the breast. LCIS differs from DCIS with regard to radiologic features, morphology, biologic behavior, and anatomic distribution in the breast. LCIS almost always represents an incidental finding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=see_link&amp;anchor=H20980309#H20980309\">",
"     \"Atypia and lobular carcinoma in situ: High risk lesions of the breast\", section on 'Lobular carcinoma in situ'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100032993\">",
"    <span class=\"h1\">",
"     POSTDIAGNOSTIC EVALUATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100034633\">",
"    <span class=\"h2\">",
"     TNM staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the TNM staging system developed and maintained by the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    ), DCIS is designated as Tis (DCIS) and stage 0, as it is confined within the ducts (TisN0M0) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100034640\">",
"    <span class=\"h2\">",
"     Role of sentinel node excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sentinel lymph node biopsy (SLNB) is not indicated in the evaluation of the patient with DCIS undergoing breast conserving surgery (BCS), because the axillary nodes are rarely positive for metastatic disease, even with extensive multi-focal high grade DCIS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Axillary lymph node metastases are present in fewer than 5 percent of patients with a final diagnosis of DCIS (ie, after surgical excision) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/3,46-48\">",
"     3,46-48",
"    </a>",
"    ]. In the event that an invasive cancer is identified after BCS is performed, a SLNB is technically feasible and can be performed as a staged procedure.",
"   </p>",
"   <p>",
"    The evaluation of the axillary nodes by SLN biopsy should be considered for patients undergoing mastectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. This is because 10 to 20 percent of patients initially diagnosed with DCIS extensive enough to require mastectomy have occult invasive breast cancer identified at surgery, and SLNB is not feasible after mastectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/36,50,51\">",
"     36,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sentinel lymph node biopsy is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20296?source=see_link\">",
"     \"Sentinel lymph node biopsy in breast cancer: Techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100034474\">",
"    <span class=\"h2\">",
"     Risk assessment for hereditary breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of risk for hereditary breast cancer (eg,",
"    <span class=\"nowrap\">",
"     BRCA1/BRCA2)",
"    </span>",
"    is made following a diagnosis of invasive breast cancer and DCIS. If the patient is at high risk (greater than 10 percent chance) for carrying a deleterious mutation as determined by published risk assessment tools, or wishes to undergo genetic testing for personal interest, a referral for genetic counseling is appropriate, particularly those with a family history of ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/33/6680/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064311\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local and systemic treatment options for patients diagnosed with DCIS are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37561?source=see_link\">",
"     \"Ductal carcinoma in situ: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18125558\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37561?source=see_link\">",
"     \"Ductal carcinoma in situ: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/26/3492?source=see_link\">",
"       \"Patient information: Ductal carcinoma in situ (DCIS) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H556311236\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of neoplastic lesions confined to the breast ducts and lobules. Its diagnosis has increased dramatically with the introduction of breast cancer screening mammography. (See",
"      <a class=\"local\" href=\"#H556311110\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of DCIS increases with age. It is uncommon in women younger than 30 and is as high as 88 per 100,000 in women aged 50 to 64 years. (See",
"      <a class=\"local\" href=\"#H556311117\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of cancer-related death in women with DCIS is low, estimated at 1.9 percent within 10 years. (See",
"      <a class=\"local\" href=\"#H556311117\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of DCIS are detected only on imaging studies (most commonly by the presence of mammographic microcalcifications). (See",
"      <a class=\"local\" href=\"#H100033227\">",
"       'Mammography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Percutaneous core biopsy under stereotactic or ultrasound guidance is preferred in the evaluation of mammographically-identified microcalcifications. Fine needle aspiration biopsy is inadequate for the diagnosis of DCIS, as it cannot distinguish between invasive and in situ disease. In technically challenging stereotactic cases, wire localization biopsy may be preferable. (See",
"      <a class=\"local\" href=\"#H1064112\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sentinel lymph node biopsy (SLNB) is not indicated in the evaluation of patients undergoing breast conserving management of DCIS. The axillary lymph nodes are rarely involved, even with extensive multifocal high-grade disease. Evaluation of the axillary nodes by SLN biopsy is indicated for patients undergoing mastectomy because occult invasive breast cancer may be identified at surgery, and SLNB is not feasible after mastectomy. (See",
"      <a class=\"local\" href=\"#H100032993\">",
"       'Postdiagnostic evaluations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ (DCIS). file://consensus.nih.gov/2009/dcis.htm (Accessed on April 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/2\">",
"      Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 2008; 100:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/3\">",
"      Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010; 102:170.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf (Accessed on October 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/5\">",
"      Kerlikowske K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010; 2010:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/6\">",
"      Roses RE, Arun BK, Lari SA, et al. Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol 2011; 18:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/7\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/8\">",
"      Schwartz GF, Solin LJ, Olivotto IA, et al. Consensus Conference on the Treatment of In Situ Ductal Carcinoma of the Breast, April 22-25, 1999. Cancer 2000; 88:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/9\">",
"      Kerlikowske K, Barclay J, Grady D, et al. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst 1997; 89:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/10\">",
"      Claus EB, Stowe M, Carter D. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Breast Cancer Res Treat 2003; 78:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/11\">",
"      Claus EB, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 2001; 93:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/12\">",
"      Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 2005; 293:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/13\">",
"      Hwang ES, McLennan JL, Moore DH, et al. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol 2007; 25:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/14\">",
"      Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 1999; 281:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/15\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/16\">",
"      Richards T, Hunt A, Courtney S, Umeh H. Nipple discharge: a sign of breast cancer? Ann R Coll Surg Engl 2007; 89:124.",
"     </a>",
"    </li>",
"    <li>",
"     Ernster VL. Epidemiology and natural history of ductal carcinoma in situ. In: Silverstein MJ, ed. Ductal Carcinoma In Situ of the Breast. Baltimore, Md: Williams &amp; Wilkins; 1997:23-33.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/18\">",
"      G&uuml;nhan-Bilgen I, Oktay A. Paget's disease of the breast: clinical, mammographic, sonographic and pathologic findings in 52 cases. Eur J Radiol 2006; 60:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/19\">",
"      Dershaw DD, Abramson A, Kinne DW. Ductal carcinoma in situ: mammographic findings and clinical implications. Radiology 1989; 170:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/20\">",
"      Holland R, Hendriks JH, Vebeek AL, et al. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet 1990; 335:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/21\">",
"      Ikeda DM, Andersson I. Ductal carcinoma in situ: atypical mammographic appearances. Radiology 1989; 172:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/22\">",
"      Mellado M, Osa AM, Murillo A, et al. Impact of digital mammography in the detection and management of microcalcifications. Radiologia 2013; 55:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/23\">",
"      Kuerer HM, Albarracin CT, Yang WT, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol 2009; 27:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/24\">",
"      Hwang ES, Kinkel K, Esserman LJ, et al. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol 2003; 10:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/25\">",
"      Menell JH, Morris EA, Dershaw DD, et al. Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging. Breast J 2005; 11:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/26\">",
"      Lee SG, Orel SG, Woo IJ, et al. MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. Radiology 2003; 226:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/27\">",
"      Kuhl CK, Schrading S, Bieling HB, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 2007; 370:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/28\">",
"      Riedl CC, Ponhold L, Fl&ouml;ry D, et al. Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer. Clin Cancer Res 2007; 13:6144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/29\">",
"      Orel SG, Mendonca MH, Reynolds C, et al. MR imaging of ductal carcinoma in situ. Radiology 1997; 202:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/30\">",
"      Kropcho LC, Steen ST, Chung AP, et al. Preoperative breast MRI in the surgical treatment of ductal carcinoma in situ. Breast J 2012; 18:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/31\">",
"      Vanderwalde LH, Dang CM, Bresee C, Phillips EH. Discordance between pathologic and radiologic tumor size on breast MRI may contribute to increased re-excision rates. Am Surg 2011; 77:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/32\">",
"      Kneeshaw PJ, Lowry M, Manton D, et al. Differentiation of benign from malignant breast disease associated with screening detected microcalcifications using dynamic contrast enhanced magnetic resonance imaging. Breast 2006; 15:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/33\">",
"      Goto M, Yuen S, Akazawa K, et al. The role of breast MR imaging in pre-operative determination of invasive disease for ductal carcinoma in situ diagnosed by needle biopsy. Eur Radiol 2012; 22:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/34\">",
"      Esserman LJ, Kumar AS, Herrera AF, et al. Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol 2006; 24:4603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/35\">",
"      Liberman L, Dershaw DD, Rosen PP, et al. Stereotaxic 14-gauge breast biopsy: how many core biopsy specimens are needed? Radiology 1994; 192:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/36\">",
"      Burbank F. Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: improved accuracy with directional, vacuum-assisted biopsy. Radiology 1997; 202:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/37\">",
"      White RR, Halperin TJ, Olson JA Jr, et al. Impact of core-needle breast biopsy on the surgical management of mammographic abnormalities. Ann Surg 2001; 233:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/38\">",
"      Darvishian F, Singh B, Simsir A, et al. Atypia on breast core needle biopsies: reproducibility and significance. Ann Clin Lab Sci 2009; 39:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/39\">",
"      Eby PR, Ochsner JE, DeMartini WB, et al. Frequency and upgrade rates of atypical ductal hyperplasia diagnosed at stereotactic vacuum-assisted breast biopsy: 9-versus 11-gauge. AJR Am J Roentgenol 2009; 192:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/40\">",
"      Irfan K, Brem RF. Surgical and mammographic follow-up of papillary lesions and atypical lobular hyperplasia diagnosed with stereotactic vacuum-assisted biopsy. Breast J 2002; 8:230.",
"     </a>",
"    </li>",
"    <li>",
"     Schnitt SJ, Collins LC. Pathology of benign breast disorders. In: Breast Diseases, 4th edition, Harris JR.  (Ed), Lippincott Williams and Wilkins, Philadelphia 2010. p.69.",
"    </li>",
"    <li>",
"     (American Joint Committee on Cancer) Cancer Staging Manual, 7th edition, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/43\">",
"      Intra M, Rotmensz N, Veronesi P, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years. Ann Surg 2008; 247:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/44\">",
"      Schwartz GF, Giuliano AE, Veronesi U, Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 2002; 94:2542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/45\">",
"      Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer 1982; 50:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/46\">",
"      Silverstein MJ, Waisman JR, Gamagami P, et al. Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 1990; 66:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/47\">",
"      Intra M, Veronesi P, Mazzarol G, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg 2003; 138:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/48\">",
"      Julian TB, Land SR, Fourchotte V, et al. Is sentinel node biopsy necessary in conservatively treated DCIS? Ann Surg Oncol 2007; 14:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/49\">",
"      Dominguez FJ, Golshan M, Black DM, et al. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ. Ann Surg Oncol 2008; 15:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/50\">",
"      Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23:7703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/51\">",
"      Cox CE, Nguyen K, Gray RJ, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001; 67:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/33/6680/abstract/52\">",
"      Bayraktar S, Elsayegh N, Gutierrez Barrera AM, et al. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer 2012; 118:1515.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14219 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-E2D9733EE5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_33_6680=[""].join("\n");
var outline_f6_33_6680=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H556311236\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H556311110\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H556311117\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H556311124\">",
"      Mammographic screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H556311131\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H556311145\">",
"      Chemoprevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100032938\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24099782\">",
"      Patient presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100032954\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H100033227\">",
"      - Mammography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H100033269\">",
"      - Role of magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100032985\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100033001\">",
"      Pathologic diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1064112\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1064173\">",
"      Core biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1064180\">",
"      Wire localization and excision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100032970\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100033965\">",
"      Microinvasive carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100033991\">",
"      Atypical ductal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100034972\">",
"      Lobular carcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100032993\">",
"      POSTDIAGNOSTIC EVALUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100034633\">",
"      TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100034640\">",
"      Role of sentinel node excision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100034474\">",
"      Risk assessment for hereditary breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1064311\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18125558\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H556311236\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14219\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14219|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/14/29920\" title=\"table 1\">",
"      TNM stage breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=related_link\">",
"      Atypia and lobular carcinoma in situ: High risk lesions of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=related_link\">",
"      Breast biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=related_link\">",
"      Breast imaging: Mammography and ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=related_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37561?source=related_link\">",
"      Ductal carcinoma in situ: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23002?source=related_link\">",
"      MRI of the breast and emerging technologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/14998?source=related_link\">",
"      Microinvasive breast carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=related_link\">",
"      Nipple discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=related_link\">",
"      Paget disease of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16040?source=related_link\">",
"      Pathology of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/26/3492?source=related_link\">",
"      Patient information: Ductal carcinoma in situ (DCIS) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=related_link\">",
"      Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20296?source=related_link\">",
"      Sentinel lymph node biopsy in breast cancer: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_33_6681="Scleroderma glomerulus light";
var content_f6_33_6681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light microscopy of glomerulus in scleroderma renal crisis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph showing fibrinoid necrosis in the preglomerular afferent arteriole (arrow) in scleroderma renal crisis. The normal muscle layer of the media has been replaced by the fibrinoid material.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_33_6681=[""].join("\n");
var outline_f6_33_6681=null;
var title_f6_33_6682="Examination of the hand for malrotation";
var content_f6_33_6682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56239%7ESURG%2F69061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56239%7ESURG%2F69061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examination of the hand for malrotation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Assessment of rotational deformity after a hand fracture can be accomplished by observing the orientation of the fingernails to assess rotatory displacement. Normally, all fingers are directed toward the scaphoid and there should be no overlap or rotation as shown here.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malrotation due to metacarpal fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 576px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJAAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCyi/Mp2SIQTuA6ketI8b+W+1JSSOD6U8u6zKSZPL2jcGBP400zHa+95N5+7g4H5VsfPaCESGONA0jEHa3HTNOQlZWBLqh6Bhnn09qUllaMmYqxHzsq9/enRyMryq0ilf4C55zTENdpSilJd7K3Kkdsdan+cOUCRNn5ySc5qN5yEicmNwWO4BefrSlgszIIdwxu5bHXmiwXGlo3RpBbtwwDBenvSx43wrIjx5HyspzTVCmInEozwQM8+9ToYw8ex3jkHCeYBz3poQxzFtmBkkLNwdy8cHnNOY58pBJFEF5X3XPNJ5iESEXCnzPlxjpUnlbjBsjiJjG3B7+/NMkaFIkmkkRGEoxuU8VFIjpbjETQyBsDblhj+vFLHuVrgbGxKOkfQU4K6LC6s4I++HPBH+NMBXdPtTGOYiNuh24HSo9zSWuSIi5YLz3B9qd5jlygaMqASoUdBSljIqu8KDfwVJxjHpVEMY+WnVF2xORkMucDA5zUMYSWNsTPh8kK/GfpVhgDK6MSjKucJyCOwFQ4EqFY5Mnkqrrgj6UAiZI/NZC0TFvujBP6imwsY15YB85UyA5UCnpFNK6uYpN4Gdmeg6U0PKqbQAGB+YsOcelAySLfLJCmxJMjAZBgipQyBN0kbRIp+c56+hpmfNmCbEB25DRZ7UwOpjyyyIHOD6ZqkS3YnZgJGAklEqLt5Bxg0x48xKgnTYCXyv8AEO9PkkUks07eYflYdqa4VEjUMg2dBjrTRIzY0iOcI4k4YkcZHrTZECCDdGIwmGJTBz7U7yg0BCoG3fPndxQh8i73GJ1CgAhSGGccZpkiyMS8oMrhiM428c+1Md28lCY4t7/K2W6+lIryruImbeGwA68E+9SOv7xEVYSWAJ3Pk9KaQ7lfcRLOJox8pyCvT6e1SrOqrDH5TKXyOGyPaoseZFLIY2OwgYQ9c04gK0cW2WJmXchPOfeqJvYe0kYDO3mEgYdsZAOcflT2dMxq0saqDlBgc5qP7RHtO6SXaxCncOKlygI+eMeXkYYDhaQyMp5pmYKjBwAWLY/lUbL8qF49uxhkRkAn2pxiAjaMpG28huCQKVYmS4jkUFeNvynhjjvQASKWWbMcihzlCW+6aj38RnzZAcbW2jrz1pCknljAmjfeRknOAPb0qSVsu2yZlUr8pEeKLCuOSfy0mLSqXRhtB5OD1oVXLKJdhVl7ELtqIOY4FI8vzfutnnp7VI7ySGTKxuI1Db1+X8KB3I9xCltkLjcBhOpHtTiirI6eSA4Bb5m9uelIkjIU8yJCkjYATkgmo/NMYLLAQI+vzjJHr9fagQjPEYYyVmCyngdtw9amGwFnDSRvHwynJYA1GojO1Ssz5+dVwcL7c0u6Joy/mugf5So5JbPp6UB5jHVCEi/ejPKmQcE5602KWMu5E4y+AQQRmpNymRisjCROoYYwPWo8LLH5fnJIXOQCMGgZZUshVHkjXaOB/wDWpGjcxOu2Mq3O4nr64qIsd5YmLc64C+napUiDGNCsKonzZZsZH+eKhjEMbNIWWIMGXb8rcUu1k8tmQ5U/PsbnnpTnhG19qZyQ4VW+UCnFFEjbQVLDChG4Y+9IqxE0b7GJVw24gE8kU9TvJDtIwK5Ue9GPLjjJSVTjLEHNIwb523TKwbCAnt7jvSARZjviDStuJIJC9PrUnnNtdjIjlHwpblsHrT3kYnCyYUJncq45/Gm+YTFCHMW88H5c4x60i0SHc5ZX2Mqpu3kBenagBndB5cbF1JAXsPWmFgVLyIrhWwzdN/4U/bmR8xDeoDZQ8Aemf50AMBXYAYPYkHO4+lQyqI/mdJBgFSxPA9OKnby2CRrFglSVCtnP1qIlRtDRSKZGAZjzz9KQyvGQLhULMUI+bf29xUXz+U58w5XoCuMkd6sQ5a5AaUGMr95/WmiR3ifLhyGwBt6/jWRoxyyMCCHUKwG4AZ5pUc/vh8m5PmRicZ/Ch1dLmMK8QDKCQRkZ96NxaOSSSNZGTnPQU2IVm4iZkjdGJGFHIPrThGoZ4xbsHUHJLY96aZAoi3QqqN0KnOM05o1aWQPHcFkBDEnr70WAjzF9mGTIFb5NoJO01OpUzDZId6qCA6YpgkjMSDzyImztGOff6VJn9+ZI5d20YG7qOOaYDTtdWCTxEORx0p3ku7xkRRtgbduSOO3WmtAWhZcxSqx6DggUskJldP3DgEBTh/SmS0JGrJDMMMjMfkAGQMdxSySyebCvmFlcYbfxj6UiyNHA6NKyvuyuUzx3pw3STQrlZVYYJxg49PaqQmNdmG5QsB2ggNnJ/wD102UDCt5R3HDYzjaR6etOy6rK5jiO3rg9Rnj8aGVWePzIWO4BlwMbfamSyM7SZ8yGNkGHUjNN+WeGELMjEA4A4bIpWZEEoD7RnbJnqDSskbSwuJFk2fP8vUD0oEgKt9oeUib51yNpJwaTdII0wymXkOWPPsDSF3jaU7pAx5Bz3609MmSIBImLgM25uSaBsGI82QY8tkBJMTEhx6CnqI5SsYaRVJ3KJB0P+NRoyr5pB8lQ2yVfXPTFSx7G2qsgkZOeRj8qpEslOFZyZY8SjGPQ+1NxiRWKopUbTznJ9aR42kikBZCJRkBRyO/FR+U2XJjz8uBk9D61RLDyiI0iSNiFfu3rS/6qW4ABQycdNwB9aXcGS23ecwRcNzjNQAsonG8bwRszyQKBDpJHCKyzsx3YKuuCeMZ9jUrhhO6qsTKASCx9uaAzO6oxik3j+7gg59aagwk5ESAIMZZsZGaYIiQ74N5ilw3ylc4/H3qWOQNKwBkiliHVvTvTMqWi2iclsHGM4P0NM85VV2yyFTtYd8elMT8h42MgXztxJ3BG43Ht9am2q7s22AOy7CuOVNRbVlMe1ll2fMFI5P8A9b3pJYlZXCrEPM5G3rmmw6EjWxCRIIxtXoN5/T+VMjXbJKQZFLqQqA5C+9Mcb3j/AHTYVMYc55HXNATbbtGgkBzvyB0FAh7LseBmaRY8/NvG7g01pHRJsStuzhVC9RmkIaO55aRUK4w5J+akVpGt1cTbirchlAyPrRYdyVmaOSLDQbXUZL8jPvTCSqM7LCWBHBOAQe+PSmSyFZmjTywoUsCBu6j+dKu7yImKR/P97eegz/k0WELGwddjIpXbuBjbBBHbnvSZ2Kp8nCucEBst+VK7NmUtEpeJsgpwGpQyA7HjKMw+Qrzjv+dAxGB+Yt5jGMbS340Oy4VVaQljuVVXrTRJCAzESgE7SxP9KJnw6ku7SRDog6CkMQurF5DMdxO19wGR6UkZSRo8FZSnOGGCfc00yJtjHmld3zA7c5Pf6UAoQZQ0cqkeWzPwR7YoBMmSIbHBWFtxzlTyaQQbp0PloBtxh3yc+wpkCoyosawsyjcoXg/TNOKgl8iNixwuGO760mMk2OqRrslLKxDYfjGaJEdVmEfnfPghRjAH86NgdgxEm3aAQX/iHSnIjqYo28wrk7/pioGKqYf5fMweMYBycdacGdBGWlYcchhkAVGG2xtHHI4J+6AM4H1NPib5mDSttK9HXcc+1IoQyyCMneMK2NpQ81P3ZB5PHz5POeOaZE7DyW85SxOCHGAB/jStKzhgnlHaeBjrzSHcSMrIyERLufjG4ce9KdpGWgY5O1sHA/Cnlsb0SKIEDeWz0NQoV3RkwMwfLKucc+tIocW2s4COsinGF6AfWm7ooiFhLo6jcvB5HqacXVk6y7CdrDHFI02xpJEZlkI8sjb0FAFVctOVcIyYyT05xTGll8tiDEw3cqB1qSNzJcFGiQsQW3A4GQKimk3RiVooh8w6DkmskaNllNwmSMRxncu4Fzn6io25R5WgO2JgOv3qmVEEoVbUux+YZOO3SmebE8LEpIFU4ZcnvQA7em6PdCYyR8hzn8TSHaol2tKJACrEjIJ9aDsVo0/eo+0bNx60heEqzfaJS5XEmR3BpoRIhDxIFmjCAblyPfmnbVaVpfkl7H2GOtNcB0VS0YA5jJGMg9aa8YVpGUI3mcZGQMfSmJimORVKBEDZyCp5AqVzvlExE7A9ge9RrCwQAqyuP41Oenb6UNIRcZSWQRkbhlevGMUxEiyk22RIu8HI3rk4pNxMyxOEl+TO5OCOOlNMrmESusRfJUkHnbjjinDY0rRsnzbd+6M5HFUhETMPs7SGIBMjeQcmlkaNWTfK4bhlXk/KfT6VFNJH5AMiuiM2Ceoz71JkCc5kYsi4AAyMYpksayloSyyxqJOSxAOTQ37u4SZCJAgwNhxnIpAsawKGeMCR8gnk57iliLLM7YDbwV/d/wAPpTZKdmQuWhVwryCRWz83Iq0qDzQDGGQ8lt3t2NV18yOJdvmZD5bce1S7gDjyQ0aggEuM49R60Feo1Jdlu7F1QMShDjPzetPUBnV22SiIDA6Yz7U13RY1ZpR5THhWGSD3z6U4Sn7QX2pN5eFOD2x1x+VUiWIIwU8tQF5ypU4xjmiYZ87ClQ33ctyD60bCuwPCpKtuOw4OB6U2ZfMeVliKMzbkAOcAVRNyc5e6HmeccR5Lqep/Co9xWLDlTIDgkr0HbigANLMzCURsgIOcYNMLERRLvTfzuJUkn/IFMm+o4IXkCcNGV5ZVwRimO3lxF3gZRuAIDZPT0/WnyfPJJld6om4Mgxk/SmYYBd0LIJCej5+Y0IGOIxJgeczAZJA4A68U0SqYQyuu2TuByGHb1oaXaHJjuFZBtZgMhvr7UJIirHiQBT86/L1HcnFMRKJQ0gKiOQqMbs9RUAjBj2COPKtvypwR9KcHiLSuoicHKNIegFNbCLGw8oiM9Yu+aAHsqsXYxBt/HJyVqJCyRIoeXbGTkY/rSfZy7yny2ZmPytu4+v1p7bn2Fmm2qvUYHT1xTAN0kcco8w8kFARkr6806MsvlHzleN/vqw4HPbFRiRkt1EkpAyckLlsHoKdHjfsMimMjKlvlJOOnvRYVxryPmQr5fynAVVzkZ6Zp82d8Y8qLaV3HLYx+XaoklYQK58oqW/eKowceuadjyzKsaxjBwoLc+uKLDuAkXaskkJw/yEA8fXNOB3SSq6OixkEYbdkegIpSgZgghZ92GOWxg+nX9aajgxbmjlBGU2A8H8aQDR5ZCKBIqOxHzcgEVJv27y/mYzgvtwCf8KY5EblCkkLqoZc/NkfUd6AQGBZJwsh6t0z6f/XpOSGot9AYBZY0aU/L8wCLmoi0eDJvhxJz0zkinvOASS0qlBsLryPTmkJEe2IuEIO5cLng/Si9watuSoySuGUJIUBXIJGKBbAQgBAWDbzhuozTfleJnVldZThjjbkjtTliBlUx7GVflJjPt1NIaQoiJ89thUs3yNuzin8uTuE7RonOc9fTimJEGBLcshydr5IHYU50bD4EmSQQ2/pUFiIZBGi7pCqtg7V4A+v0p6yMkchVjw2VLjJ96c25iNrSrH5eDgYz7nFCtJsjUthvutleg7UhoejHzCGZCpTJ3AYBpwd2EYCpIGPPYfWlWUrG7MI2KsMbh1z3xSkr8+9Y2QJnI+XBpMaGIQEZ1EJXds4PzHmgReXK2FyY1J+Z+RUirvaPdDHhxwF6r9aYpVUGYywdtmFPOaRQ04LxriTH3lXPFIiq65JkKv2A6mnvhfMfZJmP5SxcdPpSHAwirIQi7l7bQe9A0UwuS6CEK684PPHpS5jK7mt3RCc8Z49vpQSqtKEd1ZSWYHOcU5fLMSKTIEc8HHBrLoaDsxxybf3xlXoVz0NAkjEP+scRt8pBHQ/SnHAnkJnkLqpGByMYpq/cGyYLCeQf9qgB6yK0ylHyVXIyuD9KdGwnBCzg+Zycjj3FRuC1wjxyJKyDGMYpzxtsxG0LBj124xmmhChQ5QbYhswBlccf4UGFknkZUy0xKgrJgf4U1o/NkjKwKVQhSC360kCFllUb13/dC+1NCHojIinbLGx+/nkYoMvlSzIJSEYZUBMCoYZW8xMSNz9/d6U4yyhplV4mjTIAPOR2FUTckBJiQtFG27Kn5vyNLlQ8qCMxyKOQvQj2pvyhQ0kDFZewXBXmgyqQ5RmXy8h8ntTAP3KQxsRJGu7owznNOdkjdy8xBC44Gf5e1RqRJGqpJuCE9uv0pIpWPms0il5VwQF71RDCRVCRxh48DkEj7w7mmoNrzFVy0nyko2KXY37uNFiZU4z3P59qjUBYpl2lWm+fCt0xT6EdRUdhGmTIEz8yv0P40u4MJHMUeF4VQ2DjPFMDrujUl1QA7xIeD+NIWO2R5oUIBGSrcrSGSswVkBkISQAr8pO2kUqzSsu2QH5XZTgfWhzsZEe4UMCH78jHHvToiJWbCiRnGD/SqJG7RHsyMujfMVPLCm/Orf6kpufdu3ZO3vT1i2MjmNsrkOF4znpUO1l2HB3I2SN3YnpVC1JpFUi5YRy7CQVIfGDUquGSNvMxxyNnU9yagkidVIWNlZiSGBzilWcLMJTIEBX7pj9KYuo8hQk25d+wgIR8oIPXNM80Bo1+eMsMhw27/PSs3UdVS2tVeWPe7ZQ4IHFc3e+It0higjPmHkGM5/Csp1oQ3ZtCjOWyOyN1CFLtNKFLYY4p5uAir+9QkLgBRyR2rm7HznQPcZUtz5e7OKvorn2rhq4/pTR6eHyu/vVH8i950bLKotlPmdS7ZNSRbmdNiIpC7ABxkVBHFlcEkHsatQW4zwx57+lccsXVf2j04YCgvsFLSby11SzF1YHdD5jR7iCp3KcEYPvV541kV9+8Mw42PgD8Ky/Dd5FqUd/5Vl9kFreSWzIBgOVxlxgDrmtxLfIyc/nR9aqxekingaE1rFECROBEPPLDb8+F5zUSuxR1laHfGfkyMnnrxV7yD2P4Gq9yJFTdGEWTuxGSR6V3YfMOZ8tT7zysVlPIuajr5ECEhsHyWjYYJwFKn+tU7vUY4Nsmbfg4IHIwO9YGta+YHljSSNiPugrg5+grkrnULu/njEjhgx5QDGPpXTVxSjojgpYSUviO8fXkMzRQRRyOOUKtzz9KtSXzvg7djcHGc4rA0m2W0tkQBRK/LsB+lbVtC0vyqK86rjJyW9kexh8vgndq7JBLI5+Z2JPvUyo5GAXyfer9rYKpDMK0I41B+51rhdVnrQw1kZCJOq4VpMHsTwaZpyaxFc3zai8TRtL/AKKEUApFjoeBzn610C+WrhscKcnNZXhjS5NP0xoHuxfNJPJMZwSQQzZAHJ4A4prESivdZTwVOT95XJUi3hQY0Ug7unWl8gO77UVSwwecfhWpHAcjK/WnT26MBxW1PG1Y7u5zVcpozWisZCxYkDIEGwfMQ2B9aUQ/KGCkuOcowJNT3FkGjkUBcsMbj0FQLCVlQgAlF2/IcD6mvVoV41VdHzmKwc8NPllsPO/LlhLuzkEEYH4U+OXOG/eKuMthcc+9QrCyxLtRhtOW2NyfapwhEbtum3EjHfBrY50KkjGNF8xQxOGHlnj0zSMxj8wN5TAMCCQBuz7U9N7EEOwyMsduMmmrKzbF3Luztb5M4FIaJDjzJciMgLnepwPpTRxKqCLAK7sqc4pjEtGGBiLbtuAMkj6U5sky72jbZjbzjP4UihuELRnymHmE9Gyc0hCqCxWQchWctkmnPHzgxIFRNwKnAFCLGSirFw/I2MTg+poBlNMCSYiV9wXLjvtNKqgrEpncrn5dwwCaI5AsjusjKcfPx0H0oBR1ijMjEAkruXAJ9qxLZIW3SuxlIYjBCLkD3pqgBVQyxrGCdpK96errukJl2ueDtU4/+tTCu9I0eSNU3blz/F61SEx5QGczRiKYgYAAwcfSo5IVaAxBUAJ6q340uGaR5cIWAwcHjbjrSPCfKCKYs9QwPzD/AOtQAoj8yRCsb7VwuC/pQmQsiF5FkJypC5IApGJaVZPKlPHJDdx6imNNIttJtaTzAQ2CASBTEyQSYeLe5dTwQ/GB9ab5pImLJAzLx7kZ6flSK5lmUOyyxlRuD/LikDhYnZkgIB52tzVEk8oT9yAJSWwyhAcimpKscR2yFUJ2uzAcZNNbyxMqKLg4+bK+4pd0a224TJsOASy5OaYMQKp2bXSV05GB70qINkv7tQD93b2B/rSDh43QJIUAOF4z61F5OI5AI9rE9c8gmqIY+OHdLG3lvhQUYl+30/rTJxtt9u9wwfIO3t/hTht3qxEmNm05J696jlUCOJTNJlW5YLnI7daogWbe0ojLh4wmVz6jtUayDaHlhkRi2Qynj8f8alcmWR2kzKVGU6KS1MikYRpGyNHIzHBPzKTngUityXzNr7JLhBOmQSRnI9PypqJsMiJu3nEhETY/CmKwklkDNCzFcMCQDnPOKbIEEOyPzV8tuqnI5qkSWOWkYFJF+UAKG6v9aaIF8wEmUHbtcg9W7VG7SCKTEhAH+rXb8xbNQahM0ImMk3GzcoA5LU72BJsdNKbeFT+8Rk+Zy5zkenvWDrHiCRDKI5kDE8RhR3rK1rWSZVCyOdyEPu5y1c2biT5mMgZyehHWuGviekTsoYa+si7eXc88itIqMzHLZbjPtWxoGniNftMqBZG+6o6AetY+l2/2m8VSnyrhmOeMeldgvC15dao1oe1hqKtcswLz7VpRqu0Vm2waRgFGfWt+1sgFHmHn0rmUz04UmRKFUknHHarEcgIwFrRitFI+SMD3NTrZEDnAz7UGypnMaZf3l1e6rFeWnkR21wIrdwp/fJjO7nr6cVrRkjBKtj1o0q21QeIdYTUYU/spPJOnyADLZU+YDjng461ti0TaQOQexpytcap6GYF3c8014ww9DWmLRe3FV5IMHB6HpimmKVM8q+ImnfZ5VvIAEVztfjgN61z2ioy3TvK+5UA25HOT/SvUPFln9p0+eJhztP4Ed68tspPJt23Hc244OMd62jP3WmcNXDXqprqdbYjf06k4rqbCFY0461zXh9cohbuM11EAIwPbrXNOpc9ClR5UX4xkgZ4xUhdUPBJNJAhKMSMYGeaIlXDblLk9/SlZm3KU9RnhXT7triUW8AicSSk4CKRgt+GaTwtpsWm6PZWdq7yWcEIWOTu6nkNxxznNP8TQaTHoFz/b/nJptwUt5PLzuJdgABjnriugXTTFFHBCuyOJQgB64AwP0FaKnLlJuuYhU4z82cd6YxLHJqSW2dD3Kjoah3HOMUmmtzVJMeqblIPQ1TvbVVRgiIXYDknH4VoJ0psyhsZ6GtKVR0pcyOXFYaGIg4SMQKUmysZGPlOxuD70PE0aLxIhVslg2fl9KmuLc75DGgPmDGd2AKj8tldCikYGxirZ5r6CMuZXR8LODg3F9BzGRvNb9+Omznj8akD7jneQpTqE4Y1CkcqAGRpVIPJPIIpzB1yQzrz8uRwB34piiyQOC6EvtZhhiE6YpgZVCNKYyWJGCMn8aVywMiRyMEA+UFeGpxkAfAeNTs3E7c44oGRMVCuxCMc4BzgH8KkVwsMgMaEoAdwbFIsu1o9why4weM4pgb92vyxFskD3FIL9SrHIgEriQBGOGJHI9KkVUaRFMgLY+UMOCfakh+WJ3MqYbhjgZz2oR1LxsZUcgELuHf0rG5pYXcpZz56ndwQF6EdaeyhdqmSIIOVPqO9KjqY5D56Zbt7/AP66aoG2JVMSrHzuYfeB70xikbRKdkcmcjPpmomTfFGqqqlcMGUjtTymDKw2sG+VmzgL6VGI8LGNqDZzuVuSaZLHSKHlll2yAMP73U0w7ktx+9YSBssQnJzx1oCOTK4SQgjI2mneY5Xh23DO75KokDlp2yRImzndgEEVDI/+jLI0KElsfIeakMpcOJCrc5ViNpLehpm8OELIgOedh7fSmJk21Ufb+9JAJ3YI4NNBjFuR5q7c4ORzupN7LI4xMdiHnqD+FL8ptkJkVYydykgfMaoXoKmBMHUCUxjGE4496iki/dmJYmV2Y/OG6Yp/ytL5mEYldhKt29ajaALEgCbGViwZWycelNE6isD5jttlK7Auc8Fh6+1IG/1QdnyvEhUYCn3prSBpXK+YI2TIycAGoJ9QWF0Mkjg4w20AZNVdJak2b2HRMdsuAzShsqZOMDueKkQAPCEIUgcODuUH6VlJczzo3lgkk4Dv0C1ZS3c87ipHHy1yVMZTh5ndRy+rU30RYkMEiygNCVJwwIwc+uaUTpiLZPKmwbSEXr75rP0uWG+1TVLKOCQHT2RHmYja7sudo9x3raFko5AxXJUzGa0SsehTymH2mVpJXZSY2beDlSy5/wAmuW8USails4Cu6A/KyjP412a25AwOfrTJ4wEORjtWLx9R6M6FllJbHjhmkMrliGBH8Y/ipBKwUHKuT1HTFdP4m05WkeS2AjmHXHQ1yayMWAdhtXhgRjFKnUVTVGdWg6TszqPD0SpbFlXBd/XPArdHPA9aw/Dj77SMjGMkCuitE3TjPUVwVZ++0evQpWpxNzSbQoox1PeujtoEHJHNZ9iMxrxzWtCpHXpUo60iUOoGADx3p4bdikVAw4605BiqTNEkjPgsdUHiW+u5bgPor20aQQ7uY5gfnOMdCO+a1Y+oBWshdOm/4TKPVxfEW/2A2hsSThn37hKBnHA46ZrbXkg1cpX2FFWHFA/UYqKSLA45xU5NI/3TSCxzevW+YHb2NeEXTGO+kjxwGOPzr6MukWRGB6GvAPF1g2m+I3ifkFtyn1B5FCY400/kddox2opx0A6V1EMgcIAOlcdpsu1UA9q6vS8yc9u9ZQ3NqkLamxbrJM4iU9TWs6waa8aTpvkHJT/GodKMcE5mf7qKSM9yKpGVru5eWQku5yc11K0Vfqc0tdCt4r1m0kl0my1GwFzHf3qxW8YUEJIo3Bz9K3N88jlnlYt1JzWHPqHleJtK0v7CJxcQy3BuiOLcoOMcdW6dQa6GMc9KcpbXM4rccjygBWbeoOcGqt0V8wlVx7VfAqtdIpUkjp3pc1zWnvqVYz3A4olJUZHQ1JCpztp08e1TxxUM0kjHu1DyoBtG3k5bFVwofeY1ysnICvgcU+72eflxESBwG65qJIlGVCxgK27JOAa97DX9lG/Y+Ex9vrM/UlCbSNokAYbSAQcn15p0bNFtLl8j5XDANnPSmGIhGVQys/zDD/KOaGQFn2hyGUgDcDz3Nbs5BVeZCv8ArBtPQjIx/WlZmKvgFcH5V8vj3pV3R7Q7Ngrg5Gck0qO48ve7IB97cueKQxjOd0m0pjsAvUml8wbyFESkrubjIzSea0YDB2zuwFdMD6/hTlZtr7HVgG4GMZNAyiFVoyY2j8uT7z4yQachVpYwHR3RePlwCfamr8kZcSxBC2CQvRqkRlJGJQXCAAMuPyrEsQiMo481MHBI2/4VJwrpueKNkAK/LnI96BLG8DESgqxG75eBQMCSNt8YKjgAZ47UwBI1VXx5bq5wxPQH3qOWMK8LIEJTk+W3JOaRSoUoQmx+C2e/WnoGFzFJEi4jHIjPLUIGRGKTM5CSZJyGLZwTSOzNHGomlzGMMcYyfrShWCOArli33w3TvSs7OybGcBRhiqgc1aII1kCLIGdXfqhcdDml3eYISFRskk7B0JpS7JHIGKkjlGccn2prIfNiUgfOBnZxzVCYjYTzCUlULxu9venPKh2ozxoo5QYzx3qF5AsUjtFLtyMtnqPcVUu72O0CgXCE8EZX9DQ2ktRJc2xcnmQGaQKjl/lJHyge5rIn1JIVUAKrRncWU5/Cuf1PV2mMwVkYP945PrxWQ7PKVAPTj5D1+tclTFJfCdVPDN7m5datJdSv5KyMznj5uhrZ03TXcpLdM0koHc8Cq3h/TBaxiRwTM3Jzzt9q3iWC4GRx2rzq2KlPS57WGwMYe81qSRwIi8kU6WRIoZJFDOVUsEQZLEDOB7npUUVu8o+ck1Dq1nqhtoI9ECLObiMSyvjEcWfnIB4Jx2rmTTep6HI7Fjw9c3V7o9pc6hbJa3kyb5IUBGzk4BzznGOtbEYz71MloobKrgVOIAvJHWk2maezKbICDiqtyBtIP4Vo3EW3lTnPWs+dSc+tS3YpQOE19jHdMDzXE6o2ycuD8rdR6Gu48VoRcKfUVxWpoWjYDgkcGlhp8tQvEYfno6bmr4QuPMt3VvvK/wDOuz09sT4Pc15r4PuTFqRt3ZsSrxn1Fel6VgzqG71GJi41n5jwjUqC8jrbB/kAFa8bDbWPY4ArTVxjiqWxqlqW4z6Gpo1ByCarwAk4rTtbeMIZJ5AqDt3NVCLY21Hc56/02xfxdoupXF8IdQihnt7a1JA+0hhlsdyV68Vu+ScAngVj+IDog1zw7d6jJIl7DcvFpxBOGldMFTgdMDviujgliY4myFPcVv7O9rkKVmyvgDgHmo3x0q9cxQbQYZdwP5is24k2SAEH61E4OJpF82xFMuFJrx/4y2bR3dheIOGBXPuK9lyHQntXmnxdjDabaE84mI/SpWjKiruxyuj3AmtIZV/ujP1rvvDwDRD3rzDw5IE8y3bpnev9a9Q8MsBbgmsY+7Ox1VFzQuXtYlMFqwB4JAo06TclWtRthcafPnk4BBqhokMksmxfug8mrqTs1YxUIuHoW7S81BvE1zZtbBdIjtElS4KnLzlsFQemAPat6LPYVn6Fp2qJrGtNqjodPMsY05F2k7Nvzk455bsa6aC2APCD8aGm2YxtbRFABj2qC5RipBBwRW6YcDgAVDKpUcqDmnytdRq/RGJb7mt13DlTtz61NKv7sg+lWQhG4FcZOaiuBtU+lCZqo6anK3IjE8iuy/MQuCP60oCI4BWFdq7du7PNLd7XuPLZmDMdwVgNrVC5jLEtIpV+B8mB9K+koaU4+h+e43XETa7j1jQJGjqoAJPzP978PSk8vYXUAKu7cCG4x0wKQFWk3SeWuAFIC8D8aedq7QTEAoIwR1HUGtTnQMvySKm7DcqM8Um1hK4/ebCnA+9lqGiCRhSUCht3zNjI/wAKfsfyyEQgMwdcNgD6UhsCWVow7tjb84I6HsKVGdmRhIu09dwxxSFZVdwpkBPI6N+OaVmfeyNuYY+UYySRSGiiVwgV3jVXOQw7mpPmMwaKRHdRgArjj8aZ8qwgb0VWJxIB1b0p4LCUyb0kdV6YxkfSsiw3II/JMq7SeQV4zTt5WUBpY1KjaAR19OlMzG8XlLLGVc4x704kxy5kljVwu1lx7dfypiIyiNAQPJCO27cfX0pSpFwjoEkKr0U4/GlEY2bEaMIx3hsdT3FNZ3W4MwCyEfKQp4+tNCZAIgYGKDDbiAytmlDSmdGHmgBdrhfUc5okjP2fy9m0k5Dr3+hoPzStJibaUwSrdTVITGNK5h5MZcNxuHIXvSMf3gEmDEw5KcEHHoaRpmjthlh5m7BOOQvbNY+r6mIpZQXR4x91gMHNEpKO4Ri5BqWqLCju8RD5AIByeK5O9vnmlZGZyBzlV6VDfX73Mgd0X5zjKnn61Tab5mXc+4DBK964KtVz0R3UaKirsNymNsFNpOS3vW94asBLcC5ZRhOFK9DXP2sf2kxRxbSXbgEd+9ekadbpZ28Uca8gdB61xVp2VkelhKKlK72RpRxLGm9sL7U6P94wOMrUe1mIMp/AVbgXPReK5b2PZjHsWIlwvWoYrCeTxOupfbwbKK1NuLNCf9aWyXfsTjgDqKllkS0tpbm4ZY4IUMkjv0VRySfaqXhjS7bTbOaWwne4j1Cdr5p3PMhkwQfpjGKE7Jsvl1sdQmD0p5x0OMVVjZiBmrKjIqLlcpDMmYyD+YrHujtkx2rZLD5hn6VjXvEo96UnpcqMdTkfFkWSnrXFX8WVYgV3nir/AJZY64rlbiIFTXMp8szshG8DgZJpbPUlkjYjy3DDPr6V7DodzHdQw3CH5XUN9K8f19DDqDYYjcvAx3r0H4fTFtOKE52kY9uK9LFJShGoeVhU4VZ0uh6dYyfIP1rSiBY8ZrGsDuUCugtEwgNZwVzr2Lts6wr5hGWXHBprytcTNI3Ge3YVHfsFWNAMEjJpbUE1s3bQnzMrxVcaTYxaVc63bPOBqEUdqyjPlTtkK/UcDn1+ldMI9pKnOQcGsHxhqdtofh99RvLAX8MM0Q8kgEgs4UOMg8qTmumKYYgnJ9fWrT0Rm92Q7OmDzUdwvmLzjcKubBVK/BVVccAHB+lJ2sXDexXX5Frzv4w/LpVqQP8Alt1/CvSWXjjkCuL+JWnNe+HJvLBLQkSgevrWTN4/EeM2lx5NzFKOdp5+les+HJgYhzxxXkVtAz/eG1TXfeELzbEsTtkocfh2rkrS5XdHdCDcdT0+2jE0BXqCKm0eya0k2SLhc5JHcVU0u5UqFzxW0ZgIHZ5UjUIQZGIAQY+8c+nWlF8xhKNit4P0zUdMgvYtZvje3E97LPE24kRRMRsjGegA7e9dLGqqTkVzXgvSo9A8LabpkV4b5bdDi6Jz5u5i27qeOfU9K3JJhxz7V089mzGMXZIsPJkngY/lVeYrgFufaoxKATntVO+uGAHljOTQ5q1zSMB8jYLEng9Ky9QuCkTknPFWbiUJEMnmsDVJWKDIBBPQnApUY+0qKPcxxldUKMp9kUWYtKxUSK6HOMBsUq7QgQs2W+ZSyY5qMMQrEpjBxjdgMP509VUbgVIZMfdbgg9s19SlZWPzeUuZ3fUerh4ypkfDtgblwDTi4G8NIMEBD8uBUcIA/dlZEI+dTndin5LlUxIu4k/NyCRQNbCHakgZnj+RduAOlIqgNEHeL5MnBbrQWJBZnlAkO1gVwCfSlLKMsG2sw2Y2cD8aQEgjZYUUEBdxb7+ODSBHAcJv+8D17UxSoYKWiGxcYKk/macI0BQFk/dknHXdmkMp4dbcASosR5U4HNSxnfO8oaORwuGJHQVEVIURu6Io5QlfvDvUkbZWRhKpbJB+XBVTWRoBCSERiWJgDwGGM+lSSHYzu0iK/QoBnBqICNvIj84OOcZTgmnu4O4+cgLDBXYMA555o2AayBI1CeUqltwPY+tRsVaZ5VAfcCu5Dx9akZY1CASogHK5HDZ601YjtkYeWS/DEcAe+KpCfYgKGONQAFKnOVbP4UkvLO4E4V1zwcY+tBi4jOxN6fN8jcsazb+doxMwVgSMqd/PPtTbshWb0INVvjHGsaNhwfnbb+VcXfXck8sh3KdvI7ZP0rQ1S7kmkXLzYUbWIHesdbe6uAxijLnPykjGPevPq1eZndQpPoisZGDAFFLN1x2qH5TuYo+4ZBYH9a1v7GvNwz5Y9earzaXdRqcxFh2KNz+VYqpHa52exn2NPwhbeddNOT8iDCj0rvIeCNq5NYHhS0MNgjSZ3sc8108CBVycYriqy5pHs4WjywVyWCAsxLke5NaduYUA+UufaqCN5uF7fzrStoyQMClFJHS32M7xFd6W62uj6rbSTR6xIbVIYyctgbiSQQQo4yRW1HHGiKkabERQqr6ADAH5Cs/T7tb/AMT6hYtpv/IKSMpeyL1kkXLKmR2HUg1v+WCDkZrWUFZIUHrcpBcc9qerZXINJLlSyHkgZFQo+FIxWDib2EJ+YnHFZuogYjb0bkVoSPtcY79ao3/De2aiS0KS1OT8THdPGAegrClT5cY5PFa+qN5t2x7DiqCpvYv0A6V5s5e9c64rSx5741gKS714IIFdL8OHxbMpPUCszxdb+dDNgds/lVj4byfuRz3xXrc98KvI4fZ8uKb7o9e0wZCV09uBsrntDXKiunhXCiiiypooXsyPdKFJLbfm9quWzcCsa5Xy9SuOeARWhaTYApuerKdPsS+I7+80rw9f3+mWYvr23jDxWxBPmncARgc9CTx6Vt27F4InYFWdFYqeqkgEj8KxdVub1NFv5NIUPqawObVSAQ0uPlBzx1q9pM9zLpdk9/H5V60CNcIMYWTaNw4465qlNWIcNTRJ4qvcqJI2U9xTneoJZTjpQ6iBQ1uJbrui287hwahu7ZZoJI5FyrAgg1Pp7mQunden0qeRQBzSbuht6ngOs6WdP1We3C5CscZ9KjtA9tIJEPIOCPWu38bWG/Vg6jqvNc99jKA/LXnVHq0e5SkpQTOh0jUS8a7G59K1NZv9Pl8N6jBrd39j0+eEwXE2cFVf5eODzzjpXLWVu8Ns8oHzM3HtUetXVhLZ21prkUkkN5cxwRogPzSZyucdsipoyfOrHLWS5ZHqWmmGx0+zsrTAgtoEgjH+yqgD9BVk3Hy8kZrl4r6RB8yNx3AqcX8khxHE7H6VspSephZRN17gHPbPvVaW7VV681UjguphmRkhT3OTVyG1hhO5Q0r/AN5+grVRk9WZyqJbEBV5MPKML2HrWVqhy+0GMYBPzjP5VtXMn3iTn3rndQkY7/LJDduMg/Wu3AR5q8fI8XOKrWGl5kUcjEplY9z9cnIBFLu3Dc8S787MbsA/SmrITIVUpwA3C9T9advV5VGIVLDLHqQa+jPiehIp/wBZuRgqEAEHgg9qUERh12OrJg4zkY9M00Ajb5ixs5OCN3HsaUkHeJYxndtxkgGkWITscfLKpVSyjOad5gJwGkww3AN0Y06JsGQshXB2ja3BBpyMBKcCRSg4IwQR9aTBIaWVwwMjkSDjcvA9qehTDHeDu4YbcD8KROTtIkQoA478Uq4BCoXGPmXK5FIZUbcqRh2iTYflyOoNCMDI+94ySxDkDOPSmJhfLXKgr6/xCnwqAsrkphzh3PasTQkV8iJRIkrR8qOgNNEi/vAZVKn7wx+YpRl5Ytk0bsoyoIxn3qPzlET/AL4bHIBAQ4/PtTBkrkBoVzCiD5ox/eqEoWEu0KwkPJ3cDHrTgT50SF44wg3LxnINQXDrBZyHMYRjuLk5wfSi9tWK1yDUHSJw+BhBgAEc1y14z3jukajJP3geho1O6lu75SijaPlVUP4ZNXtPs1t4ggwWxyfWvPxGK6RPRwmE53eWxVt7COPBctI4HJ7UyGa6/ti4tJbTbaLGskFwmdrdmVvRs9AO1bDgKnvWXrUVzdafNFY3Btbk4Mco7EHOD7GvNdS7s+p7cKSS0RYbHpVdgGcDuTQrs6/O0ZkXAkEZ4DY5+n41Z02DzrkZ6LWSlqbql1Nazi2xDjpUzHe6RIxIHJqwyrFDn0FVdMGWeRurGrbS3OyMPd0Ni0iAxxWxbAKCSpbaCdo4LcdB9azbcFiNopPEFlrF5ozw6DcC0vGlj3XBODHHuBcrwfmxwM1KmpOw3DlVy94VuNVutAtJvEMMdvqb7jJBGMCIbjtU++MZrWYcVXywY4Bx2zSNOQcGr9qm7jVLoVbwEODn8aj2/LyOaewaaeMDqrZC+tWnhKsQRjPOKbncq1tDIuScBvQ1Q1aYJE7/AOzWpeIVJ9K5LVJXuJ/K6Rp19zXNiKqhE1hG7MsJ5jH3OSaSdNqYHSr6xhVx0xVa5HymvK5rs6kcnrEIcSDqMVk/D/8AdNcRkjKTEfSulv4+GNc14fK22vX0XTcwcV6lKXNQnE56sbVIyPa9Bf5B6108DcA5wcVw3h66GFz1rs7Fw/WilVsgqQ6mZqA3anJwfmANallZE89BUt5p/wDpKSqQykdq2LGPEYyAOKuzlLUiUtFylOayc2Vwlu2ydonWJ/7rlSFP4HBo8N2N/baBp8OuuJdWjhVbqRTkPJ3OcDPbtW3GuM55yCP0rG8FaPd6D4WsdM1HUv7Turfer3eSTJl2YZJJOQDjn0rpjBcpi7uRcaHPQHFQyQjvmtPOOMZpjIGI3YFS4IqxSsrQr5jrx70kpyTzWnHIv2ZxgbhWPcShUZjxmpdkkkTFtydzB1KzW7uSW/h4pJNCieNiFVXPQelXbfLvuI4zmtS3TcMkflVQhGW52c0oJWZh2OkRmyFsFQtuw2OufSsnUY9NtfEnh7R7zT/tVzfPNNby4BFuYlyXOe/OBiu1gVLa+SVvuE4JFZLanK/jiTSItOJsY7E3n29weHMm0RA4xkjk85raFGNvNHNUqSTt3HvaIgIUVRKbJgNxUHvW/ImRkj2rH1FCvTtzWXLZmcu4KyDoWc+wpJJwDyc/7IpiK8i/KuB6UjQLGu6Vsf7IpSuxIhlcyEnoo71jTtIZdyl0AOfUEdOlak0xk+VAAvpWTMNl0xBI+XBwf1rtyz+K/Q8TPG/YL1BS68hpFbPAI+WpCzZlKNj2C8H3qHy2UIzlxg/MN2Qc0uCFTJlUhiThs/LXunyqZMGXcSHXkZYhe9LG6jy8hPMYckjOKYu8RvsMoJbChgMYp3mON+z+7kNs6mpZSBzvVBiJWJ+bJNOyFwCqfe2jP86AzEkKyfdz/q+CaVWJ2k7AGX0zz6Uh7isVwQyKxB243cPTyCodvLCqhAJDYDUin/Vg+Tlhk8ZxQhLKu4RgknIPIGO9JjSKhAJjUyCMgfKEGcrSniKTLjYW+Y7fmBHSo45AJY1Mh3AfLsXOR2pN37ty0jkM3zcYJNY+pqWFffIGEu6RV4DLjjuahJVFZROTGzDAK8U8PtcsGIZFz8y/w4prlNkYZpApbgMvencWlgbIkDNL5bqMAKARiuU1u4EsrQJKojzncP4j3Fb2sXLwxyv5hVyNo2rkY9vwrk5VG1AGG3O4HbznvXJian2TalBbk+mw77l532nbwpFbKjAzVSyjKRD1b5jxirQ5FeLVqXeh9JhqPLBJkU2TwDVZl59TVlutMK1wyqu56dOlZGDdR2GiXF1qU8kkS3jxxyDrGH6ByO3ua63RIdoJPUmsu4hinheKeNJYW4ZHGQR7jvVvwlfT3Nxf21zaNbtayBEYZKSoRlWB9fUDpxW1OXMr9V/wyLceV27m5fFVt23DJIxxVnQdPEkSs/GRkCkuIPOiK/pW1pcIRUxkYUDBque7L5XayL1tBGgxGmfc1S/stL7xhbaqL5ZF0y3ktWsYm4SWTku+D128bSPQ1rPPDZWc91dOEggjaaR26KqjJP5Cqfgqy0qCyuNR0WSaaHWpjqTzTElpC4GOoBCgdAema3g7K5Eqaukajw5ztjNUriy83lchq2+AetRGEO5PT3pSimhpcuqMmKzEaqx+8D1qZoRu3GrZVjgH7opkvAxSQ9zD1SIBCQOlcLIn75zn+I13urELC/PauLkiwTXDjJXsjppIpsvFVpgCKvSAYwOtVJ+vTiuJbmqMO+TCkHr1NcLLkeIHaM4bGQa7rWH8uNz/ABHgCvPL64EWuI3+zg/nXrYJNp+hz4h2Sfmd5oWrtbyos6naTjcO1el6PfBtuWGDXjdnIsgBzxXW6DfyQgLuLIOgNZzptO8TVNWsz162mBXk5rQjlGBiuG07VRwGOPrXQW2oKwGCOaqFTuZuJ0lvcbXVgMkEEA1heCdPsdG0m5sdM1EX8SXs8kjAqfKkdtzRnHcE9+eatRXQwDnmsbwsuj2Fzr8GjSu0z6g9xfoxJ8u4kAJAyBxgDpmuuFT3XqYyj7yZ1wcd6Y0wH1rPe6UDhqp3WqQ28ZaWRVGM5JqXVK5TRuLgKG2nGetYV5eCSQRKfrXN6h4thupGhsm3YOC46Vb0w78EnLHvXPKpd2RtGlbVnR2q5ANalrwcetZtmpKDPbrWlEBvz3HFdVNsUi1Lb7lXGDmuf0GbWJPE+tWV/AIdFj8kWMmOZyVJkOc8gHgcCumjk3CNG4UHJrm9DttctW1aXXpkkZ9QkexRWBEVrgbFOAOeuQa61b4jmlfSJrSRsjFW6djWZepu3CtqeVZVWTcCx+8MdDWfcJulJXlTzSqR7GalfcxhcPCvlAcj09KryF5D85OPQVNfRBrg9uM5FUJpnhO1gA3rnP5VhNdyYksm2NOe1Y0gRnkO6PDt1JPUdsVoLHJIQWyF64PWqc6hLkDPzDkALnNdmWSXtGvI8XPIt0k+zGptByGjwQVJyQopylQY2Tyzj5Tt469zTUKSEjzF2P8AN93kkdjSO6PyGjw/BJXHI6V7Z8uO8ryypIyVOTsfdn2qfa5wDuGDuBVv6VCApcvEUxjaecAe9KE2srAodvBIfv70DRO6Sg7gXGTkHI4HfinfNhyDJ/s8DHucVCihtp7p12tnP/1qegwR93cpzlWzx6VIyRw+WK7xhcKdvBNCs/zbDJhgM4TjdTDvIyGIYNnIbPFKu99xUMzA5BDdB7UiiiYz5gX94zgZXZwAKQPGUUlZWiPyHPGD61IFBkXJlkYDAK8cY4pmY3jUhZGiVtu30b1rKxTFQK/mYWRWX5iBzx6ZpCFARhG4ViQPmzj3xUipy+2OUOBuwDnI9DSOqZjzE6rnGVbJFOwrnOeIplWdoSJBsGXJbBx24rFd1ZodyS7WOV7AVoawA1/cZVsrwzM3P1rM2LsjYCRgwJAJ6c15dV3k7ndTXKkdOo9etPjU4plk4lt43HTGPercYGOK8G7V0z6+mlJKSKLD5sGjjkGr0kGQSKqSIRniueSaZ2RsV5MDNV2fUs26aTcxwzRzrIyS/cmj/iQnqOOeKlmzkiqrSNG4ZGwwOQa0pz5XdDlDmVj0Oz2SOCpBXPrmtqBRjPevKPCeo6doE5sWuZIjqNy8kMUnKK5GSqnsD15716TaXm7ABrVrlemwld77ieKdVsrSDT9N1Cykvl1m4FgLdMfMGGWZv9kDr9a3bRRbxJBCipFGojRV4CqBgAewAFc5a6rc3Hiq8sHsAthaW8cqXjqcvK55VM8EAdSOc8V0Ucq461o+iCOt2XUbjnrTmkwOmarCQEZzTWlq+YLXJ2kqtPIACc1HJMAOtZV7eLkIGAz70nOyFykGpS+YxUdKxZosngVpyTxKPvj86qT3Ee07VLH2Fcc4uo7lqVjJniK54rKvnEY5yW9BWpdSyM2PlRfrzWJfzLErMTz+pohhm9WP2q6HP6xIQjNJwccVh6fpDXLNNIuWfpkdBWy9rcapqMcRQpCPmOeprs9O0UKijZXXd0lyxDR6yOPtdEZQApIHbFdDY6fIhUlQwrqItH46Vo22nqoA20oyle5M5poyIIv3ahoD+WamMMqgG2V0Hua6KG0XHTNTfZF28jFauXNozFabHPxHUFH31/GsexvoU17XbazXytQQxTXzkECUsvyEc88ewrt3tgVxiudWS1k8YX2lCyCXi2cV1JcgD96hbaFPfj3pRgrPQqU3dGZc3eqTQuyybFA4wOTXIak11Ox+0TyPz0J4r1p9OBjC44xXn+t2fk3bqRjDVjVXIk0dFGXM7GToUIjaRCMZNd3pCSIF2kMK4+xQLP8AWu40kgIuOeKyg+aRvN2R0NqWRlDkcgHiteEAkD161l2wBC5HJHQ9q04UA+YEiu+n5HNJl6DaJCxHA4GaxPCGj3ui+F4NP1XUP7TvkeSSS6yxD7nLADdzgAgfhVjW0jk0DUoru9SwtpreSKS6YgeSHUru544z3qx4c02LSPD+n6XDI8sVlbRwJIerhVGGP1611Rfu2OWfx37EMyGGQEZ2kZOKRwEiyDnPfsav3aZCnGCBisuSEqSOcZ59vehy5VYHHm1KN5gRuFG4sOo7VjSQsGztyf5V0bwkoAw/Kqc9v1AFc8pNvUTjoZkY3gk9azb8COYkCQnH8PYVrTRMhyhwf51lX7kyodgyTg5OMV14HSujyM2XNhn5WIEbYy8vhRuUgdM+tLGwXg7jGx3rtXJNRg/KSqK21scPyRUjAqzcFtgx9/nn2r3z5DcQEMTICMu3XZkn2IpxcMHIA+f5WO3p+FLtJJVdz7V3A7sYp5LDbhCQRu+9jFIoYoQOSrLyuw/LwKnQRgsQEJC7TxjH4VEjYAbEhDHcAOPxpVfzBkFwZDkrjkketIaRJ8ibTlCVGMkYxkelIpTcFIX5BzwQee+KUgSMCd2HPoMkinD94oyz5c4PAzke9SUUSCJRzK7ADaVOOD2pylRCPlkKhsEc9fWn/IWj5eQONyZOAPaoWkG0kISFbBUnj65rNFMnUO8khRMZGclvbpTHKJCpWAYwQMPkk04IjSOPKAJG4HdxwOlMR2MassMTAk8A9PegDkNTjC3k6spLA5LZ+8PWqRQKVymVcfJzitrxDAIZ5BhHA5JPXFY5xth/djbITtBPSvKqLlk0dkHdXL+hXASaW3IIOcjPIz7VvDg57dxXHL+5n3jcPKYE88Hmuyi+dVb1GfrXk4yHLLmXU+jyuq503Tl0LVv8wAYcGpZLMSKcCq8BMcm05x2NasDgLmsYpSPTu0c3eWTICe30rDuI2DEYP5V6BPEJVxiqCaYruzlQVUc1p9Xu9DaNWy1OGl05LsJ9oiWTY4dQ3Zh0P1q14Z8R3r2xe4tZI2jkaOSFycgqex7g+tdkNJUrkAVz3i/wxreoC1h0G8hto5CY7jzOGVcg70PXIwRgetbRocy5WTKsl71vkXPCXiS6k0tP7ekRL9pHYoANsalvlXI4Jx3rrbbVInX5ZFP41zUnh9Au0gnHAJ6/Wo4NK8vcpzwM8VLw8pNtaGi5UrJnZnUoV6yqPqRVK5162j485WPoOa4PxNo63cUOC6yRtkbWIqDRIpInaCYkuOjHuKj2dt2S3Y62518udsasB6mo1ukfLMC596rLbliAOM1Mmm7/ALztQuVbku76jTqEaHCoPwqOe9nkG2GEkn8hWtb6VCg+4CevNaEFmi4wo+mKpS7GbSORGnX1yw3P5YPp1q3b+G0B3Nln7lua7CG2HTFWhAu3FNXZDnbY42x0VVuRLjluOnaumtbFV5xViGAAjjoavxx5xxxQoDdRsrR2646VI0AUZq2E4FJKcD+VXaxHMVUj6U5lAU461JxTWpNFJtsAox71jG8uV8ZQaX9hzYS2L3RvQG+WRX2+WT05HPrW2ozWXfz6xF4k0mGzhWTRJYpzey4GY5AP3XOc8njgVcLFO5pMgANcP4utP9JVwOo5rtDOC230rK1y1NxZO+ORzWFb34NI2pe7K7PORHtfkV0Wj74wmH/dk/lWTcRlWrV0aURkA8oSARXDRlrY7Z7HXWMh56HHBJrYR/lGOawLZShzEcA9FPSti3Y7Nu39eK9ODaOWRR8bR6LeeG5dO8S3Eltp1/LHaloyQzOXBRQQD1KjtXTouwFBwF+XA7Y4rkfElxo76n4d03WrQ3E15eGSxXtHNEu4SHBHAB9+vSupjk98knJrpTskc9k5OxM8e7k1SeP5z6Ed6tl844NRNgrknn0qm0xRTRVaMEYz0qpNHyeK0yowPUVFKgOTisZAYVzDgHHWsi+hwpbAJx3rqZocjkVkX8HBGMelOE3Bpoxq0Y1IuMlocrzEVBLFC2GJQDr9KdCpQ8FB83Py9vXNXLqE+WQCcmqQ3ljuY8KVIJ7172GxHto67nx2PwTws9NnsOJKMflXIOB8pGR9aR3HIKKSOm7PIpieZxucnnBG7NKA7FG3P8vBywIx6VuzhHMwWTG0YUfLnJz7Cpn25JwOB0OTz7Go4zKMEsRhuRwRinjzHUkyMAGzjgj8qQx4Kl8Lt3YyMknn2p7koAoCHIzzk8+gNMXeoGDjnOODgVIS/wAw+dQrcYIIx9KQ0VDtMkYSMtvGVLHAB6Ypm7yt7sibozjrkMKcFVSgCg7+QGOMUhZRC7FF3K2OTwRWaLJjguRIsagr26cVHGwMcbqkRyx3AcfjRnLbSYwMBsgYwcdKQSFtrFkyTgjbjP40AZuvqjROreW4UZB6kj0rmpCv7s7EAcDbzkCux1FV+yTKu0ov3crnI9M1yMhAZQUjVj14yBXBiY2lc6aMtLFSVkMTsUGEPJz1966vRpfOsIXyOmOK5IspVsIp2ngAfe98Vu+FpwwmgOMrhwAMda83GQvTv2PWyypy1rPqb+3cvv2qeGT7qknOeaiBxTlXEgcfjXk0p2lys+la6mvB6mplKxLIMZ3rUdsMoDUojab5UBJ9q9OnOxKjcdbqCozWdcabpeseJ4LmS68+60eKSCSyQ4CGdMbm7htucVa+1R29tJNK4SGGNpHY9FCgkn9KpeGJdMeyl1XSYpkXV3+2SNNnc7EYBwegwOB0rSNSybIdPmaQ3Rbez0GG18N/2k91eRwvPAs4xIYdx4z0IXp68elXozi5XPAbg+4qLWLWKXy9S+wC81DTo5JLQKcPkryqnp82Mc1S0XURqumWOrW8ciRTKHCOpDIc4ZT9CCM1Mqu0vvNYQt7j+Qajb7Z2Q8gH9KjbTAZA4HOOtbOsL50rSAglhngYxVq2tw8EZx1ArGdmynokzIht90eD94Vat0wvzDkGtEW2GzinfZw2SODWbRBGkXzKezDAq0sYz9KZGMKAc7lNWAMcVN7EsFGDU4PT0pnAHvS5Ga0jOxlJEkUeAee9WIx24qvERnNTqTye1aKRLHk4BGKrScj3FTMRnmoW4pjWg0HtS4B69KjQ80/PBpNmsUSgcCsXX4dWfVdEl0ucJYRSyHUYiQPNjK/LjjJw3pitgNwDWB4p0671OXRzY3/2M2d8lzMCSBPGAQ0fHXOe/FQp2Lauh2nCW4vnByI0PJ9a6F4QYihAwRUdlAEHA5NXio2mnSjZajqPXQ8412x8i5YY46ismBmik4rufFFrvh81RkjrXDTApJk9q86tH2dQ7aT54HY6dOJYo2XqOtbdu42YH1Ncfo8xWPaOcdq6O0Y8MDg9wa7aVS5hOOo251O1PjXTdGewWa5NlLfJdsB/o4DbNoyOC3sa6BMZJIrmrHVr658V6pYSWRj062gheG7IP792HzKCeCB3x3roA5wARzXc2YRT11Lo6DbxxTHJK5HHzYpYW3Y4GKXHBwRSuJDYxuPPbJFOaPIHvREPl68Yq0kaumSx3dAKpLmIm7GbNFjjtWdeQ7ga3ZEyM8elUposjpUOI07nK3dryQBisa4gVGYnA/2sZzXY3cQIwBzWJfwDGRwR0rTD1XSmmcmOwscRScOph7Ynyyug3cFsdPakEahWbegDfKTjpj2qXHIwDgtnp1P9aYSrYyJcMc4GOor6JWauj4WScXZiFEBJynTaSARj8KEZFfhk+7tJwenrTiVYFh5p3HBA9af8rM2fMxu2kDH86LBfqLD5YHDJuHyk4qTYgYFSMoMHg8g0o2gN8smCdrDHftzT1AJbcJcfddc9fxpDTKCoqujBUJfDDceh9KYuVEjbVDK3GOc+tJGwdoj8i7vv4GcH/wDVT03c7CQxb93tXqO9ZGg5ny+0spTHJ285xxSB5gI9+5mB5BXgin7n807t7LtAyV744/Cm/vdqghxIp5JOQaBBKSyzFPMMZGUwvAzXH3albrC5BxiQqvfrXYSq7iRog4QjI+bGD6YrmdXt5I5l2qxGMOScE1zYmLaub0nqYkjMFLEkOD8u1eSO9WbC6eDUo9pzGRgkrjmmOsgXaQ2/d8vPQUx2KSHcJFUD6/NXnTXNFo7KUuSakjsEuQRzwaDdxqfmbisBnuSowM5HSqklvcSnkEfjXgShqfaU/eR6Lps6yxLtbcD3rTgLRtlcjPUDrXn/AIduZ9Oby5WLQk/9813FtdJKoYHPvXTGr2Hy20MbxdqCaV9lg+xPfLqFylosIHBD/eLcEYA9a6DTtNjjjRECJDEAiqowAo6ADsKqfadQm8UvbJZouixWQkNw4+aWct91T6Ada3bYYB5Fa3V0mSm3sTJAqoAifQmsa7j1r/hKYkjigm0Oa1IYjCyQTg/mwYcYHT+e75hrO16xTVtGvbCWWSJbmJo/MiYq6E9GBHocfXpWl4icWVbuP5dp4IrVtINtvEMfwisDRWSUppD6il/qOnxRLeSAbX5HDMvbIFdUABUJWbuKbukM8oA571G0YHIA5qyc96hY0GaZVlTHzCmI+4e9WJFypqqF2EqTnPNS1fUbH7+M5p0bDjJqIAc+vSnAYwaaRmy0jc8VLvHNVA+DT2kwp5qybk5YdelRMSeKhEvOKkVskHNWC3H4460dj3owaGIA/CplsbRIpZQkec1z/iXSrXWtMh/tK/GnwW93DcrOxAAZG4U5IHJOK05m8yVUAOO9VfF+n6TfeEr+38Rzvb6SAkk8yEgoFdSCCAT1x271jTf7xGs1aDOujXLMxGCTnHpT3IxTIXWSJJEYFXUMp9QRwfypzLkZNdEWZvVmfqEXnQsh7ivPNUtmimZSORXpki5/wFYOvaeJoTIoG8c5rDE0udXW6OihU5XY43Tbnym8pup6Guss3WWOPnn1FcXeRFDkcHPWtPQro+YpDng8qa5KNS2jOipG+qOh8Py6s95rP9sRrDbLdbdOA2/NBt+8SOuT681voTnOa5LwourWulGLXbgXN+Z5HLhtwWMt8ig4HQV0cTuU5Ir1HP3tDkiny3ZpxEj+Lr7VKM5HNUoyepbmrELEjk1W5LVidCNoHPJq15wK7MYB4Zh6VSUEng9KmUfKOlPma2Ikkx28Fmx0HANQSpnrxmrHTpio3GMnOaSfclaMozoCOKxdQjAUmt2c4GfQVj6krOmE4qGV0OTlZS4CqScZBJximNtLIB3GcFuBVm/iKEhCd3XgZqqvmDeI87TypKivosPPnppnwuNpezryj5iq6sVwvXnG7pTw6EJvjBLHkMehFRkSLuKAgY+XAGCachckuoyGA528Zre5yWJ0cSKmUAJOMMfTvUkeCFLxpycY3dx3qALJt3ANjGM4GM1MuWxtzyMZ28FqQ7FFSVeIq2GPEmxe/rQCzI4y5YN8hPGPbNCq2IgrFmXh9vHelyxjkUAjzGwuW4X61kzUkG9HDLv27cMM55IqOKDCoC2XBzkNyacEKyFlwAFwQD19zUeAAqGSIkHO7HX05pokkk5eUlVy3RSeRWbqcG7ynYLtXj5jncKvNjMjb4wzcMuPu0PEu2MbhkfcAXduFTKN0NM5C4tGEbJuABbcGJ6e1UzxLuGCq8EK361091aKIHUMuGYgttyQ2K5eeLbNISFyV24PGPevPrU+VnVTnc6tYgyqQO1Na374qxpWJrOA5z8oFaQtcjkV85Ug7tH2tGacUzC8k4PFWLF54JVEeSpP3PWtqOwDYqtr2hm/0W406G+SwuLweVFM3J6gkKMgk4B6etZwpSclrY3lOyuReE7jVYrOf+3JTNdSXEjqEwVijJ+VBgDoPX1rpIb5R6j6iix09LaCKNASsaKgLHJOBjk9zxWgkYU9OK6Um3chS5VYg+2AjChmPsKdHHJOfm/dp79atDp6ClXk5/GrUe7E5voYuurpnhuK78VjTJrm9tbXyJWtz+8aDeCSQTg7euTyAK6C1uIrq2huLZxJBOiyxuBjcrDIP5GkA4PQj0Pes3TZtYPiHVba+tYf7JVI5bC6i4JyMPG467gec9MVvuvQx2fqbDtjioS2aGYdD0qEnnioK2H57VWkG1sn7pNTb8Hmo5sMpxjNQwuRluelLnIOKYoBANSAADk0k9SWiPcR05oLFvc0pQ9QKVEPpWiMxEGTVqJeKiAwelSK20/WqbKiWBjFU724WJfUngAVLLOEQ5IFZZZZrgs56HArOTubxJLWOVpCzYGTUniBbL/hGtUOtRNPpi2zvdRrnLRqMsBgg54q3ahcdRVi6EYsLozRCaFYXZ4iM+YoUkrz64x+NTTj71y5vSwuh3VteaNp91p4P2Ke2jkgyOfLKjb+mK0FyetZHg/UrXWPC2lahYW32SzuIA0Nvx+6UEgLxxxitcnnNbcvK2jNNNJiEfTFVLhAykcYqZ39Kryvx2qroaRx+u6ZtYugyp7YrlbtZII59jiIsjLvJ4XIIz+HWvSdRmiWImRlA75PFeUePbzT7nT7u1afy4Jx5TSqQMZPTn8q4p0VzpxOmFRuLRu+DtQTTNJsNOuLoyywRhGlkP8ArD1zk/Wu5tLtZI+GGD0NeS6datc2UY2lGiwir6BQAP0re05pIHUbpYx3GeKpVJXuy/ZxSSR6TBJk4DVajOK460vpARtkZh6Yrbt7qaQDCH8a6I1DNwN6Jh3/ABqYOM8dKzbYMB8596uDGfmPFa810YyVmT5pjkkcU0yKOM00yM/3cgVNyLEUqcc1RuzgEJyavupbO41XlQc4pgchqcRyXYHOelZW0lgoK5HzHBIOK6vULfcDXNygLIxcMAnBI9PavVy+pdODPms6oWaqr0IvlBXa4LA7hjIJqTCFQY2Vix3YGQabwCxUSZUcZI5FTIVAACuAo4zgjn3r0mzwRVHB3OCSdwAJz9Kl27u67mOQQcEU1PlbCq3yDPbgUoOcDc2QMjcAeKQyl0K7iPlzyT96mlUVZAMbHOSQeF98U9SirGAyjB+TAzn1pMLiYk4YnDkLyOeKzLH4BcbBGWCY29PqaTMWxELAxk8ZXvQSVKgM28r8vyihShjV3jcDPrnB+lMQjMQ0m/cDjDbU4p68PblCWAGFwMce9I7hnlDI29cZO7GRSSOGMQKZ8wZBc4xTERON0LEl/L3YdcYz71yGpxCO9mwzgjOQRn5frXYSMDExKAKpAKluCPWuX16PGpzqijJUMWVuDx0rmxS91M1ov3rGp4Uk/wBE2AlgjEDd1rr4FDD61w3hSVTNIijaCoYDOfau9s14GTXzuIVps+wwEuajEuQxgDmsua20jWPF1sxuXk1Pw+DIbZSdkZmXhm4wWwOMHitncsMMksrBY40aR2PQKBkn8hWd4Pm0/VNM/t7TbGSzOrn7RL5oxJIVyoZuSOg4x2NRC6Tl/Wv/AALnW1dpf1/VzbWMHpTtntzUir19KkC5xQimiHZ9KRY8VYCdaGToauIEYGMc1j+LNLudZ0WS0sdQl068DpLBcxk/K6tkBgPvKehFbLcA8ZqJj+XtWsXZ3RnNXVipBeQ3gl+z3MFw8D+TOYWBCSADcpA6Hnp2zUvcVzmrS6N4PnuNakt54hq91DBdzR8xRPghZXHRR6sOSTXT42nBHINOpG2qM1K+gzbg011yQQRU5IycGq8rbTmuaUjVIhTI3AjjOQalK8ZHNM3ADKjn0p6kEZ6E96hsdhVHOakA/OkQcDPNKSBz6U1OxPKGOahnlWPBPLdh60Szj7sfzE8cURQHaXfr2FWm5aFJWKsiSSSrkjPXb1xVuG2wBwKltoR97uauoqgc1eg72IYohk5WrCryB6inh1A7ZpwkXzE3/dzyfahWHcw/BOsXeueGbXUNQ046bdSNIj2uCNm1yoxkA8gA/jWy8uMgZrA0DVtUl065fxLAlteJdSpGAAN8AP7tsZPUVO13PdRsttGUBP8ArH/oKub96yFD4U2W7m7iiUmRgv1NZU99NcMVtU+X++amTTi8gac+YRzk1cYQ2yZbCqB3ojTctWU5pbHPzaU90C1y7Pnselea+MrTTLSSC11MuFluFESrn5nXkZx2r1G81N59yWUZbtuP3RXnHjGxhfX9OttQEk99PHJcwsB8sQXgn8elXKnHddOwRm9pdRfC+s289/NbYJGN4fHH0ru7aKORQQQc15npkaWepxErhXOw/jXoVjasFzG5APauRb+6dU0jbt0jQjpV+N1XoKzbaF8jkVqRQ4xk81qk2Y3ROspYYANWUBbAJpkMfYfSrkcIBBq1F9SZSQ0KoHIyR61J1HSpQozxSrgdAAatIyciDYfWopIeKsS8cim9U5oJcmZF3GNprkr9dl0RgZzzkZrtrpetcnq6hZlJ4zx1rpwkuWqjz8zp+0w78tShtAIYqCwPZex9qULhNowSW6Adqaw4UEnhcHJ5qRBsA3HHl9ck17p8hYlUYDcKSDj7p5HuKQ/czsGQ2AQDyPpSr8qAO3OM5z1FKN4C5IIX1bGRUjM7KF0ILMpb5AvBBp7FTvA3Hb99fXNM2rhCoJ3cgE420uU+d9uCnbOQ1SMeUUusYiIJGFJbIHemMyhfNES4zggNyKcrKxAwgDL94HpTBL8qswQnJyNvX8aAHb1RpUKx8LkZ5JoLr5kW5Y8Nyc84NIzna2wYTG5Pl/rT03M0ZXKcfOFGcGmIZn92CyISOPXI+lc74miBuQ4C52ZG04Bx2rom3CPgjzSeqrzisbxOmI0PBUcKWGDn0rLEK9Nl09JGToNwqarCNiqZEIGO3evSLBwUFeWWcxjv7dmUdQDlcba9M0tgyKDXz2MVpJn1WVTvBx7Mn8SarcaRplvLY2Dahc3F1FarDg7QHOCzEDhQM8niugRUj/dxBBGvyqEUKoA9AOgrAil1j/hKooo40j0FbJmkl4LSTlsBR3AA5PY1vx1zbJI9WOrbJ0HvipVqNR61IM4popgeOtIeQM0pIApjk9qadhDX65qNlGfY0rP1zULyYGK050iGrj2ijkBSaNXjJGQyhgec9DxWT4futWuW1KLW7GO2ktrpo4JoiTHcQnlXXPOR0PvWmJOc1keIbLUL2XSptK1E2ctpdCWVHBMVxERhkYDqcdPf8we0T91kONtUaz1UmUZPzYI5xTJdRhliD2csc6OSEaNw6nnHUccHis+a0uJGLPKxGc7RwKxs2y7lpryKBmDsBj3qAatFyFR2A6EL1pbfTFaXceRx1FaUNkv8Qz3o5EO5nQXdzcvhAIoz0LDmr8VpNL/rJCR37VejgXHAH5Vcji24xTSSFcrQWscSZVefXvSTZxgCrbA5GcHHNV5Ooq0xobESBjaaSecImWyMd6r3l+lqoAOXbgKOpqlFBcXknmXJwueE7ClfWyKt1ZJ9snnci3Q7R1JqVLW5mOZ52Vc/dXitK3t1jxheBUu3OMVoodzPn7HNeGdL1S3m1c666TxvfO9gwwSttgbVOOhBz15roiqImSOKztI029sda1+7u78XFnfzRy2sGWJtlVMMvPABPPFQ61qJVxBB80rdx2+tbytF3M4Ny0H6hqKW2FUFpG4CjrWetrNfSeZeH5OyDoPrTrG1KnzHJaRurNVppZMYRQQPaocubfY2tbYnitoolxwAO1c3qeqQTeIb/SHsE2W9is4vmHd2x5Y4/Hg/hWpNHPKSN5Hpiuegg1e/1LWYL+N4rG1mSOzfaQZ1K5ZvQjPHFbQnGzSRnKLurs8/1WdIZW2sMg5HNd94ZvRf6dDOp4ZRke9cl4t8LGDMyhsd/apfATtFYvb7irwyHB65B5rhnFRPRupRuj1W0K7Rjk+tacRBGO/aua0+5BUbhj6d63LaUNjAq4SOaUS/G2DwKtxgnqKqQ/p6VcjfP3ea1M2S84wTxTeacozyaVhx1pkMjIz9KRhThSP0pkMpXKjFcxrcQJBPQGuqn5HtXP6zHuiY+lVF8skyKkeeDj3Rz2V35AJGdhwev4U4EFuVzztPzc05VcgHYSMYOQMZ9qUIcqSW5GDkd6+hT0ufDyTvqJxwdrMQccNSOwwSVJIOCAe30pUZhw657Y24xSjdxuX5T94baQWKGQqAkLkn5hjI/KnAko+0KMH5CB1/CkAc7cF9+cNgYyO1KA4WQckk7l9QakocHBYbthQryCuAPSmjzHUYLBgcHKU9Vfcu8OV2/MDz9Kb5TKyDLBgcgl+tAhmGAk8oSbM/LzwPwqUEq6kbjtGGAOCfemPGpMx+UBucFuRzSYAnQuRlVx8xzu9DTARTIUUHO8tlSSBx6ZrP15Gks5A2SM/LznafWr74MaqdgUnOfQ1DcRiSG5VjH8y4yOAo7HFKa5osE7M4o70dCyucfeOc5r0TQZg0cTk/KQCfpXn8odZEKhW25yFP3q1IHhuvDb6ddXws/tytaJIMbtzfwqD1JGRXg4qHMkfQ5XU5ZuPc7vwxaahYx37atffbJbm8kniCklIYjjYi56ACujiIIyK5zRFS2sba0twwit4kiTJ7KAB/KtVZXUAEZJ9K82TbbZ9FFJJI1VYU8Pj0rOWRwBkjPpTlZ2B3EqKabHYuO2apy3PlffyB60pG7IVyfc1GbfH3iWquVsQxryMkhct9Kge6B4AP0qZ7QOcgY+lCxBGG9VyO+KrlsSRoZ252jb9aQLcynhtgB7DrV5E/KrEaZ7cUCempx2nW2ieDb2y0iMzwf2xdSyW+/mFJMAmMHomey9zXVPGPSprq0imVPMghlkjPmQ+coISQA7Wz269RyM1leGL+91TRIrnVtOfTtQDvFNbsDgMrEbkJ6qeCDWktVzfeYp2di4oAJx61ZUAVEqYJBFTKOMAVki7gHwSKnVyR71AV+YHpVmM4Uk4qXqVdEZYKpOayL++IkWGDDSt+Sj3q7qdyIoyUALngCs3Trc72aTBYnJoV1oWtrj7SwJk82U75T/Ee1bEMW0A46UkMZUcdKl3YJDVvTiRJtj2fgkce1NMgX8qjZgeQazNVvxbxjvI3CgdzWi8yLX0MSSOGy8Y6zfWt55t9qUECSWnH7lYxtEnXOD9Ku2drtJZyWcnJY9TWPY2NhF4wa7muWOu3Vht8jPymBXzuAx2PHX8K6VsABM47/wD1qU5czTZVONrpCqOSF+bnpViGDIy/12iltounGM9qndgo6496cVcpvoh4ijVl3YC55wOa53w4dXS0vT4ieM3LXkpgSPb8lvkeWCV6nGff1rQuLtpBIkABl2kKx6BscH86yPDOn6hpvh6xs9XvGvdQiUie4LFi7Fiep5OAQPwrVTSjZE8j5lcTxJAtzZSovJIyM15v4fnNnrjQMcLMpGD6ivUbwjBHcV5B40Y6fqZlhO10bep96zqwc7NHTQdrxZ6tYhWj5GRWxbx4+6SAK47wtq6X1lGWwkuAWT0rsrdw3fgisYvoKaZfhyDnOfwq5Fu9Rj6VVg568GrsfGBjmtUjJsnTJP3qkZQB71Go/Cn5GOvPrVoykMb9fSmt+tObk5zUbU3oKxXmHFYuopuQ5rbm6VlXi5Vs0gOW24DZcDPGOeDQe/IG7jjOAafIuydwQxOdy44oDAhSQ5P3ueOa9yhPngmfGYum6daUROikBx84wOuAaRQDuAYAY2nBNKSG2lSwJ+YDpzUROSuAw3c4JxgjvWpzFNxJ5SKeinOS3X8acn/LcqcK3B54FCopVD5h2knb8ucHvTuPnxuAX75xyRUoocqjcoTaWCdA3XiolRCqgumd2c88fjUn3igydwGV3LTVEewD5wrHkZ6ZpoQrKv71i5X+8oXI/OmjBZAC2duUKjPFPkcIJhyxXAJzjP4U3gPGjDIIypLYx7UwGbYxGpDsylscD+KiTGZd5YkL8+5e3tTWYFFJUYzggt096kZjmUE5AHrww9KGI4q4Uef8rKzLnaGGM0eGY9O1HWI4XLy3mmN9pRQSETeMc9iafdFDcsfuj5mznOB3pPh5c294kl7b232Zro5bdjc4UkAmvGrXUJM9nANKrG56fZR8DbWlFFheOCaoaefkFakfIFeSfUJj0QDgdanWEt1PHpTYxVhTxWkRtjRCPSneUCPu1IKeOelaqxDbKbR7ahlUHg8Vem6VVcA1EikQI20gH8KtRHHHaqzqKSGQg7W7d/Ws9hvUvMehPNYup22qN4j0y+s7+OPS4Y5I7+0mOFZSMrIh7OD68Y/GtcN8vNRXUMVxazW9yiy28yNHLG/IdWGCD+Bpp2ZjKNx2VIDIQysuQQcgg9CDTlXmub8PPpnh6Sx8IQXlzLdW9qZ4Bdcs0O88K2ADt6bR0ArpC3FOatoJaocc856UySTahzxinF8D2NU7t2ZW29h1rO1zRIq4M1xuboOavW8Y44qnbfdLf3jgVpQnA5H5U1uWThQq9xxTHI79fWnOTgDIqF29RXRBmbIridYo97EAAZrn7fffXjXMgzGpxGD6etO1mY3VxHYw8FvmkPoP/r1p2sIjVV6Y7UTd3ylR01MfUJ9Is/FmjC6jkOt3NtPFaOAdvlr80innH6VuWsZc7nHP06ViazeWVv4h8PLeWQmur25ktbS4wM27bMseecMOOK6dFAHAqmuawk0roXeIlyenv2rEu71rqfyLb7g+8/rS6/ftAqxQnLvx9Kh0yIQwjnk81NSf2EaxjpzCazpsd34d1K0lvEsBdQNB9pcgCLdxuySPX1FXILdNL0qzs1csLaBIQ56ttUDJ+uM1geOP7L1HRF0vXJjDa3tzFEm04MsgbcsY4PUirt4Lu5Ykfu1P41SmowSRKi3NtlPVL5EEjE8eleMeObyfVtZS0t1OCRuYdhXr1xo3mZ8xySeTXMyeHorW9lbBLPgAnrVwreRqoa7lix0oyaeklqzJPGgwVPXArb8P6nczRhS481DhkYYpumK1sRG+djdDSaNGg1K5U8Ojk8ehrKpBWTLUm7pnYWeoE8SqVOK1oblHUENn8ayLWMFOcVcRVBAAqowdtGYuxqpKh6mpvNUD5Wz7VnovFTKitjGR7etUoyIaRdDKfemtg8g800RYGQCMdu9NdTj5TTfN1IsnsRyfNWfcrnNW3LA1WlORzUj5TmtSjK/MoGVPeqhDMxZAAB0JHWtbUF3BgO9ZSMSRlxlecZr08BPRxPnM5o2lGp30GPw5Kg/7Py5BpSzNuwOD0G3vTWJJXa4LA5GD1FMGWcclmzu6Yr0LniMr8CMMR8rHGM8D/wDXSnCrKCMBeeDkNTF3BPlyzgjOB1FPJY+YCMEZ2nFQUITGVUDABHUN0psbr8pWNc5O4DrUil8/OuU2jI2ikKuTEpyOcE+opiYjHIZVXPGUJXr+NAfDDnC9WG3PPtSvuUPtYhCOPmxt59KGBUqQeQMEE4yfWgQm5ti4HzY5AXPHbikdWLHd1zlRt70u1tibmBK8g7vvD/61JyVk2kbWPc8KfrTA4TxPc3Nr55srVbi5LqqqVIAyw5OOwFaWjypFqcRwoL5XgY5qHXI79PE8MiMBpwhYyLkMZHPT8B1zUSGSO4iYgllbJPUYzXl1o3TiehQnyuMj0/TmyorZg6Vzmly7kU5rft2yMg14i0Z9fF3Rej4FTAVBGelTCtEMk/nTs8e9RZJNKOeKrmAJOlV5OBVlhkU0qMYx+NVYE7FDjPXFDEH/AAqw6CoJBtpOI9winH3TwRUhfcPl5qmwJO48YqxGRgEcetQ1qJopa1EY7SXUrewgvtVs4ZGtEkwrZI5RX/h3Yx71Lol+dT0iyvvs81sbiFZDBOpV4yeqkH0NXcenNZAi1ePxVNcPdwy6DNagCGTCvbzg9V9VYcnJ4qtHG39ehOzuacjM3AHSmyLtiY+oqxHHhfeobkfIVqYxsrlEESbfLAPHJIq/GGA6A1RLfvgg7DmtCE7RSirsJbAASe2apapcC3t2djgAE1cdsZNcn4gnN5fxWcZ+UNvfHp6VvfljczS5mS+HojOWups+ZKd3Tt2FdBIvHA7VBp8QjjUL6dKszfKnTv2pQWl2U3qYniHVZ9FGjG3077aLvUIrOQgEm3R85l4B6Y9utbN5MIULdetY/ibUdVsNJSXQIFuLw3ESPEy7sws2HI5HQc1Frt0GZ44iduSAc9q1bUYJiim5tGcZjeam0pPyjgVuR7dgFc/Zko2AOO9bEDHviuWLu22dTRS1v+xptb8P6fqsbyX8k73Vgqg7VkiXJZiOMAHvXQeWCflz+FYaX9hP44h0p7HzNTttPN4l4wBEKO2woO4LfliuoRB6V1W0SOdPVspmLjlSTWdd6cJpQ23AHSt/Yc4pfLGOlJxuUp2OVuLExqDgkDpWHqaSWd7DfWwJPSRR/EtegSwhlOQMGuc1G1Ic7R8mCMU3tys0hPW5paRewXkCyRtnI/KteOMMOOtcFBBNaSiW0fYSPmXsa6jS72aVQCRuHY8VMZNaMUo9UbiRH1qVUI/CooZmPG3D+lWo5eB3PTFappmLuSRoWUHd74pki4yeaUMy8rwfSkZ92c05NWJVytL3PeqkoFWpuc1Tk65rC5aM68X86wZsxu4B5Hr6V0N3hgfWsK9U+dwQPc+ldeDlaovM8zNoXoN9tSupVVY+g6Z6ijcQhwOFwRznPtSjeAuSuc9z2pTkAgsB/FnPb0FeyfKFHaRGFBG0H5ST1z1pWDbHCuoDffx/DR91Exu2lsrgcg+9K5wrnnGfmz1NQA5DtClSGO3ov86asYUR5cbifkIGOfrT1wSoG7pkH+lMDjy1A3FSSOTnFMYrkM02Tg/xZXPNIOJFbd8wXjaM5FNcqVkDA7sjnd1pTjzSPbIO7H4UxDEKnbydmTtIHfvQhCq7MeN2XBGMH1pd4VY8rkE4wTjBrP1yWx/suW31C5NrHfMbJXVvmZnBA28HnrTBK7sYcunS2t9qFxPfC7a9lM6FRhY48ABV5I49R1qBUbEQDBioyOMbq2dSsYrDT7S1tUKw20KxL82cqBjH1rHUZKbC2cfLzXnVvjZ1Qd9TtdAnEltE/qK6m0c7R6VwvhicNDt6bWrtbNunPWvDqK02j63Cz56aZqxk4qdSQKrRmp1NOJ0kop+PxqMdaehNXoIf1FAXil9M0nPpxWiJ3IpQOaqTkDgVak77eT71WZfzpMpEQQEHucUINrbT+FWESo5lxyKloLkinj6Vm69o1t4g0W90u+DfZruMoWU4ZDnKsPcEA/hV4HdgLVmJcDFEbp3QmtLGXot/ZtLcaNDfveajpMcUV35oxIcqNrngA5HJI4zVyY5ZfSsvxVPHoNnd+I7fR/t9/FEkMxiOJTb7+cf3guc4rQmkUokiZMboHXIwcEZHHY+1aSjpcmD6EEB3zyN17VpJwtZlmCEzjrzV/cMVlTV2VNlXVblba2kkZsbRmuc0GFp5HupeXkO7nsOwqXxJMbieKzQjk73+grR0qMRpjApzfNLl7DiuWNzWiwFHYU26faAc8Uu/C8GszVJvlwOuO9brRGa1ZgeMZdVfRLuLw7MseqEIYHbGB8w3A54+7mp3UOd7cnjIqprdpc6hpF7bWVwbW7miKRTgkeW3Y5HP5VahR4bW3jmYSSJGiO4/iYKAT+Jyayk7xNYq0iS3hL46CtSCFRjjPFV7eMhBkYFadsoOB+pqIItsz9D1Ge78R67YSad5Nvp4hWK7KkG5LruYA46KeOK6VAMVh+FZ9Zu01T+3bVbVIr6SKxQDBe2GNjnk5J59OldAq7cHp2rqas7I507q4wqT2xRgDpyamIGMUqqMU0gvYrvGWXn6VTubbKngD3rUcZKgDpSSRAgjrx1ocRqZyawBZVVh1yK1rC2RgrAAdqjvLZo5lcD5B1qS2kKO+BjndUWtqa3vsayW/TGKsiFUOc47NUMEgZevNTsxIHeq5kZNO4ORjHX3quwwcg8U8tjg1DK3FS5XGlYik5yRVeT2qYnj+dRP0OKzZRRuFG05rn74/vBuyAM8gZrfvG2oTXOXbEy8gED1rowmtVHn5m0sPK5GwCk7ScA5xjsaQgc98ccelCg7ckYA9R1FN+YENjA7jHavcPkCvklRhcnPzD/Ckcv8w8v5uSvH50Z4j54B+XnrTRzG+G249+hqRskAbJDLhTjHGOaUb+C6dM5BXAIpFcljk7htwRn9aVDgxsXDHnHJ5oATc+PkHy/wsAPyNL83LLHlTnjg4pAFZZDuXJPPHINDZLNnG7HIPP40wBi3ylQS3R8L1rHeSx1HxEthJEZr7TUW9SQr8kW7gA8/e74IrbG390hYbcZVuufWsXw3enVtMOoSWS2Lyysg3KQ7KhIUtwDzzwelMa0uyxrqu9q5xyCNvHOa5pzkLujOMcnGMH2rq9QTfZ3GD82OccY965fEitu4IHUA9feuLEK0rmtF6Gj4fkC3DDAUtzj1967uyfKjjFeeaaxiu4ckMCSM5rvNOf5BXjYpWmfTZZO9K3Y34GyKtLzVC3Y4q7GTWEWekTj2qQdqYpp+cVaAeTxSDJB7ChR+NOB7VaYiLaCeOlRug7VaC5H1qFlwMVQ0RLxUU/Q4qwBxUNx0OOppvYLFa0OHPf39K0VHFU4UCqPWrcRJGPSlFWJkDEjkcEelcvAutLquspqbwz6c0iSafKmFdVI+aNlHof4j1/l07nr6VyPjXSF121gtBdTWdxHOlxb3EPLRyKeDjoeMjB4qk0tGKz3RtW5KgCp538qFpCeAM/Ss/R9SstVE0thcR3AgmaCUp/BIvVSOxqPxTcmOxEKHDzEKPXHelFcibfQb95pIyNP3Xd5NduOZDhc9lHSuitgFXFZmnQCKNQPStLcFwAOfeopp7sqTJi2Dkmsq9PmTbedtaH3hnGfftVNk/wBIINaSehMUVNSsRe6beWruYluIHiLjqoZSN34dar+H7BLTQtPtorhbtLeBI1uFIIk2jG7IJ/nWxIiyROjAlXVkYexBBrL8FQaZbeF7G20K6N5p0CtFFMTkthjuzwOhJHSj7LQX95M04kJwD0Na1qgB5Gf61Vtotw5FT6hbT3WkX1taTrb3U1vJFFM/SJ2UgMcehOeKILUc5WRB4Lt9Zt/DttF4pnSfWd0hmdCCAC5KKCAAcLitzGRWf4esZtO0PTrO7uWuri2t0iluGJJlZRgtzzyfWtTGMH1rd6tmK0SI9pNOQe1OxyPSnYwc9u4o0Q79BOlSR46Yph560qk7gAPxqosh6iXMStjcvG0is0Q+U7ADIYY5rUkP51WnUnkdevFKdmXTbEtI9yjaMt3HpU+D61VgkKs24de9Wt4YDFZWTNbsjkY4qvIWI5qy2MVA2DUWsO5BzimyNtFPk471UuHHJzUvQLmfqMwCn3rDJG8uW+brj2qzqk+59imqmduenBxjOcivQwFPVzZ4Oc19qK9WIAoPU5HHI7UjFcfMT/d6YpDub05OD34pvzDG5RkdePyr1D54r5UBAF+XPGOCDTm6NkEjoff3pr7wqfu8uDyMdqcwO1srjnK8Uhi4USAKSSV5yc/hQrR4XgjnPBztpMhTuK8EY6dD60/5mQCRQR3xjJoAYdoJ3ZJBAIz1pzIgcAgnAOG3YJoG8pgbRzgE46Uz5iTt5Udsjg0wKPiKa/TRpZNEtxPfnCxIx4Q7gCT7AZNaIYmEGT5iPlYg8Ej+IVQubbUpdc0ya3uBFYW6SG5iBwZ3IwufVR1q/h1zhfnHPHQj0oG7WRHcIHjnyWAC885yK5NhslIQkHGRnkV2BRh98D5h8oPHNcpdqVupVKbQOpxiuXErZmlIghYboWUnAbIBrvNKcMq5rgQRlQ8ZXsSBjFdZoE2+FOT6V5OMjome5lU7ScDsrV8qKvRn3rKtWwQM1pRMDXEme8XEPeng5qBanH3elXcRIp5pwHNMANSrVIGOHXnoajZcgnuOakOcUx/atLgiI+pqFl3HNSuO3c0KpA9aE7jehFtx0p6/LzzSgZobIGKsgjlbg1hTuZbo+3ArVu32xN6gVmWKFyW75rOXYtK2pnX9zp/hOZNQGmyEaveRw3tzACfLYjCSOvcduPxqPVpDd655Z+7bjB781080gt7Z3YkADJNcP4Mj1WeC8k1uKMTC5fy5osbZoz91sD7vpg+lXV+BLqRDSR08EZCqcUsx+cDtjFSqNqD2qEAyO1StiizEPkzULx/vC3Xk1bjX92fXFMYZAPvTYiJFZnAXGTWN4IOkHSJYPDyyJZ211NCyuDlZQ2X684ya3kT95x68VkeFL3T7q51y20yw+xGx1B4bgAACaUgEycevvzVfZYnujoYE2t9OazvGul2mteF7zSL/AFL+zIL4pD9oyuc7wwQZ4JYrjFbCDGKyvFVro2pTaDYa3O8cz36XFjEjEedNECwB4Py4PQ4+tVS0kmZ1NVY6KOPYoTGAqhQPTAxUgTIxnigHcxJPJ5NPBx061Qhu3GQeopcZOO1JJz0HNLHQMR1xjH3aQZAqZh8pHaoCCp2n8DTeglqMJYvk9KG61If0phHHUClsVcrsMMWFERBX/CpHXINV2Hlj8c1LLTJyOOtRvx6UhcEYFRO/GO9QwTGSNisu/m2o1W7h9oP0rntRmywUkn1FKMXOSijOrVjRpupLoUpPmdnJGepGe1NJwoLOcAY+tLuQMcqTjjrjim5C4YL3xzX0FOChFRXQ+LrVXVm5y6i4GBk9sHIzTHPJGM7jgZFP35b7oGc5OKYGbBzjp+RqzMr/ADbAC2RnKnOee4pcnbIM5APz47UnyiMFskZ5Hp70FgQxAJx+OfWgbJE+8Rx9zPIxkUqj7gV8Z4U4/nTFIL8DaAMDtg0KpBXKYBznjFIQrANG4xjnnjoaayHe+4jO3LccY9fypWDgElfmJGDjrWfrl5ZWtk0epSSRW90fsqsgJdnkyNoI59ee1MaV3Yj0LT4Ibq+1G3vftg1KRZUdeUVFGAg5wQOea2OsYG7CknHqD6VW06wh061tbG3j2QW8YiVSc7ce9TnaIwWGcnBAP5GgG7u47DHflxgDB9q5zUlkjvnK7WBAyPX3roSuVZsfKPfO4Vi6wmLjcM8L1zWFde6VTfvGagcFWGHxyQOpH0ra0GQ7mDcENxWLGp2x4Zt/JUGreizeXchSwO7ivLxEbwZ6mBnyVl5nf2j5Gc1pwHArDsnyoxWxCT3ryrn1K2L6H3qxHnFVU7VZiPFapgywg71IMVEh7VJnvVImw/tzTDyDRuzTW9c1Vx2ECg5x1p5AAzTA2O9G4scdauImhCMMTniiThTTgD3qOY4XFadCTMvzhSO7cUlpFt+YDim3IMk645Aq/Cn7s+wrKKuzR6Iw/FFwY7EoOr/KB9ax7jRJLu40e8tr+Wyl02YytgbkmiK4dGXOOR/EenNXPETeZfWkPbdk/hWvZqVUY4xzQ5v2l0KUVypEVrd2t9p0V5YTx3FpLkxyxNuVhnHB+oIp9quTzisPfpPhW/0/QbSzmtodWlmmikUloRN95o/9kkcgDAro7ZQB2qprlemxEZXWu5OBjNQsuGx6GrA561HcKQQ3bODQ1oNbihfasnRdTe88Ra/p0mn/AGZNPkiCXAUgXQdM7s4wSOnetmPkCqFnd6tL4o1GzurULo0FvC9ncBTl5G/1ik55x6Yq47MlvVGygwCMcjFY95Po8/jfR7C7tmm1u3tJr60lwcQJnY569T05B/CtsYIz+FZOmapa3vjTVtNXT1W80y1hLXxAyyy/MIwcZxxnriqhuzOb2N8cfjThnuc0fw8daFxSGLznPpSg7W9j0pRikPP1pgSZzUUq5HNPT3oaquRsyqG7HrRnikmGTxTAxwAetQzVajs5I9KjmG5T708k9ajkYYxmpbEQk4wKjc4pXbP1qCZwFIqGy0Ub+Xahz6Vz0js7ljjHX8K0NVlwCoyfWsxiu3uQK9HL6X/LxngZxiNqK9WCnB5bse/al6dWyQPemAgg4Vj269qRt/3enqPavTPCA7Rn1PHSkyuD8p5/DmjL9gM4xz60xs/3gPXnvQCGfNtGcbunHGRTXckuCcDsc/dPvSBlEfIyuefY+tOO0lwFGe/+0KRTQ5V+YnIJ24Kg9vWkBwY/mBB6c9TSBssMZA28H0PpQu04YAg8gg9vcUCFQ/KwydufU5HtWZPcWd54mGlTWhmmtoFvxM/KwPnauP8Aa7g1pgDIDdSwwc9qztCvbu/tJ7i+sxaHz5I4VOQzxqcKWz3PPtQVHZs1ASrjJzx6/e96T7wBDNkH7xPB9qTALIMY445xtPpSjHlhicAtjHoaCBR8ynaSGzwew9qzdbjJTPccD61pkDZIc/KevH61Wv499pMGIGAM+uPaoqK8Wiouzuc6fmAVhtOM/jUMEvlzxuFx83OO1WJAyEbmDALgAcGqSZaQDfkjLAjvXnPVWOyL5XdHfaXNlQM10EDZUetcboM4liQ5zkfrXWWTggA14klyux9hSmpxUl1NWM1ajxiqcPY1ZVqpMosKakXBqBT6U9WIq0x2JDx9KTtmmk0p6Va1Cww8mpUGRUeOakUkVpAUhx/XtVW5f5W/SppGIHP4VTmboD1NXJiiivaqWkYnrmr7kqhGOTUUEeCcDHOakuP9X9KUNEEtWclfjzPEEXUhUJroYRxz6VhIN2vSHnAUc10US/LzWMdZMqeyIbqORomEJiWfY3lNKMqr4OCe+M9cdqz/AAtNqVzoVrLrlkLLU8FJ4lIK7gcZXHQEcgds1qy/eWsbUbGWDxHa68NV+yabBaSQ31vMx8p1+8sg5wjA9W7gYrZWejMXdam4vanOm9GFIrI6RyRsrxyKHVlOQQRkEexFSxcsaXWwX6kEXGMiqUMesnxlIzGM+G208ALld63W/rjrgr+FajptbI6H+dZsthqMniuw1GG82aTDaSwXFoWOJJGOVcDpkdMmrgraMUndXNqLk4PGeKy/DuqX2oXmtxXunmzgsr021q7KwNxGBnzOeoz0I4rVi2iVRJ93v9Ky/CMmtTaKJPE8Sw6i08o8tQoCRbj5f3ePu85ppaMmT1Ruqe/agnDcAc0gAHQj8aG5yPSkx6Dsg9qCewP6VGrcinEmmmIcWA4ycdaaX460wjjJ7UxzjHP40C0EIJPBpCvFKTnimO3BpjuMYnHvULtzz1pXbJpmOpNZSZSGE4BwPxqldyBYyfSrUzAKT0OK5/Vbnny1Jy1KEHOaiupNaqqVNzfQoXMrSSM5AGenPao/mRVKkdc9R0ppwFAPfkAimMAuMDkDNfQ04KEVFHxdWo6s3OXUe7kfxfX6U1scKSTxg980KoLfKpwO9KobOOMf0qjMY2GJPPXB46U0nJzjH+NOBO05IwODUZAJwT7ZoHqM2kKSAAf6elPXedxCEZ/SoyB5RVvXPHf3qSPdmXB7f99D0pDE+cyAFQePmUnr70nzb0BPIJ6H71OXDONuenGf5VGWUheNuCQRn9aaEU9c/tAaPe/2SFa/xiDewAViepzxxz1rQiWRYx5jq0oRRIw4BbAycdueay76znudX02aO7EVvZyPLPCpOZ9y4XOOw64PWtRgNzAfN6H1FDKe1h4LbhgHpzgdfelyRt+UEnrgdRTMgFSScgdc4x7Uo+UIW9TjnpQSO6gkDnOB9PSkkHmJKCvXoB/I0xZCEPUAnke/rT42OyTGSp6nv7UPVAcveYjmYAndt69h7VnxbVYN5e3I/I1qa2m2eXfgKQCcdqzVHzNlwcL0x2rzmrNo6k7q5uaDOSWUgKR8wArtLF8qK8602VYLqH52wRtGa7jT5eBXk4uHLO/c+lyyrz0uXsdPCcgVZTpWfbyZANXUesEekWUp/FQqc96cDiqAmpcgVFuyRSmqTsDQ/PpS5phOKa8mF461tFktBKcnbUBTdIPapU6eppV5bpVPUL2HRe9NueV96U/Lz2NR3Jyh+lO9hW1Obt/m1ec+4FdFEPlrAtExfuxH3ia305TmsKe7LqDZOn0pk0EN3ZzWtzEk1vNG0ckbjKspGCCPpT3+6OeRToeOnStFuZMwdEutL0fULfwfaLcxSWlktxbeeSwli3EEK5+8V7jsOnSujj4NZevteW+lXtxo9tbXGqxQs1sk44Y9SmRyMgHAzgnGauaXcPdWFrcT20lrLNErvby/eiYjlT7g1b197+rkLTQvsodCPyrB1TSFu/E/h3VG1H7M2nGdRbEjF0ZExt5IyRjPQ10KEbeK57xZaaVJfeHr3Vr02clnqCtZ/MAJp3UqI+h6ge3Srjvch7G3cxTyWU6WeBdtE6w56Byp2k/Q4NV/DVvf2fh7T7bW7g3WpxwBbqfduDydyDxkdunaoPFlhJqvhrUdOgv10+a7i8lLpuPKJI56jk8jr3rVto/s9tBCCzCKNI9x5LbVAyfrimn7oa8w8dcGpd2BxUR5GD3/AJ0o9MmkkMceuSPxoH1NAB2/LyaYWYA4BosIczVGRwabvJOe3SlZuPahsdhhJwaidx9aWRs9KhOSfQVLY0gyeTTXYAEUE4zVaeXA9hUPQpFW/uPLRiTxXOSSGRyxYDJ4z1FWtTuBLNs7e1US43YbIz1NengKHKvaPqfPZtiueXsY7Lf1HL8zcEDn8qRySTg4JPA9DRGycjawJ5znvTS3PyIB6Z9a9E8XoNQqRkE+tC8jABPt60E7AdpAyc/jTA3T5vegNheSTxx6e1Ix5wSOnakLbW2gE4GPzph5PT2pDGjcM5PfK9OnpT9xAcAduM9jUcqBS3IIBG7H86co3F+c/KOncUiiRm5UHoByM5z701izbCSCVOeD1HpQi4K8/wAOATTAin5XGQcqVPYdPypiMrRYbCS5v9a067+1Lqbp+8z8qhAVCL7ZzWuxOJBuxnqCelRWtvBZ2iW9tCsVvGdqxJwFHsKc4A3g8twCM8Ggcnd3LCsQzLxnb0J6+9PyQQF645z396r7Rvxznbxzj8Kk242nO0YyP8KCb3HKCuBj5v4uOooOctuHI6dhigLlEAc4JyMjpT9xWI4I256+hoDqYWuoCdwGSRjr19qxBGEyAAM9D6Guj1ZQbaUuc8jdjtXO/eEg+92PuK4q0bSOiDuhhchj0IxyPT3rs9Gn82FH55GD9a4qTZhjySBjjv7Vu+HLsK5hz23Lzn6iuDFw5oX7HqZZW5KvK+p31lJk8elaEb5PSsawcEZrYjHQ8V5aufTFxO3epQPaoI8gdeamU5rQQ7aKAT25FNzyfSlHrVIBWx6kVGgLOT1HTFLIc4A709FxVR1YnoPVTigDBpyfjSkfNitiBjDNV5jlWBq0y4FVbrhcgdeKJFRMyBADn0NaUf3RxVOJcjj0q9FwMdazgtRzGleD7U6PI6UuOcetCj0q+pmwl5UMO1YtvbXdh4m1DULrVozol1DGq21y237PODgeWTgBWHUdSTW+BuGKyvEGjWevaPc6Xqce+1uFCvg4ZSDkMp7EEZBq07PyZD1Wm6NoZAwRg9CKw/Go0MaVaXHiVZTZ2t9BLC0e7KXG7EZOO2T9Kn0PWLG7vb/SLaaZ73SfLhuEuB+8IKja+T94H+93P1qDx1f6bpnhO/1HW7D+0NOtNksluACWIdQpGeOCQaqN1NIiTTi2HjXTLDVbW00vWdQ+xCa+ieIAjNxLGdwjGeua6R3LOzEcsc1zusPo174j8O22pPK2qp5moaei52/KuHZiOOh4z+FbqMc5U5o2SSDdtjyOKQdiOtP4I6dPSmMAGJU/UGkFxwPHFMY470mewpGPH+NNBYQ460zdSsPXk1Gxx0qWMG5zjpTCMe9A9j+NNkcAdakoimbArF1S68uPjqeKu3k21T6Cuau5zNIzclRwPetKFJ1p8pzYzErD0nLr0Iw7AEkAk9fakyx64PGPXmg4A+Ue31puR1IPPBr3krKyPkJScndi5YhjvAHTPWo3G4HLHOelPzwMLnJ5FNPA5UehzTJGfKVGPr+NIck8KB+FObOQARz2A6U3GMHBPekOw/JHO4YH8qjbk5GfQ0PkdAAPeo+jZ3D3+lAxy5fI2hew/wADSggbsrwB6cg+tR8AuCcj2704FedvPy8e/tSGSKckbl3Aj86blmkG4j0+vtQCABhiFAwPVaapBxuB4zn296BCh8fxcZwPX6GnDkvj5V9M8qaawAKkqTk84PX3pXIYuDySc/WgB4JDSY5GOQex9acCSAGKgbc89/eoiQrMByQBg/0p7MCRkZGM9f0oAkA+7hM9/wD64psgQKeDz1H9aBIMLuJVewHao2YFAM5yfvAcj60D0ILhC8DhV56c9xXOvEys4XHXg5/SunXC7c8jPP8AjWFq0CxSHaSELZIB/WscRHS5dN62KDbir54z05zii3mNrcLKB8q4z/jSSMB5nUjPzYqGRgN4BbOOQe4rjaT0Z0Qlyu66Homl3AYKQeCMiugt5eBk9a4Lw5cE2sfzEgfLz1FdfZzZjwa8Sa5JOJ9jRn7WCl3NpHJ71MrZ4qlbNnvwatrjtTizQm7e9ANM3nFNLYB7U9hoehy5z2qbPHFV4eBz1qcEVcWTJD0bB96eDznvUG7n2p6k1smRYkc8VA43Kwx1p5/OjsaL3GkUIR27jIqwv3uKilyrK49cGpBg4IqI6Ow5ajnz17inrSHG00J61ZDJV68HiiVflzjDD9RTkGRTz93mmtdCOpz3ia9utH06TVtI0ePUrwPElxHGv7+SDdg7Mcsy5yFPHU9qqeOfHOgeGbS5guri3vNU8otFpWDI8rdQjhQ2z/gXSk+IOq6hplhYadoLhNZ1q6FlaS8HyARmSX/gK/qfaqfgvwvceB7LxDFaSWt75zNPp1xMo+13EnlkmOVsDdlxwAc8mtoRXKnPf8/+AYzb5moieGfG/hbxR4qgitFCa5BYjbJcIYmXeRvt0DYLEHngcjkV3SnDkdK8+0pYfiPpeoWni7w+LG/s/Ija6Vdk6TtHuLRtjcuw8AZINaPgDVdQurXUtI1yRZta0K5+yXEwPNxGRmKXHqy9fpTqRS1j06Cpyez6nbZzTCCDmmo+QMnBpSR65NZp3KegMcdD9aY7A0hbGd3aoz8x4BoGkBYn6U0Dn3pQhB/+vStgZz+lLcojY4FVp3wOeoqWZsCsnULkImQaiT6DWmrKGrXJOVUjcfyrKBC43MPUc0+VjJIWIPPr2qMDB+6M44Jr2sLR9lDXdnymPxX1ippstgZs8lsd6ROFID49PcUY6EAUhz1AXHXrXUcIpI6Fs44ppIJ7+lOUHHJBB549KYeDgNn6DtSAa4ODgDNKxLLjP/66R9oHGSOnNMZipUY5xz7UDQD3yceppu3bwAMUpcHP8qaGUZ4Iz60gAsRuIHQjoOlL1BBIIxkAUDHzDGOMjjj6URAZXChcjJ470WGKSW24fcT2pSw+Xa3ToDSBgxHBB/i46U0r8oyPmJ5IHUUWC4bxkAFgM4x6GnBgC4Z8EEcf4U0qdo6sCfTtQwJyI9xA+6SP0osK4522lgHyO4x196dvA5LYOPTrUbE4JRSR246etKRkZUHGP7vQ0coXJPN6DIxt7jr/APXpgGSp3Bc9DikOcAKO3OB3pckBSF+Yj5gen1p8orj0zhMAcE4PrWdqyZVHPBBxn+laCZ2qGAznjJ4qjqeGi9Ru6Z4rOqm4suFrmLKAqttUA5/yDVV1JZtwwvH4GrrBcEY6noe9V5V4I2nr+dcB0l/w7Ntnmj3ccEV2dk/AwfwrgNHYJf4xtzkfWu4smOAc15eMjadz6TK581G3Y37ZzjmrsbZGTWbA+VFXIzxXNE9Qtg88UrgkgfnUaE9BUwxmtBCquBxT8mmqecU73qiRy5NPB4pinBp2RVpksWmt6UE+9J25qkNDCOG74NMKmNsr90/pT/4iPWlBxz7c0twYDDCnqp9Kbt28j7pP5U4H0pp6kMmjPAzx70/HzdTimRnnB6U84xwMVRD3OG8ehLTxx8PtTuHC2cd5cWTseiSTR4Q/mCK6XWNCstaexi1RJM2V2l3A8chRo5F75Hb1FP8AEOjWfiHRLvStTRmtblQCUOGRgcq6nsynkVykeseLfDUItNd0O48SW0KhYtU0plMsijp5sLc78dSOvv1rZPniuV6oyfut8y0Z0nhbUNW1Syu5tcsls51vZooIghUtCrYRiD3PPTg1zng1hefEXx9qNuVa0Elpp4dTkNLFGd/5EgUybXfFviKI2vh/Qbjw9FKpWTVNXKiSEd/KhHJb0J4H6103hvRrLw5odtpWnBvIgBJkkOXlc8tI57sT/hRL3E77voJXk1bZGjvKfQ1KJDgc4quzjODSLKO+AaxUraGrV9SZ2Jpu7I9qjMuT1pN4/ChyBIk3cUx3AGM1G8oAqldXaxKSxCgVPN2HbqLdzhVPPSuY1G5M74H3AcH3pb3UGumKxkhP51TOGK4J4H+RXp4TCP8AiVDwsxzFNOlS+bDOCSTn3xSOyknqKAB6ngfpTcKAR83pmvTseFdCEknIBz3pysvBCkGkIXn5mxjkUhCgZyw57UrBcGccYXGOgqNnx0wD2pykZ7kd/X60mDnIA/wNFgv2GqSTznHqKDg5BP5n9aOhyG+gFNBBcYHbjNFh3FCnn5j16gU1sE5wTn1p5+9kHHP6U1mHQUASL93Pcr2OaaPlZQOTj160o2ggbdvGePWkUcruXH94VNx2BRkoc89s0mACuS3yn8qlyWCjA6/eHeo8kYyRnPBpgOl6kjhs8gCh2wz5PI6+/wBKaQ3bHXgVIQcEKoHHU9RQFiN/mLjPzEc46GlLc4zzt4OP880pwCQo4I5HpTchWPY4/wAkUXAkG4KufTA+nvTW2lUBJx0GP60qM24A4BI59/egltowOR196LgyNeAuQcZIx71X1CMPasQrZzyM/rVwM24YADAfTNKQzLggD39vSm9VYlaanHvKAxVgeDyv9RSmcMrg55/WrOpWrJIfmUfNkE/yrMkQgEb1yTkY5x7V50lZ2Z1J3JYZdlyHXOVcHB7iu802QMoIPHavNpSwzl8ZPYdDXb6FPus4d3XaK4cbFWUj2soqWlKB10OBirkPJFZVrLkgVqQMRgV5x9AXYjU4AxVdMfnU6niriSxSOMjrS5460hPORTTwTV2Fck3c07NQZIOB09aeG6UJisS00tmkBJ70mcGmmKwMNwGDgg9aB1+lL601ucYOGp7gTIR+FLj05H8qgDkEBhipQ/FJSuIcGx61KrnjNVmYZ4709GJA9qvmJsTB/mxmlL/LnioSRio92OO1HMKw+Trmoy3XIprSVE8vGaTYWHuQfQfjVdnIPtUctxj0qnNdkcEjFZ3GaXm47ioJrxYxlmAxWTPcyBSxO1cVzN3dyTzNvJ2g/KM10YahKvPlRzYvExw0Odq50V7ry5ZYAHb17Csia5luPnlbd6AdKpJkdOuOKsJwAvfsK9yjg6dHXdnzWJzCrX0bsuw/ccYxgAc8U7/ebBA64pEBxkbT9aUA/wAQB/qK6DhEBY55GOmcUm4+oJ9hSsCMen17U3BAAOPegBxfLdqQksAcqT2pGPTKjPv2oJAGML07+tIdgyVHUex9RUbtxg544+tSM/AyB7e1R7l55OOvFA7CLn+IAD+tDsCcknNMAABIH50Nyck4x6UgHk/LwOPWo92P4h+VBweQSSab05GARQCJVIVlwT04LUgKjaV3A+/ag5yOQ3HT1FPB+58wY9PrSGKm0Z5Yc5HtTSFDbtp69uhpy42gZ6GmLgFstj5vu+lAD5CGOR65z60SD5mIPOOCe9Icgsc456D+lEhO5+fqP8KABm5LMS3H+RQc7j3GOD6e1D/LkHGSO3QignPPbHX1oEKpywypxjn2NPIAxktx1x2qInkDJ6df6VKDnbycAUAImSVGCcdvSnIQB0xzyPT3pmcMuG47H/GpDyFw2Oe/8qdwM7V7YTQZBIIP+TXLOuxdpG75uf8AGu2lVmjHTnof6VyV4pSQjpljgjn8K5q8bNM1pszZGBTG043dP611Oh5OnQleoHeuYuCcYJA57Cun8PLu06Pb1ArzsWvcPXyz+IzprCUMgzwa2reTKDn2rmbdvL4YVr2z55U8eleUz6SL0N+M/KPWp1asyCRgOOatIzEdKqLBotlhgGmls8CosNnH8qcCavmJJCaQNzSA9aTk0XArLeX1xq1xp+kaFqGqTW8EVxM1tJboqLI0ioP3sqEkmJ+gPT3q0YPEx/5krWv/AAJsP/kmtT4W/wDI9eKOf+Ybp3/o29r1Gvaw+CpVKUZS3Z5VbF1IVHFbHjH2bxP/ANCVrX/gTYf/ACTSG28T9vBWtf8AgVYf/JNek654u0bRNRi0+9nuJNQlj85bWzs5ruby843lIUZguQRkgDIq94f1vT/EGmR6hpE5ntJCVDGNoyCDggqwDAg8YIBrb+zqPmZfXap5UbfxORhvBOsn/t6sP/kmmNa+KP4PBetfQ3Nh/wDJNe00UPLqL7h9dqniq23irv4L1n/wKsf/AJIpwt/FIP8AyJes/wDgVYf/ACTXqGv+IbTQ7zRba7jneTVbwWMBiUEK5R3y2SMDCHpk5xxWxR/Z1Hz+8PrtU8ZMHijH/Ila1/4E2H/yTTWt/FB/5krWv/Aqw/8AkmvYNQvIrC0e5nWd40wCIIHmfkgcIgLHr2HA5PAqn4p1u28N+HNR1q+SaS1sIHuJUhALlVGSFBIGfqRR/Z1HzD67VPJ3s/FTdPBes/8AgVY//JFV307xa3/Mmav/AOBVj/8AJFe0x38D6UuoMWjtjCLglhyqbd3IGe3pTdE1Wz1zSLPVNLm8+xu4lmhl2su9CMg4YAj8RS/s6j5h9dqniT6R4tfg+DdXx/19WP8A8kU0aJ4qByPBer59TdWP/wAkV7J4s8Q2nhjR/wC0r+OeSDz4bfbAoLbpZFjU8kDGXGeemetbFH9nUOwvrlU+e7nQPF8wI/4Q3VR6f6XY/wDyRWS/g3xo0rMPCGpc/wDT3Zf/AB+vpqit6OGhRd4GFeo8RHlmfM48HeM85PhDU/p9rsv/AI/Ug8JeMu/g7Usf9fdl/wDH6991TX7XTde0TSZ452udWeZIGQAopjjMjbiTkcDjAPPpWvXQcf1WmfN58KeMMY/4Q3U/X/j7sv8A5Iqhq1jrei/Yv7c8PX2nwXcxt4pZZ7Z18zy3kxiOVmHyxtzjHFfT9eWftA/8gnwv/wBhn/2zuqTRM8NCMW0eWl/lHycDpzStypPJHr7U3GMEdetGeOcgmpOEBk9efelZR1YZ96a3ydAfxNIMAfLjn3pXBAuR1xk0HngHvnimtwwwRxSFgxPJFAxQSMeg7moyQA2Tn6U5iW6fmaY31A9qSATOQAoalUkEEY4/nTTxjLGj8h+NAFgHGNy/lSxsABhO/IFMXh15wR69qF24BIYEH8vekgJS2cHAyT24zQ4I5AXAP+c1HgYyM9aUnP3lz7jvQA5mIYcKM+vagbiT0B9D2pCvzZ27h2J70pwyE4JwOtADG3ZccKOuPSnMx3HawXI5H9RSNj5js3DGM+lJgsx4GMfkaYMer5DAsASPz96ep4zkZ2/nTB91gRhgPTpQpy2MAcfMMd/WgBYwSy4I6Hj1p6g/KfUfnTVGDkgYxyP6ilyBt47UADKSF+XP9RXL342zMNueeR7etdTklQGyMVzOogeawbIHPI7VhX2RpT3Mi5PAAAzzn0IrqvDOTYQn0GDXJzuAi8MQP0Ndd4Y/48YwRjIzXm4r4D18t/iM32t/MXK9RzSW7NG3OcVZgBVQ1StAJVyvXPQV5Ul1R9DFkltNkgA81pxMxAPFYiq8TYYZq9BIR/ERRFls0vn44NSKrnjiq8UjY+8KsJJn0rRIhjvLfPJpBG2etO3+hpMmnZCuavwtUr468UAnP/Et07/0beV6jXl3wu/5HrxP/wBg3Tv/AEbe16jX0uE/gx9Dw8T/ABZHlfjqDT9M8bS6xH4sl8HanPapBJc3kML2V7GpYqAZON6luQGVsdsHNcpNr1x4hi8EX/xGit18Km5vorieaFobO6ddq2s8yPwiOA5UP8ucHuK9/orpMD5+8S3Pgq41TRtM0q18KQaAtpcz2+o6zDJc2hYy7Xhtod6K75GRtboRsBFYnh240a70L4Qv43ubSTS1h1aN5NRk2wkJIqxq+8424VQA5I4AOa+nKyNR0C1v/Eej61NJOt1paTpCiMAjCYKG3DGTjaMYI79aAPBrbTbTUbTw9aCEyeFLrxtN/ZcXzJG1mbWThOn7ov5mAOCD6GrOu2cGj3Pi/SrOFrXwjaeJdMe/tLZSsUNpJbxvNhF+7GXKlgOMZ7V9D0UAfNHi/wDs/wD4R/4i/wDCHfZ/+EN26Z5f2LH2T7X9pXzPJ2/L93Zu28Zx3p/xJfw++nfFT/hMTZv4pV3TSUvAGlW18hDCbYHkDcZNxTvndX0pRQBzj2Saj8O/sclulys+liPyXUMHzFgAg8GvDNBPhuw+Gvw6vtNGk20+maxp8viCS3WNJLdhFNHuutvKkM5GX6ZNfS1FAHzP4z1TTNY/4WhfWt1HcaXJqegg3ETHY6h4wzKw6jg4YcHqDV/xBGgm8bS/CPyjpA0KFLhtH+aF7rz8sYyhAaXyN+Sp3cryDX0TRQB89wDS18P+JxoHizw/dWp8NXpk0nQ9Oe3jJ8viaYGaQJKOnzBXbJznbxoa7oWkaN4N8DTtYQ22gXk9q3iG4VPmnj8hjGbmT7zxeYVzvJHIHSvdKKAPFJP+Ec/4TDwX/wAK7/s/7J9u1PH2L/j2+0fYf4MfJt+7nZ8uc981gfDLylm8PPd+K9H07xR9sVdUsU02RdVu5ed8VyxnJdSTneY9o+Urt6V9FUUAFeV/tA/8gjwvnP8AyGe3/XndV6pXlf7QX/II8L4OP+Jz/wC2d1QRU+B+h5YQD/ez6Up5YZB/+vSKOM800kggLyKg8kXoDkZwKacZ4UA9+aCfnOcfnTScNz0PWkMUgD7ppEPHHNITg46Uh67hmkAZA9APU0ZBx0B+lNGCScfKKQk7T8wA9aAGvknjJpCCB8oGPTPalAJ6ZI/rS+3AxQMmVuVHoTSq+4jnueDSckDGDz+P0oU/Tr0P8qQD0x03EYOcelIchzycZzgUwZCnBHB/L2pxc4OCox2PagRIcENuJ5546Uxv4uTnHbvRzuIJ2+3pQcfMAcD+7/hQMVsEkMT060vGTjkgY+opNy/NufAx09fcUhIBb3HbvTFYcxznGScY/wDrGk3YbndwMc9vaghcn5u3bvTmClskk8Y470AHIOcFsDH0oYjO0A8D8qMAnhj04/woG1jzuPHUfyoAAcjv04wOlYOqgrO2CB8vPvW8zBc/MemAR29qxdQ+aZuRn3FYV/hNKe5zl02fvE5I/MV2Hhj/AI9IfYdK5W/jxlsLnHPsa6rwycWkPrivMxT9w9fLf4jOri6DbVlFz8w4NVoCdoarak4BH5V5zPfiwcBsBxz/ADpBHz8pzTztYEH8KcqEUrXLHx/L16VOhA6VGm4dRU6AKelUiWPUj1pyn3pQBj7tC49KZNzL1TQtI1SdZ9T0nT72ZV2LJcWySMFyTjLAnGSePeqf/CH+GuMeG9G/8AYv/ia6AnrRkiqU5LRMXLHsYI8H+GeP+Kb0b/wBi/8AiaD4N8N/9C3ov/gDF/8AE1vhjQzHHFP2su7Dkj2OfPg7w2BgeHdGx/14xf8AxNIvg3w1/wBC5o//AIAxf/E1vh8jB/lTlfNPmlb4mHJHsYH/AAhfhrr/AMI7o3/gFF/8TTl8F+GOp8O6Of8Atxi/+JreB5p4HPUfhRzy7sOSPYwf+EN8Mf8AQt6L/wCAMX/xNNbwb4X7eHNFz/14xf8AxNdBimNxzVqcn1JcI9jAPg3wz/0Lmi/+AMX/AMTTJPB/hhUz/wAI7o3/AIAxf/E1v5wKrzuMHmh1JdyVCPY5yfwp4aAwvh/R8/8AXlF/8TWPd+GdAJKR6FpQI7izjH9K6a5lLcIapOuAD37VPtJPqVyR7HLah4b0KC2Zl0bTN2M/8esf+FYsOhaRs50rTj/27J/hXUa5IBCVB+tY0BOB09ea9fL23dtnh5q+VxSI08P6Mw/5BOm5/wCvZP8ACrCaBoYUE6Nph/7dU/wq0uR/dx3qyrdgenoK9Bnjcz7mcfD+hAj/AIk2nfT7Kn+FS2ujaVZ3AmtNMsoJk+5JHbojDIxwQM9CavbiSSDj8KE+YHJNIOZ9xynu2T7UMQDypJ9aQcLwD+JppYADIwPc8UCEcngbefrTsDHIprHntSA4PB5+lSA7PakJJ9setICxJ6/Smk5xuHHuaBgpODxj60Z+XkgD2FIzBR70quCeB07YpMAzwM5J6Uwdc8A0OWYk4x9TTACO4x3xQMtJjuD1604jOQfXr6j/ABpgKjjJ4OcUpYZPDZzyO1AgI9u/X1pwTqQAfSmthsDng9u9PYYbH3iO/rQAHJI6YHTPX6U5jwxUAKOx7UxuT0J9/UUmQxO0ZX1oAc2CWyAuBnFK2Y2IXAGM+v401/ucLz2Pp9aOQpz6flQIcyks+CM45/xFLvOWGccdu9NJwTyOAOvalxjcOBQMV3IZhxkikZsE/MfmHYdaa+MMOhx0oYkZHQkZ+vvTEK/Q4bnHp1rGvHInbcR+PetZgQ7duOQKxtTOLonOOmaxr/CXT3M+/TIJ2c+ua6Pw8MWsfY4rBuhujOBnPUg1t6Ax+zxj0rysV8J7GWv94zq7VsBc9K0I8MMZ+lZlscDPar0I4zmuE95EhjbecGpUyMZpyDjNSfX86mxVx8bKRUgx0qJcbsd6mUDdz1pgPH1ozzSH0OKTHoaolgDg1Jlcc1HjnFO2+uPrQA4gDpmkYUuMj2pp9qTQ7gUzTkXHakUmnAHNUgQ4UpxQCAKaz8cU9gYMcDmomahiSajc4HWi5A2WTC81nzsxGOAKsSNz3qu6EnJzikMrmP0JyahuMInABx2q4fkB/rWZfOdjEd6aQjmtZY/Zm7MWqhbkhFBwRirOtv8AIqj16VXiBCCvZy74Wz57NX76RdgPOBirCsD3xVVOnJ/SrCD5ec4PcV3s8klbp+FJtGeOlAP1/CmFucc0gsOckEZwR703GW+6PxPSkPOCRmgcc/L/AI0NgOBIzwMelNDBc8n8KN3B/mKAcHr19KQxWPPBY5ppADDj86aV7jqPekJI+8RQAp6k9aFJwfvY9RTQx28CjnHPApMaFfp0pCflGP0pueetNJJbjJFIGXmYc84wfSgsdxXOD7UwnO4AjAPT0pxOCT9PwoAG256kdOlDHLnknPp3pGIBbnnPbt9Kd8o3Z7+n86AFdhzzn+tNJJDFSfr60jH73PP86M8tznp0HWgQp+dT94kYAozzyGYdj/Q0r8ZOTkj86QYIJBPT86LgBPGAufTP8qdISchRgcZJ6qaaxUnOCc4/GkY4cnBIIwD6/WmArDnIx1p0hY5yqj8ajwMnjK0Bcn5Tkds9qYmSEfMTlV9R6ViatkTnLAD0x0rZbqeAP89Kx9WHz8Hvxmsq3wlw3KiOXU5xnPatnRsiPHvXPIxD4JG3PTuK39Gb90Oe9eVil7p6+XP96dNbOdoJrQt2yOMcdqybY4OOxrRiypyOleej6A048YweKkC8ZqvA2cdPrVlW9MGmA8DK5I/KpVJx6imJyOPypy5HT8qAFKnGepoJPHalzk8EU0g5yOaYhd2TTwc4qPbznGKM7TTTESFtppu8E8Un40u2i9hrUcrVItRAU8cd6Ex2HkcVG3NBJpCcDJNMlsYep5qN29BkCnOcjjgUzAGfSlsBAQ3J/KmE4XLD61JITxUUpyAoz70AQynOTWPeknK9q1ZjgetZV0P3ZYnBNNbiZy+ssPMjUDnOahjY45OKbq75vEPT2pUIxnJr3sCrUz5rM3eqWoyc896mXnpk4quh+tTDBU5z7EV1M80kLfU0DABIH600DgHPPc0ob5uOKTAVzhc8CkBz35+lDsB6ZpAwAyeOOopMYEggcmlHOO49SaZuwcgfjTs8dMUgAnGQQKZgY60Eg0g5PXFACnIx1xSdc9qa+eB/WlJ4wOtIdgBGOlIe55H40n8jTTxnOKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The abnormal orientation of the fingernails shown here demonstrates rotational deformity because of a metacarpal fracture. Normally, all fingers are directed toward the scaphoid and there should be no overlap or rotation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_33_6682=[""].join("\n");
var outline_f6_33_6682=null;
var title_f6_33_6683="Congenital anomaly patterns";
var content_f6_33_6683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recognizable patterns of multiple congenital anomalies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Pattern",
"      </td>",
"      <td class=\"subtitle1\">",
"       Definition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Syndrome",
"      </td>",
"      <td>",
"       Pattern of anomalies that occur together and are pathogenetically related",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sequence",
"      </td>",
"      <td>",
"       Pattern of anomalies in which a single known defect in development causes a cascade of subsequent abnormalities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Field defect",
"      </td>",
"      <td>",
"       Pattern of anomalies caused by disturbance of a developmental field (a region of the embryo that develops in a contiguous physical space)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Association",
"      </td>",
"      <td>",
"       Two or more anomalies that are not pathogenetically related and occur together more frequently than expected by chance",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_33_6683=[""].join("\n");
var outline_f6_33_6683=null;
var title_f6_33_6684="Causes of hypercholesterolemia";
var content_f6_33_6684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Primary disorders of cholesterol metabolism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lipid levels",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmatory studies",
"       </td>",
"       <td class=\"subtitle1\">",
"        Physical findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial hyper- cholesterolemia (definite)*",
"       </td>",
"       <td>",
"        High TC; TG usually normal",
"       </td>",
"       <td>",
"        LDL receptor defect by cell studies or DNA mapping",
"       </td>",
"       <td>",
"        Tendon xanthomata in patient or one first or second",
"degree relative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial hyper- cholesterolemia (probable)*",
"       </td>",
"       <td>",
"        High TC; TG usually normal",
"       </td>",
"       <td>",
"        Exclusions include secondary disorders of cholesterol",
"metabolism; tendon xanthomata in patient or relative",
"       </td>",
"       <td>",
"        Corneal arcus; xanthelasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial combined hyperlipidemia",
"       </td>",
"       <td>",
"        TC and/or TG &ge;90th",
"percentile in patient and in one first or two second-degree relatives;",
"apo B &ge;90th",
"percentile",
"       </td>",
"       <td>",
"        LDL-chol/apo B &lt;1.2",
"       </td>",
"       <td>",
"        Xanthelasma; corneal arcus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial hyperapobeta- lipoproteinemia",
"       </td>",
"       <td>",
"        Apo B &gt;90th percentile; at least two first- or",
"second-degree relatives with similar profile",
"       </td>",
"       <td>",
"        LDL-chol/apo B &lt;1.2",
"       </td>",
"       <td>",
"        Xanthelasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polygenic hyper- cholesterolemia",
"       </td>",
"       <td>",
"        TC &gt;90th percentile; TG &lt;90th percentile",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Exclusions: tendon xanthomata in patient or family",
"members",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Summary of diagnostic criteria for the different forms of hypercholesterolemia.",
"    <div class=\"footnotes\">",
"     TC: total cholesterol; TG: total triglycerides; apo B: apolipoprotein B.",
"     <br>",
"      * The laboratory and clinical manifestations of familial defective apolipoprotein B-100 are identical to those of familial hypercholesterolemia; the distinction can be made only by molecular biology techniques.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Summary of diagnostic criteria for the different forms of hypercholesterolemia.&nbsp;Data from Rosenson RS, Frauenheim WA, Tangney CC. Dis Mon 1994; 40:369.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_33_6684=[""].join("\n");
var outline_f6_33_6684=null;
var title_f6_33_6685="Pediatric causes of heart failure";
var content_f6_33_6685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of heart failure in infants and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ventricular pump dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Structurally normal heart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Primary cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Dilated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Hypertrophic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Restrictive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Non-compaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Arrhythmogenic right ventricular dysplasia (ARVD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Secondary cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Myocarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Myocardial infarction/ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Anomalous left coronary artery arising off the pulmonary artery (ALCAPA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Arrhythmogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Complete heart block with bradycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Supraventricular or ventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Drug/toxin exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Anthracycline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Noncardiac causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Congenital heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Complex congenital heart defect with concurrent ventricular dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Complex congenital heart defect, surgically corrected with late ventricular dysfunction (\"burnt-out\" congenital heart disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Preserved ventricular pump function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Volume overload (increased preload)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Left-to-right shunting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Ventricular septal defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Patent ductus arteriosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Atrial septal defect (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Aortopulmonary window",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Atrioventricular septal defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Single ventricle physiology with unobstructed pulmonary blood flow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Valvular insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Aortic regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Mitral regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Pulmonary regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Pressure overload (increased afterload)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Left-sided lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Aortic stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Aortic coarctation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Right-sided lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Pulmonary stenosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Hsu DT, Pearson GD. Heart failure in children: part I: history, etiology, and pathophysiology. Circ Heart Fail 2009; 2:65.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_33_6685=[""].join("\n");
var outline_f6_33_6685=null;
var title_f6_33_6686="ARV class adverse reactions I";
var content_f6_33_6686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66245%7EID%2F77005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=14\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66245%7EID%2F77005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=14\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antiretroviral agents, class adversereactions - I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Reaction",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lactic acidosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hepatotoxicity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hyperglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Defintion",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Gr III = AST/ALT 5-10 X ULN",
"        </p>",
"        <p>",
"         Gr IV = AST/ALT &gt;10 X ULN",
"        </p>",
"       </td>",
"       <td>",
"        FBG &gt;126 mg/dL",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Frequency",
"       </td>",
"       <td>",
"        1.3 percent NRTI recipients receiving AZT, d4T, or ddI; median onset at 4 mos",
"       </td>",
"       <td>",
"        <p>",
"         NRTIs: d4T, ddl, ZDV (7 to 16 percent);",
"        </p>",
"        <p>",
"         PIs - (15 to 30 percent) especially RTV (dose related)",
"        </p>",
"        <p>",
"         ABC+NVP - hypersensitivity with hepatic necrosis, eosinophilia and rash;",
"        </p>",
"        <p>",
"         NNRTI: NVP-hepatotoxicity (15 percent); EFV (8 percent)",
"        </p>",
"       </td>",
"       <td>",
"        3 to 17 percent with PIs",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Agents",
"       </td>",
"       <td>",
"        NRTIs d4T+dDl &gt;d4T&gt; ddl &gt;ZDV &gt;3TC = ABC, FTC &gt;TDF",
"       </td>",
"       <td>",
"        All antiretrovirals",
"       </td>",
"       <td>",
"        PIs",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Risk factors",
"       </td>",
"       <td>",
"        <p>",
"         Prolonged use NRTI (especially d4T)",
"        </p>",
"        <p>",
"         Female, pregnancy, obesity, ribavirin, metformin",
"        </p>",
"       </td>",
"       <td>",
"        HCV or HBV infection, ETOH, female sex",
"       </td>",
"       <td>",
"        Preexisting glucose intolerance",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        GI (abd pain, anorexia, nausea, vomiting), wasting, dyspnea, cardiac arrhythmias",
"       </td>",
"       <td>",
"        Asymptomatic or sx of hepatitis. Note: &uarr; indirect bilirubin with IDV or ATV is inconsequential",
"       </td>",
"       <td>",
"        Polyuria, polydipsia, polyphagia, weight loss",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Lab",
"       </td>",
"       <td>",
"        Lactate &gt;2 mmol/mL; life-threatening if &gt;10 mmol/mL",
"       </td>",
"       <td>",
"        LFTs; liver biopsy is usually not helpful",
"       </td>",
"       <td>",
"        Fasting glucose &gt;126 mg/dL",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Treatment",
"       </td>",
"       <td>",
"        <p>",
"         Lactate 2-5 mmol/mL + Sx - D/C NRTI if sx severe",
"        </p>",
"        <p>",
"         Lactate level is 5-10 mmol/mL - D/C NRTIsLactate &gt;10 mmol/mL (medical emergency) - D/C NRTIs + supportive care: ventilator, dialysis, IV HCO3",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Hypersensitivity reactions to ABC or NVP (fever, eosinophilia, rash, systemic response usually in first 6 wks): D/C drug immediately and do not rechallenge",
"        </p>",
"        <p>",
"         Asymptomatic elevations of LFT (&lt;10 X ULN): repeat LFTs every 1 to 2 wks",
"        </p>",
"        <p>",
"         Symptomatic or elevations of LFT (&gt;10 X ULN) or hyperlactatemia or hypersensitivity (ABC or NVP): change regimen",
"        </p>",
"       </td>",
"       <td>",
"        Use standard diabetes treatment with diet and exercise. Preferred hypo- glycemics are: metformin or thiazolidinediones. D/C PI only if uncontrolled hyperglycemia.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Monitor",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        LFTs at baseline and at 4-6 wks",
"       </td>",
"       <td>",
"        FBS baseline, at 3-6 mo, then yearly",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bartlett, JG. Pocket Guide; Adult HIV/AIDS Treatment, November 2003.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antiretroviral agents, class adversereactions - II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Reaction",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fat redistribution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hyperlipidemia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequency",
"       </td>",
"       <td>",
"        4 to 50 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        NNRTI: 8 to 16 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Agents",
"       </td>",
"       <td>",
"        <p>",
"         Fat accumulation: PIs",
"        </p>",
"        <p>",
"         Lipoatrophy: NRTIs d4T&gt;ddI&gt;AZT. Also occurs without antiretrovirals.",
"        </p>",
"       </td>",
"       <td>",
"        PI",
"       </td>",
"       <td>",
"        <p>",
"         NNRTI - NVP &gt;EFV and DLV",
"        </p>",
"        <p>",
"         PIs - increased risk with sulfonamide allergy",
"        </p>",
"        <p>",
"         NRTI - ABC*",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Risk",
"       </td>",
"       <td>",
"        No clear risks defined",
"       </td>",
"       <td>",
"        Risk for DVC - HBP, diet, obesity, genes, prior MI/stroke, diabetes, age",
"       </td>",
"       <td>",
"        <p>",
"         NNRTI - 1st 12 wks",
"        </p>",
"        <p>",
"         Female",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Sx",
"       </td>",
"       <td>",
"        <p>",
"         Fat accumulation - abd (visceral), buffalo hump, breasts, lipomas",
"        </p>",
"        <p>",
"         Fat atrophy - extremities buttocks, face",
"        </p>",
"       </td>",
"       <td>",
"        Cardiovascular disease with stroke or MI",
"       </td>",
"       <td>",
"        <p>",
"         Common - red rash",
"        </p>",
"        <p>",
"         Severe - Stevens-Johnson synd, TEN, DRESS (Drug Rash, Eosinophilia, and Systemic Systems)*",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Lab",
"       </td>",
"       <td>",
"        <p>",
"         CT scan, MRI, Waist: Hip, Bioelectric",
"        </p>",
"        <p>",
"         Impedence, DEXA, Ultrasound",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &uarr; triglycerides",
"        </p>",
"        <p>",
"         &uarr; cholesterol, and LDL cholesterol",
"        </p>",
"       </td>",
"       <td>",
"        Eosinophilia - variable",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Treatment",
"       </td>",
"       <td>",
"        <p>",
"         Plastic surgery (but expensive)",
"        </p>",
"        <p>",
"         Exercise?",
"        </p>",
"        <p>",
"         Change PI to NNRTI?",
"        </p>",
"        <p>",
"         Lipoatrophy- d/c d4T, ddI or AZT",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        <p>",
"         NECP guidelines:",
"        </p>",
"        <p>",
"         - General: diet and exercise",
"        </p>",
"        <p>",
"         - LDL cholesterol &uarr;: Pravastatin or atorvastatin",
"        </p>",
"        <p>",
"         - Triglycerides &uarr;: Gemfibrozil or fenofibrate",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Most rashes do not require drug discontinuation",
"        </p>",
"        <p>",
"         Withdraw NNRTI if severe; may tolerate other NNRTI (NVP &rarr; EFV)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Monitor",
"       </td>",
"       <td>",
"        Appearance",
"       </td>",
"       <td>",
"        Fasting lipid profile at baseline, at 3 to 6 months post HAART initiation, then yearly. More frequently if high risk or treated.",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * DRESS: Life threatening complication that is seen with NVP and ABC - usually in the first 6 weeks of therapy.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bartlett, JG. Pocket Guide; Adult HIV/AIDS Treatment, November 2003.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_33_6686=[""].join("\n");
var outline_f6_33_6686=null;
var title_f6_33_6687="Lichen sclerosus child";
var content_f6_33_6687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen sclerosus in a 4-year-old child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the subepithelial hemorrhages located proximally at the edge of the right labia minora and the V-shaped bilateral distribution of hypopigmentation lateral to the labia minora extending to the posterior fourchette. The hymen is crescentic in configuration with smooth, even borders.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Celeste Wilson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_33_6687=[""].join("\n");
var outline_f6_33_6687=null;
